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Life on dry land requires the presence of a barrier to prevent water loss. That the skin provided this barrier was intuitively obvious, but it was not until the 1940s that the stratum corneum 
emerged as the specific site barrier [1]. Skin is the largest organ of the human body, it has a surface area of 1-2 m2 and accounts for 15% of the total body weight in adults [2]. Next to its function 
as fluid barrier, skin functions as a mechanical and permeability barrier for exogenous substances. It is also regulates body temperature, contains sensory receptors and has a role in the immune system.
Structure of normal skinSkin consists of a cellular epidermis and an underlying dermis of connective tissue. These are physically separated by a basement membrane [3]. The 
epidermis is a stratified epithelium that itself continuously renews. It is made of various cell types, the majority (90-95%) are keratinocytes [2]. These keratinocytes are arranged in continuous layers (Figure 1), comprising (from bottom to surface): the stratum basale (single layer), the stratum spinosum (5-15 layers), the stratum granulosum (1-3 layers) and 
the stratum corneum (5-10 layers). Epidermal keratinocytes originate from mitotic divisions of stem cells in the basal layer. Daughter keratinocytes migrate towards the skin surface while undergoing a process of terminal differentiation.
Epidermal differentiationDuring terminal differentiation, the 
first change to occur is strengthening 
of the keratin intermediate filament network to increase the tensile strength of each cell. Cells accomplish this by synthesizing large amounts of new sets 
of keratins, K1 and K10, which replace 
K5 and K14 in the keratin intermediate 
filaments. These keratin intermediate 
filaments anchor to desmosomes, which are cell-cell junctions. Along with 
microtubules and microfilaments, the 
keratin intermediate filaments form the skeleton of epithelial cells. In the stratum spinosum, the cells remain transcriptionally active, synthesizing and assembling a durable cytoskeletal framework that provides mechanical strength. The granular layer is the last layer of viable cells. Cells of the stratum granulosum contain keratohyalin 
granules, which contain profilaggrin; 
the precursor of the interfilamentous 
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Figure 1. Human skin is divided into distinct layers. Left, skin model showing all layers present in the epidermis. Right, haematoxylin-eosin staining of normal human skin.
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comprises several genes encoding CE proteins (Figure 2) [7-9].
Members of the EDC share significant sequence similarities, for example glutamine- and lysine-rich regions that are often involved in intrachain and interchain cross-linking by TGases. Apart from those for involucrin and loricrin, most of the genes in the EDC are organized in four families: the SPRR genes encoding the small proline-rich proteins, the S100 genes encoding the Ca2+-binding proteins of the S100 family, the LCE genes encoding the 
Late Cornified Envelope proteins and the S100-Like Fused-Type protein family. This last family comprises seven 
members including filaggrin, filaggrin2, hornerin, trichohyalin and repetin. [7-14].
The first protein of the EDC incorporated into the CE is involucrin. Involucrin is ubiquitously expressed 
in stratified squamous epithelia, and 
its immunoreactivity is first detectable at the level of the stratum spinosum, several layers above the stratum basale [15]. Involucrin becomes cross-linked to almost all other CE proteins. In the CE structure, involucrin is located adjacent to the cell membrane. Furthermore as 
the cell membrane is finally replaced, involucrin might be the preferred substrate for cross-linking of ceramides from the exterior surface of the CE [16].Loricrin is the main component of the CE and comprises 70-85% of the total 
protein mass of the cornified layer [17-19]. Loricrin expression occurs very late during the terminal differentiation program of keratinocytes in the granular cells of the epidermis, where it accumulates in sulphur rich 
protein filaggrin. Filaggrin aggregates 
the keratin filaments into tight bundles, leading to the collapse of the cell into a 
flattened shape, which is characteristic for the anuclear corneocytes in the stratum corneum. The corneocytes have 
formed a stable and insoluble cornified envelope (CE) that was synthesized just beneath the disintegrating plasma membrane. Besides the CE proteins, a complex series of lipids are synthesized, some of which become covalently attached to proteins of the CE. Most of these lipids form intercellular lamellae that help to produce a complete barrier. The terminal stage of the differentiation process, desquamation, is a tightly controlled mechanism. It involves degradation and loss of residual intercellular desmosomal connections by proteases, such as kallikrein-related peptidases and cathepsins [4, 5]. 
cornified envelope proteinsCorneocytes assemble a complex of cross-linked proteins and lipids on their periphery, the CE. This CE consists of 
several specific proteins that are cross-linked together in an orchestrated way by Ca2+-dependent transglutaminases (TGases). A calcium gradient is present in the epidermis; the highest calcium concentrations are found in the granular layers while the stratum corneum has a very low calcium concentration [6]. Studies have shown that at least 20 proteins are present in the CE, and new components are still being discovered. On chromosome 1q21 a 2 Mb cluster called the ‘epidermal differentiation complex’ (EDC) is located. The EDC is enriched for genes expressed upon epidermal differentiation and 
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were described for S100 proteins, including regulation of oxidative stress (S100A2), antimicrobial activity (S100A7 (psoriasin), S100A8 (MRP8), S100A9 (MRP14)), and for S100A10 and S100A11 incorporation into the CE was shown [28]. The role of the LCE proteins in the formation of the CE has not been extensively studied. The LCE cluster, with a total of 18 members, is divided into six groups, LCE1-6, based on related amino acid sequences, genomic organization and expression patterns [29] (Figure 3). In mice, Marshall and colleagues [12] found that members of the LCE protein family are expressed rather late in epithelia, where they are cross-linked by TGases. By using immunoelectron microscopy they demonstrated that an Lce1 member is a CE component. Steinert et al. [30] found that a late envelope protein LEP (now known as LCE) is indeed cross-linked to involucrin, and trichohyalin in murine CEs. In murine development, the expression of the Lce genes starts after the expression of the Sprr genes, and is delayed until just before initial formation of the barrier [12]. Furthermore, others showed that human LCE6A is a TGase3 substrate [31].
Atopic dermatitis Atopic dermatitis is a chronic relapsing 
inflammatory skin disease with a prevalence of 15 to 30% in children and 2 to 10% in adults [33]. The disease is often associated with other atopic disorders, like allergic rhinitis and asthma [34]. Atopic dermatitis is triggered by a multifactorial setting 
keratohyalin granules [20, 21]. Loricrin is also cross-linked by TGases mainly forming loricrin-loricrin links. Also SPRRs are cross-linked to loricrin, which seem to function as cross-bridging proteins between two loricrin molecules [21]. The ratio of loricrin to SPRRs in the CE varies at the different body sites. This ratio is suspected to be involved in the alteration of the physicochemical and mechanical properties of the envelopes [4, 22, 23]. 
Profilaggrin is a polyprotein consisting 
of numerous filaggrin units flanked by distinctive amino and carboxyl terminal domains [24]. It is synthesized by granular keratinocytes, where it is stored in keratohyalin granules as a phosphorylated precursor. During 
terminal differentiation, profilaggrin undergoes de-phosphorylation and 
proteolysis to form filaggrin, which functions in the aggregation of keratin 
filaments [4]. Subsequently, within the 
stratum corneum, filaggrin is degraded into a pool of hydrophilic amino acids, which make up the natural moisturizing factor. These molecules play a central role in maintaining the hydration of the stratum corneum [25]. In addition to 
the structural properties of filaggrin, a 
filaggrin breakdown product, urocanic acid, is a UV-absorbing molecule [26] and the cis-isomer has local and systemic immunosuppressive effects, which is demonstrated in murine models and in human keratinocytes and leukocytes in vitro [27].The S100 proteins comprise a family of 21 small molecules that are characterized by the presence of two-calcium binding EF-hand motifs. Fourteen S100 genes are localized in the EDC. Distinct roles 
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Figure 3. Alignment of the 18 human LCE proteins. LCE proteins are divided into six groups based on related amino acid sequences [12, 29].  Alignments and phylogram tree made using CLUSTAL 2.1 at EMBL-EBI website [32].
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that causes IgE-mediated sensitization, with epithelial-barrier dysfunction regarded as a consequence of the local 
inflammation. Currently, the disrupted barrier function of the skin is considered as a major cause of the disease leading 
to barrier dysfunction, which finally leads to immunologic abnormalities. 
Atopic dermatitis: the filaggrin 
storyAtopic dermatitis was shown to be associated with loss-of-function mutations in the filaggrin (FLG) gene in several populations [41, 42]. Large population based studies show a population attributable risk of 13.5%. Atopic dermatitis patients have a number of barrier abnormalities. In addition to increased trans-epidermal water loss (TEWL), also an increased surface pH, reduced stratum corneum hydration and enhanced barrier recovery is 
present [43]. As filaggrin is supplier for natural moisturizing factor in the stratum corneum, natural moisturizing factor levels have been shown to correlate with FLG null allele status. This may therefore directly contribute to the dry skin phenotype seen in atopic dermatitis [44]. Interestingly, also the cytokine environment associated with atopic dermatitis appears to contribute to the compromised skin barrier function, as IL-4 and IL-13 suppress 
FLG gene expression [45]. Studies using 
flaky tail mice, which harbor a mutation analogous to the common human FLG mutation, demonstrated that topical application of allergens resulted in 
cutaneous infiltration and an allergen-
specific antibody response. These data demonstrate that antigen transfer 
which includes environmental factors, like stress and infections, and genetic factors [35]. Acute skin lesions of atopic dermatitis are intensely pruritic, erythematous, and show edematous papules and plaques often with secondary excoriations. Lesions 
typically appear on flexural regions. Although in most patients with eczema elevated levels of total and allergen 
specific IgE can be detected, a subgroup is characterized by normal IgE levels [36]. The so-called intrinsic or non-allergic form of eczema is part of this subgroup. It is further characterized by negative skin-prick tests for common inhalant and food allergens, absence of other atopic diseases such as allergic asthma and rhinoconjunctivitis [36]. The frequency of this form is approximately 15-30% depending on the geographical location of the study 
and the parameters used in defining the disorder [37]. However, the IgE-mediated variant is the most prevalent form of the disease and relates to about 70-85% of atopic dermatitis patients [38]. Atopic dermatitis is characterized by the production of interleukin (IL)-4, IL-5 and IL-13 by cutaneous T-cells, which are responsible for the initiation 
of allergic inflammation [39]. Usually this is referred to as a Thelper 2 (Th2) cell type response. In chronic lesions, there is a shift from a solely Th2 cell cytokine milieu to an environment of Th2 cell and Th1 cell type cytokines like 
interferon-γ [40]. Two hypotheses concerning the mechanisms of atopic dermatitis have been proposed [34]. Until recently, the primary defect was hypothesized to reside in an immunologic disturbance 
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through a defective epidermal barrier could be a key mechanism in atopic diseases [46].
Psoriasis
Psoriasis is a chronic inflammatory skin disease affecting about 2% of the population of Western societies. The most common form is psoriasis vulgaris, or plaque psoriasis, which accounts for approximately 90% of all psoriasis cases [47], and will be referred to as psoriasis in the coming chapters. Sharply demarcated plaques covered by white scales hallmark psoriasis. Plaques often occur on the extensor aspects of the elbows and knees, scalp, lumbosacral region and umbilicus [47]. All treatments are symptomatic and many of them have serious side effects. Like atopic dermatitis, psoriasis is also a multifactorial disease, caused by multiple factors, both genetic and 
environmental. Known environmental factors are stress, smoking, certain drugs and streptococcal infections. 
Psoriasis leads to a significant impairment in quality of life [48]. In addition to psychosocial problems, often found in many skin diseases, many other co-morbidities are also common in psoriasis. As many as 10-30% of the patients develop psoriatic arthritis, then also the joints get affected [49]. Lesional psoriasis skin has several histological features. The epidermis is thickened (acanthosis), caused by abnormal increase in keratinocyte turnover. In normal skin it takes 30 days to reach the surface of the skin starting at the basal layer, in lesional psoriasis skin this process takes 6-8 days. The scales are due to premature maturation 
and incomplete cornification of the keratinocytes, which results in parakeratosis: the retention of nuclei in the cells of the stratum corneum. 
A T-cell infiltrate can be detected in the epidermis and high in the dermis. These cells are mainly CD4+ Th cells and CD8+ cytotoxic T cells (Tcyt). In psoriasis Th1, Th17 and Th22 cells are involved, leading to a cytokine milieu 
of IFN-γ, TNF-α, IL-17, IL-22 and IL-23 [50]. In the epidermis, however, most of the T-cells are derived from the CD8+ population.
Psoriasis: epidermal versus 
immune pathogenesisThe question if psoriasis is an epithelial disease or an immune-mediated disease has generated considerable debate over the last decades, but remains essentially unresolved. Until the early eighties psoriasis was considered to be a keratinocyte disease, but the advent of cyclosporin A as an effective mechanism-based treatment has changed this [51]. For the last three decades psoriasis was primarily regarded as an immune-mediated disease although the pendulum has begun to swing back lately [52]. The concept of an (auto)immune basis is supported by the presence of activated T-cells and other immunocompetent cells in psoriatic 
lesions and the efficacy of T-cell targeted therapeutics, like cyclosporin A, DAB389IL-2, alefacept and efaluzimab [53]. Other circumstantial evidence for an immune-based pathogenesis stems from genetic data (discussed below) and anti-psoriatic therapies that are thought to target the adaptive immune system rather than the epidermis 
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report a positive family history [59]. In the past decades, several linkage studies [60-62] and, more recently, genome wide association studies (GWAS) have 
been performed to find susceptibility loci for psoriasis [63-72]. Linkage 
analysis has identified at least nine loci and have been designated psoriasis susceptibility region 1 (PSORS1) to PSORS9. GWAS and candidate gene 
approaches have now identified over 20 psoriasis loci. Several, albeit not all of 
them, have been confirmed by studies in various populations. All performed GWAS for psoriasis, however, show associations with the PSORS1 region. 
Furthermore, each scan finds its own 
new regions, but these are often difficult to validate in an independent dataset [57]. For most of these loci, single nucleotide polymorphisms (SNPs) have 
been identified in or near candidate genes but convincing evidence for 
causative mutations that clearly define a mechanistic basis is largely lacking. 
Despite these difficulties, genetic studies are a useful source of knowledge and can provide new insights into the pathogenesis of psoriasis.The strongest and invariably reproduced susceptibility locus, PSORS1, harbors 
HLA-C*06, which was already known to be associated with psoriasis in the 1970s. This locus contains several genes including CDSN, which encodes a protein expressed in differentiated keratinocytes. However, due to linkage disequilibrium (LD), the tendency of two genes to be inherited together more often than would be predicted 
by chance, it is difficult to identify the true causative susceptibility gene of the PSORS1 locus. Studies of Orru et 
(corticosteroids, UVB, fumarates). Animal models involving xenograft transplantation provide further evidence for an immune-mediated pathogenesis. In these experiments, grafts of human uninvolved psoriatic skin 
onto severe combined immunodeficient mice (SCID) can develop into lesional psoriatic skin by direct injection of activated T cells from the donor [54]. In addition, a psoriatic phenotype can develop by expansion of resident T-cells of grafted non-lesional skin [55]. Although it is clear that participation of cell types non-intrinsic to the skin are mandatory for the development of psoriatic lesions, none of these animal models excludes a contribution of the epidermal keratinocytes. Various studies have documented skin barrier abnormalities in psoriasis but genes involved in keratinocyte differentiation, with the exception of corneodesmosin (CDSN) have not been considered as genetic risk factors, until recently. In the following sections data from genetic studies are reviewed and an overview of all currently known risk factors is presented. Copy number variation (CNV) of genes involved in the chemical and physical skin barrier found to be associated with psoriasis are discussed in detail. 
Genetics of psoriasis A strong genetic basis for psoriasis 
has been firmly established in many epidemiological and genetic studies [56-58]. Twin studies showed a concordance rate of 35 to 72% in monozygotic twins, and 12 to 35% in dizygotic twins. About 70% of the patients with childhood psoriasis 
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al. [73] suggest that the CDSN is the susceptibility gene, whereas Nair et 
al. [74] reported that HLA-C*06 is the most likely susceptibility gene in the PSORS1 region. Alternatively it might even be possible that both HLA-C*06 and CDSN contribute to psoriasis susceptibility [57]. Given its role in antigen presentation, the association with HLA-C*06 strongly points at a role of the adaptive immune system in psoriasis. Although the PSORS1 region is the most replicated and best-known susceptibility locus for psoriasis, it accounts for less than 50% of the familial aggregation (estimated population attributable risk: 29%, based on frequency of HLA-C*06 in control population 0.17 and odds ratio (OR) of 3.45 [75]). Therefore, other loci must contribute to the pathogenesis of psoriasis. Recent, widely replicated associations comprise SNPs mapped near the IL-12B gene (IL12B), coding for the p40 subunit of IL-12 and near a subunit of the IL-23 receptor (IL23R) [66, 76, 77]. In several other large-scale GWAS [63-65, 67-72] many of 
these associations were confirmed, and additionally many new SNPs were reported to be associated with psoriasis. Several of these new SNPs were found in or near genes associated with the adaptive or innate immune system such as IL23A, TNFAIP3 (TNF-α induced protein 3), TNIP1 (TNFAIP3 interacting protein 1), IL-4 and IL-13. Table 1 lists the known replicated genetic associations with psoriasis to date.Although most of the available genetic and clinical data at this point supported a role of T-cell driven processes, 
epidermis-expressed genes likely play a major role in the pathogenesis of psoriasis. For example, cell biological studies suggest that keratinocytes of psoriatic patients and from atopic dermatitis patients are intrinsically different from keratinocytes derived from healthy volunteers. Cultured keratinocytes from patients react differently to stimuli like cytokines, probably due to genetically programmed differences [102, 103]. The recent 
finding that FLG is a major gene in atopic dermatitis, a disease thought to be primarily driven by the immune system, provided a shift of paradigm indicating that we should consider similar mechanisms in psoriasis as well. 
Two studies have recently identified regions in the human genome that are subject to CNV and are associated with psoriasis. CNV of a genomic segment on chromosome 8p23.1 harboring a cluster of DEFB genes, encoding 
the β-defensins, and a CNV in the PSORS4 region on chromosome 1q21, 
specifically the deletion of LCE3B and 
LCE3C, were found to be associated with psoriasis. Remarkably, these newly associated genes are expressed in the epidermis and not in immunocytes (see Figures 4 and 5), as will be discussed below.
β-defensins and psoriasis 
β-defensins are small antimicrobial peptides that possess a broad spectrum of antimicrobial activity against both gram-positive and gram-negative bacteria, fungi and viruses [107, 108]. Because of their antimicrobial activity 
the β-defensins, together with other antimicrobial peptides, are thought to 
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be responsible for the chemical barrier and innate immunity of the skin. This idea is supported by observations 
in inflammatory skin diseases such as psoriasis and atopic dermatitis. Atopic dermatitis is associated with a high prevalence of skin infections whereas infections are rare in psoriasis [109]. This could be explained by reduced mRNA and protein levels of antimicrobial proteins (e.g. hBD-2, hBD-
3, elafin and LL-37) in atopic dermatitis as compared to psoriasis [110, 111]. When comparing the expression of hBD-1, 2 and 3 in normal skin and in skin from psoriasis and atopic dermatitis patients, it was shown that hBD-2 is by 
far the most upregulated β-defensin in lesional psoriatic skin (Figure 4 and 5) and can be used as a serum biomarker for disease activity [106].Besides antimicrobial activity, 
β-defensins also exhibit 
proinflammatory properties as chemoattractants for immune cells, like immature dendritic cells, memory 
T cells, TNF-α treated neutrophils and mast cells [112-115]. Because of these 
properties, β-defensins provide a link between the innate and the adaptive immune system.
The genes coding for the β-defensins are located on chromosome 8p23.1 of the human genome. In this region 
seven β-defensin genes are located. Six of these genes, including DEFB4 (encoding hBD-2) and DEFB103 (encoding hBD-3), are localized on a very large repeat unit that can vary in copy number. DEFB1 (encoding the protein hBD-1) is not localized on this repeat and therefore not subject to CNV [116]. In humans up to 12 copies of this repeat have been found, with a 
Figure 4. DEFB4 and LCE genes are mainly expressed in skin. Relative mRNA expression levels of DEFB4, LCE2B and LCE3A in normal and psoriasis skin, several immune associated and oral human tissues. Expression of target genes was normalized to that of RPLP0. For graphic representation, per gene values are expressed relative to expression in tongue, which was set at unity, to enable comparison of expression between tissues (see [104]). LCE data reprinted from [105] with permission from Elsevier. DEFB4 data reprinted from [106].
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mode of four copies per diploid genome [93]. Based on the functional data on 
β-defensins (particularly hBD-2) and psoriasis it was hypothesized that the 
CNV of the β-defensin cluster on 8p23.1 could be associated with psoriasis. 
Analysis of the β-defensin cluster in a Dutch and German case-control cohort 
showed indeed a significant association between higher genomic copy numbers 
and the psoriasis risk [93]. This finding has recently been replicated in a large independent cohort, although the association was weaker than that of 
the initial study [94]. As six β-defensin genes are part of the repeat region and show the same copy number variation it is not possible to distinguish whether one gene or a combination of 
all β-defensins is responsible for the association with psoriasis. Altogether, 
these data suggest that the β-defensins, produced in keratinocytes, could have a role in the pathophysiology of psoriasis. The mechanism, however, by which 
increased β-defensin genomic copy number predisposes to psoriasis 
is currently unknown. It was presumed that a high copy number 
of the β-defensin cluster on 8p23.1 
provides increased β-defensin protein production. Jansen et al. [106] could demonstrate that there is indeed a 
significant, albeit moderate, correlation between genomic copy number and serum hBD-2 levels in healthy controls. Speculatively, increased cutaneous 
β-defensin production could provide increased protection against infection upon skin barrier disruption. This 
evolutionary benefit may have promoted the frequency of chromosomes carrying 
higher β-defensin copy numbers. As the defensins are also chemotactic for 
inflammatory cells, high copy numbers may also increase the propensity 
to mount a vigorous inflammatory response to minor stimuli. These 
properties of β-defensins may be two sides of the same coin, leading to an evolutionary advantage for carriers of high defensin copy numbers at the expense of an increased risk for psoriasis. 
Chapter 1
Figure 5. hBD-2 protein expression in skin. hBD-2 protein expression in normal skin (left) and in involved psoriasis skin (right). In normal skin hBD-2 is not expressed, in involved psoriasis skin hBD-2 expression is heavily induced, scale bar = 100 µm.
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Structural epidermal proteins 
and psoriasis: the deletion of 
LCE3B and LCE3CLesional psoriatic skin is characterized by premature keratinocyte differentiation and defective keratinization, including altered formation of the CE. In psoriatic skin the components of the CE are differentially expressed as compared to normal skin. Expression of the early differentiation markers like involucrin, corneodesmosin, the small proline-rich proteins, cystatin A and TGase 1 is increased, whereas the expression of the late differentiation markers like 
loricrin and filaggrin is decreased [117, 118]. The aberrant formation of the CE affects the barrier capacity of the skin in psoriasis. Several independent studies showed that TEWL of lesional psoriatic skin is higher than in normal and uninvolved psoriatic skin. Moreover, the level of the TEWL is related to the clinical severity of the lesion, suggesting that the barrier function of lesional psoriatic skin is weaker than in normal skin [119, 
120]. The Koebner phenomenon, i.e. the appearance of psoriatic lesions in uninvolved skin of psoriasis patients as 
a consequence of superficial trauma is another indication for the involvement of the physical barrier function of the skin [121]. Although the underlying molecular mechanism is not clear yet, the keratinocytes may play a role in this phenomenon, either by compromised barrier function or secretion of cytokines [122]. The PSORS4 locus is positioned on chromosome 1q21 in the EDC [60, 123, 124]. Because of the presence of FLG in this region, FLG mutations were also studied in psoriasis patients, but no 
associations were found [125, 126]. A study by de Cid et al. [85] using array-comparative genomic hybridization (array-CGH) reported four regions on the human genome subject to CNV that were potentially associated with psoriasis in a Spanish cohort. Further investigations of one of these regions demonstrated an association of a CNV in the LCE cluster. A common deletion comprising the LCE3B and LCE3C genes (LCE3C_LCE3B-del) was found with higher frequency in patients compared to controls. The LCE3C_LCE3B-del has a population attributable risk of 23%, indicating that the deletion explains a sizable proportion of the genetic contribution. The association with 
LCE3C_LCE3B-del has been replicated in several cohorts with different ethnic backgrounds [75, 86-88, 127]. In addition, in an independent GWAS of a large Chinese cohort, SNPs in strong LD with LCE3C_LCE3B-del were identified as risk factors for psoriasis [65]. To evaluate the possible function of the 
LCE3B and LCE3C genes in psoriasis de Cid et al. [85] investigated the expression of LCE3C and LCE3E genes in psoriasis skin compared to healthy skin. In lesional psoriatic skin the expression of the LCE3C (when present) and LCE3E was highly induced [85]. To investigate if skin barrier disruption might be a pathophysiological stimulus for LCE3C and LCE3E expression, their expression was examined in healthy individuals following minor skin injury by tape stripping. Indeed, in normal skin LCE3C and LCE3E gene expression was induced upon tape stripping [85]. Jackson et al. [29] investigated LCE expression levels in several human 
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tissues. They showed that LCE1 and 2 group members are mainly expressed in skin, and hardly in internal epithelia. The LCE3 group members are absent or variably expressed at low levels in internal and external epithelia, and they show variable expression between tissue types. LCE4 and LCE5 expression was barely detected in the investigated tissues. The authors discovered a large heterogeneity between individuals with respect to the expression of the different LCE genes. Studies in cultured keratinocytes showed that the LCE2 expression is induced by calcium, and UV induces the expression of the LCE1 and LCE2 groups and of LCE3E. 
Genetic interactions in 
psoriasisGenetic polymorphisms that are considered as ‘disease-causing’ do not have the same effects in all individuals. For example, HLA-C*06 is a very strong risk factor for psoriasis (OR 3-34, depending on the population [75]), but the majority of HLA-C*06 carriers do not have psoriasis. Additional causes for developing the disease are 
environmental influences, epigenetic variation and genetic background. The dependence of a disease-associated mutation or polymorphism on genetic 
background is defined as ‘genetic interaction’ or epistasis [128]. When considering two loci that are associated with a disease, a deviation from the additive effects of the two (either negative or positive) is regarded as genetic interaction. The molecular or cellular mechanism by which these two factors exert their effect is then called ‘biological interaction’. Complex 
diseases are often regarded as interplay of many, interacting genetic factors and environmental stimuli. There are, however, not many examples of genes that show proof of epistasis in common complex disorders. Psoriasis is unique in that sense as recent publications have provided evidence for genetic interaction between HLA-C*06 and 
LCE3C_LCE3B-del, and between 
HLA-C*06 and ERAP1 [72, 75, 85, 127]. In one study genetic interaction was observed between three loci, 
HLA-C, CSTA and D12346 [129]. The interaction between HLA-C*06 and 
LCE3C_LCE3B-del was discovered in our Dutch psoriasis case-control cohort. Remarkably, this interaction was not found in a few other populations with similar ethnic background. Whether this 
reflects technical issues (genotyping by tagging SNP or HLA-C*06 itself) or genetic heterogeneity remains to be investigated. Previous studies have indicated substantial differences in allele frequencies of LCE3C_LCE3B-del in controls of European descent which may play a role [75]. Similarly, 
FLG mutations associated with atopic dermatitis, although widely replicated in European and Asian populations, were not found in an Italian cohort. The genetic interaction that we observed in our Dutch cohort was particularly strong, as HLA-C*06 was only a risk factor in the group that carried at least one LCE3C_LCE3B-del allele. Taken together, the combination of HLA-C*06 positivity and a deleted LCE3C_LCE3B allele yielded an odds ratio of 9.8 compared to HLA-C*06/LCE3C_LCE3B-del negative individuals as a reference category.
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Aims of this thesisOur group was involved in the discovery of LCE3C_LCE3B-del as a genetic risk factor for psoriasis. The goals of my PhD project were (I) to elucidate the role of LCE3C_LCE3B-del in the etiology and pathogenesis of psoriasis, (II) to explore the role of LCE3C_LCE3B-del in other complex disorders and (III) to 
study the function of the Late Cornified Envelope proteins in epidermal biology.Ad I: The association between LCE3C_
LCE3B-del and psoriasis was replicated in another large psoriasis cohort from Germany (chapter 2). In chapter 3 the role of genetic risk factors for juvenile onset psoriasis were examined. Chapter 4 addresses the epistatic interaction of HLA-C*06 and LCE3C_LCE3B-del, originally found in the Dutch cohort, in a larger data set.Ad II: We investigated a possible association of LCE3C_LCE3B-del with atopic dermatitis (chapter 5) and with rheumatoid arthritis (chapter 6).Ad III: In chapter 7 we examined a possible role of LCE3C_LCE3B-del in 
the Koebner phenomenon in psoriasis patients. In chapter 8 the expression of the different LCE genes was studied 
in vivo and in vitro. The direct physical interaction between corneodesmosin and LCE proteins was examined in chapter 9. In chapter 10 we describe 
an approach to find new interaction partners for the LCE proteins using cultured primary human keratinocytes.
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�ecently, a deletion of two late cornified envelope (LCE) genes within the epidermal differentiation complex on chromosome 1 was shown to be overrepresented in 1,426 psoriasis vulgaris patients of European ancestry. Here we report a confirmation of this finding in 1,354 psoriasis patients and 937 control individuals of German origin. We found an allele frequency of the deletion 
of 71.7% in psoriasis patients and of 65.5% in control individuals (χ2=17.44, p=2.97*10-5, OR [95% CI]=1.31 [1.15-1.48]). Overall copy number of the two LCE genes had no influence on age of onset, but we observed a dosage effect at genotype level. There was no evidence of statistically significant interaction with copy 
number of the β-defensin cluster on 8p23.1 or with an IL-23R pathway variant in a combined data set of German and Dutch individuals, while evidence for interaction with the PSORS1 risk allele in German individuals was marginal and did not remain significant after correction for multiple testing. Our study confirms the recently published finding that the deletion of the two LCE genes is a susceptibility factor for psoriasis with dosage effect, while due to power limitation, no final conclusion regarding interaction with other psoriasis risk factors can be made at this stage.
Chapter 2
37
IntroductionPsoriasis vulgaris is a common 
inflammatory skin disorder charac-terized by epidermal hyperproliferation, altered keratinocyte differentiation 
and inflammation. An HLA-C allele or a variant in strong linkage disequilibrium (LD) with it is the major risk allele especially in psoriasis patients manifesting before the age of 40 years. 
This finding probably corresponds to the most evidentiary psoriasis susceptibility locus (PSORS1). Beside this risk factor and PSORS4 (see below), replicated associations to candidate genes (RAPTOR and SLC12A8) have been reported so far at PSORS2 and PSORS5 [1-4]. In addition, variants in the IL-23R 
pathway have been identified by two genome wide association studies for 
psoriasis [5, 6] and could be confirmed by further independent studies [7-10]. Finally, copy number variation (CNV) of a genomic segment on chromosome 8p23.1 harbouring a cluster of 
genes encoding β-defensins, small 
antimicrobial peptides, was identified to be associated with psoriasis in a Dutch and a German case-control cohort 
[11] and variants of the NFκB-pathway were recognized to be risk factors for psoriasis [9]. PSORS4 is a susceptibility locus on 
chromosome 1 initially identified in a genome wide linkage analysis of Italian families [12]. This locus is of special interest for psoriasis, since it comprises the epidermal differentiation complex (EDC), a group of genes expressed in the upper strata of the epidermis. While several genes at PSORS4 – e. g. 
LOR, LCE1C, PGLYRP, SPRR genes, PRR9 genes and IVL – have been proposed to 
account for psoriasis susceptibility [13-16], very recently, a CNV within the late 
cornified envelope (LCE) gene cluster 
was identified by a genome-wide scan using pooled DNAs. The deletion of two LCE genes (LCE3C and LCE3B) was shown to be at higher frequency than controls in 1,426 psoriasis patients from several European countries and to be associated with psoriasis in a large family-based cohort [17]. Expression data in the same study suggested that carriers of the deletion may have a compromised repair response following barrier disruption of the skin [17]. In addition, in an independent genome-wide association study of a Chinese cohort, SNPs in strong LD with the 
deletion were identified as risk factors for psoriasis [18]. The present study investigates the contribution of LCE3C_LCE3B-del to psoriasis susceptibility in German patients and whether this contribution to disease is independent of two other known genetic risk factors. We therefore analyzed a large case-control cohort comprising 1,354 psoriasis patients and 937 control individuals for the presence of LCE3C_LCE3B-del and also genotyped three SNPs known to be in strong LD with it (rs10888502, rs4112788, rs4845456). In addition, we investigated a possible interaction between LCE3C_LCE3B-del and two other known risk factors, the copy 
number of the β-defensin cluster on chromosome 8p23.1 and a SNP (rs6887695) near the IL12B gene which represents the strongest genetic variant of the IL-23R pathway, in a combined data set of German and Dutch cohorts [8]. 
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Material and Methods
Study groupsThe German case-control study consisted mainly of 1,114 psoriasis patients and the 937 control probands, previously described in Hüffmeier et al. [8]. The minority of the 1,354 cases were index patients of 240 trios of a family based cohort [19]. The studies were approved by the ethical committees of the University of Erlangen-Nuremberg and of the University of Münster. The Dutch case control group consisted of 213 patients and 335 control individuals and has been described previously [11]. Permission for these studies was obtained from the local medical ethics committee (Comissie Mensgebonden Onderzoek). Written informed consent was obtained from each patient and control proband prior to enrollment. The investigations were conducted according to Declaration of Helsinki principles.
Genotyping We genotyped the LCE CNV in German 
samples with a modified protocol from that used by de Cid et al. [17]: a multiplex 
assay of two fluorescently marked PCR products detected on an ABI3730 DNA sequencer (Applied Biosystems, Foster 
City, USA). Briefly, we used 40 ng DNA and the Amplitaq Gold polymerase (Applied Biosystems, Foster City, USA) to amplify a breakpoint-spanning PCR-product of 351 bp (F: GGATACTAAGAAGTTCTCAC, R: GTGGTGAGAGAGGGCATCTC) for deletion alleles and a second amplicon for wildtype alleles (primers within the deleted region, product size of 561 bp (F: CATTAGCCTGGAGCTTTTGC, R: ACAAGTGATAACATTGTCAGGAGG)). 
The multiplex reaction was diluted 1:20; 5 µl were analysed with size standard LIZ600 (Applied Biosystems, Foster City, USA) on the capillary sequencer. Genotypes passing quality control showed peak intensities >2000 
fluorescent units, and in putative heterozygote individuals, ratios of peak heights of LCE3C_LCE3B-del to the ones of the non-deletion alleles were >0.5 and <3. To estimate the error-rate of genotyping, we performed duplicate genotyping of six 96-well-microtitre plates. 515 DNAs yielded an amplication in both runs and were used to compare genotypes. Within these, 449 (87.2%) passed both quality criteria (see above) and were concordant in both experiments. 7 DNAs (1.4%) passed quality control in both runs, but showed divergent genotypes. We therefore have to assume a genotyping error rate of about 1.4 %. For genotyping failures of the LCE CNV, we used the three primers LCE3CF (TCACCCTGGAACTAGACCTCA), LCE3CR (CTCCAACCACTTGTTCTTCTCA) and LCE3CR2D (CATCCCAGGGATGCTGC-ATG) in a multiplex reaction as previously described (de Cid et al., 2009a) and performed agarose gel electrophoresis to separate the deletion allele (199 base pairs) and non-deletion allele (240 base pairs). With this method, 
we also confirmed genotypes of 37 individuals that had been successfully genotyped by the mainly used method.SNPs were genotyped with TaqMan assays (Applied Biosystems, Foster City, USA) in the German study groups. In addition, we sequenced 24 randomly selected individuals for the three variants as previously described 
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calculated with the software Haploview vs. 4.0 [20]. Haplotypes were calculated with FAMHAP [21]. An unpaired t-test statistic was calculated to test whether psoriasis vulgaris patients carrying one or two LCE3C_LCE3B-del alleles develop disease earlier than non-carriers/carriers of one LCE3C_LCE3B-del allele. To test for a dosage effect of LCE3C_
LCE3B-del, logistic regression analysis was performed using as reference homozygotes for the LCE3C_LCE3B non-deletion allele. In order to adjust for the effect of LCE3C_
LCE3B-del, we followed the logistic regression framework described in 
Cordell and Clayton [22]. Significant p-values were corrected by Monte-Carlo simulation for 3 markers. 
For stratification for other psoriasis risk factors, we used genotypes of the strongest associated variant of the IL-23R pathway (rs6887695 of IL12B gene) in the German cohort [8]. In order to stratify for single risk factors, carriers 
of the common risk allele “G” of variant rs6886795 and carriers of more than 
4 copies of the β-defensin cluster were regarded as risk groups versus non-risk groups. To test if the German and Dutch cohorts could be combined in one logistic regression model, the Cochran-Mantel-Haenszel statistics were performed. For LCE and IL12B data, the test of homogeneity of the odds ratio showed 
no significant difference (p=0.526 for a recessive model and p=0.186 for a dominant model) while it showed 
significant differences regarding the PSORS1 risk allele. To test for interaction, we followed the logistic regression framework described in 
(Huffmeier et al., 2009b) and could verify their genotypes. Genotyping of the LCE CNV in Dutch patients and controls was performed as described in de Cid et al. [17]. rs6887695, the variant of the IL12B gene, was successfully genotyped in Dutch cases and controls with a genotyping rate of 96.1 %.DEFB CNV and available genotypes for 
interaction analyses
Copy numbers of the β-defensin cluster were determined in subgroups of 317 German psoriasis patients and 305 control individuals as well as 179 Dutch patients and 272 control probands as described by Hollox et al. [11]. The copy 
number of β-defensin cluster was not available for the rest of the cohort.For interaction analyses, we had data for the LCE copy number variant and the 
IL12B variant res6887695 in all German and Dutch individuals. For the main risk factor for psoriasis (PSORS1), we had information on carriers/non-carriers of the HLA-Cw0602 allele in Dutch individuals and used an estimation in German individuals as previously described [8]. 
Statistical and interaction analysesTo determine allele frequency differences between cases and controls, 
we used χ2-statistics, with one degree of freedom for comparisons of allele frequencies and two degress of freedom for comparisons of genotypes. For 
comparisons resulting in significant statistical values, an odds ratio with 
95% confidence interval was calculated (OR [CI]). The linkage disequilibrium between the four variants was 
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Cordell and Clayton [22]. Our model contained one variable (risk/non-risk) for each potential interaction partner and an interaction term to test for deviation from a multiplicative model. 
The significance of the interaction term 
was evaluated with a χ2-distribution 
with one degree of freedom. Significant p-values were corrected with the Bonferroni method, i.e. p-values were multiplied by six (= number of interaction analyses performed).
ResultsGenotyping of the LCE CNV as well 
as all SNPs fulfilled Hardy-Weinberg-equilibrium both in groups of German patients and control individuals. Genotyping rates were between 94.7 and 95.6% for the three SNPs and 99.4% for the LCE CNV. All variants except rs10888502 were in near-perfect LD with each other, while LD was strongest between LCE CNV and variant rs4112788 with r2 of 0.94. We observed strong evidence for association of psoriasis to LCE3C_
LCE3B-del with a significant allele frequency difference of 6.0%, a p-value of 2.97*10-5 and a corresponding OR of 1.31 [95% CI: 1.15-1.48] (tables 1A+B).Association to single SNPs was strongest 
for rs4112788, but also significant for the two other SNPs at allele level (tables 2A+B). Similar results were obtained at haplotype level: the haplotype 
“GGA-deletion” (order of variants: rs10888502 - rs4112788 - rs4845456 – LCE CNV) was the most common one in cases and controls (39.4 vs. 35.7%) with a corresponding p-value of 0.011 (table 3A). Even stronger was the effect of a 2-marker haplotype consisting of rs4112788 and LCE 
CNV: risk haplotype “G-deletion” was 
significantly associated with a p-value of 0.0010 (table 3B). The p-value indicating the distribution of p-values was one order of magnitude higher in the 2-marker haplotypes analysis compared to the one of four markers. In order to determine whether the risk alleles of the 3 SNPs have independent effects from the LCE CNV, we performed 
(A)
Allele Controls Psoriasis χ2 p OR [95% CI]
LCE3C_LCE3B-del 1,215 (64.9) 1,899 (70,9) 17.44 2.97*10-5 1.31 [1.15-1.48]non-deletion 657 (35.1) 785 (29.2)
(B)
Genotype Controls Psoriasis χ2 p OR [95% CI]*
LCE3C_LCE3B-del/ 
LCE3C_LCE3B-del 391 (41.8) 678 (50.5) 18.010 1.23*10-4 1.37 [1.05-1.80]LCE3C_LCE3B-del/ non-deletion 433 (46.3) 543 (40.5)non-deletion/non-deletion 112 (12.0) 121 (9.0)
Abbreviations: CI, confidence interval; CNV, copy number variation; LCE, late cornified envelope; LCE3C_LCE3B-del, deletion of the two LCE genes (LCE3C and LCE3B); OR, odds ratio. * Using a dominant model.
Table 1. A Allele and B genotype frequencies (absolute number (percentage)) in 1,354 
psoriasis patients and 937 control probands, results of χ2-statistics and ORs [95% CIs] for 
the LCE CNV.
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heterozygous patients (1.16 [0.87- 1.55]), indicating a dosage effect.As only part of the German cohort had been previously genotyped for 
copy number of β-defensin cluster, we performed a joint analysis with the Dutch study group to increase statistical power for interaction analyses. Logistic regression analysis on data from 1,073 individuals, did not reveal any evidence for interaction (p=0.22, table 4A). In a combined German and Dutch case-control study consisting of 1,567 patients and 1,272 individuals, no evidence for interaction of the 
LCE3C_LCE3B-CN with rs6887695 (SNP near the IL12B gene) was observed 
(p=0.55). Since we observed significant differences in homogeneity of ORs 
a conditional analysis. Thereby, we 
identified marginal evidence for independent effects of rs4112788 (p=0.044), but not for the other two 
SNPs (p-values not significant). The p-value for rs4112788 remained not 
significant after correction for multiple testing.
No significant differences in age of disease onset were observed between the three LCE CNV genotypes. This was also true when analysis was restricted to patients with an age of onset before 40 years of age (also known as type I psoriasis), which represented the majority of our cases. The OR for psoriasis patients homozygous for 
LCE3C_LCE3B-del was 1.61 [1.21-2.14] and therefore higher than the OR for 
Table 2. A Allele and B genotype frequencies (absolute number (percentage)) in 1,354 
psoriasis patients and 937 control probands, results of χ2-statistics and ORs [95% CIs] for 
the three SNPs.
(A)
SNP Allele Controls Psoriasis χ2 p OR [95% CI]rs10888502 G 685 (38.6) 1080 (42.2) 5.585 0.018 1.16 [1.03-1.31]C 1091 (61.4) 1482 (57.8)rs4112788 G 1151 (64.7) 1799 (69.1) 9.314 0.002 1.22 [1.07-1.39]A 627 (35.3) 803 (30.9)rs4845456 A 675 (37.7) 1053 (40.8) 4.295 0.038 1.14 [1.01-1.29]G 1117 (62.3) 1529 (59.2)
 (B)
SNP Genotype Controls Psoriasis χ2 p OR [95% CI]*rs10888502 C/C 332 (37.4) 432 (33.7) 5.885 0.053 1.17 [0.98-1.4]C/G 427 (48.1) 618 (48.2)G/G 129 (14.5) 231 (18.0)rs4112788 A/A 106 (11.9) 118 (9.1) 9.502 0.009 1.36 [1.03-1.79]A/G 415 (46.7) 567 (43.6)G/G 368 (41.4) 616 (47.3)rs4845456 A/A 120 (13.4) 221 (17.1) 5.780 0.056 1.11 [0.93-1.33]A/G 435 (48.5) 611 (47.3)G/G 341 (38.1) 459 (35.6)
Abbreviations: CI, confidence interval; CNV, copy number variation; LCE, late cornified envelope; LCE3C_LCE3B-del, deletion of the two LCE genes (LCE3C and LCE3B); OR, odds ratio. * Using a dominant model.
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for the PSORS1 risk allele between both cohorts, we analysed interaction of PSORS1 with other risk factors only in the subset of 2,291 German individuals. We observed a tendency toward interaction with LCE3C_LCE3B-CN, while the p-value did not remain 
significant after correction for multiple testing. Further calculations on possible 
interactions revealed no significant p-values (table 4A+B). 
Discussion
We present the first replication of the LCE3C_LCE3B-del association with psoriasis previously reported by de Cid et al. [17]. The frequency of the LCE3C_LCE3B-del allele in our German case control cohort was very similar to Dutch and US case-control samples [17]. The single SNPs were all associated at allele level, while effects 
were strongest for rs4112788. This variant also shows strongest LD to the LCE CNV, and haplotype analyses revealed stronger effects of a haplotype consisting of these two variants than the one of all four variants. Testing for indepency of LCE CNV and rs4112788 was inconclusive. Currently, we can not exclude that rs4112788 might modify the risk at this locus, while the LCE CNV seems to be the more plausible risk factor. Further functional studies and maybe the upcoming meta-analysis (see below) will hopefully elucidate the role of the two variants in the pathogenesis of psoriasis.Several independent studies e.g. [23] observed that the PSORS1 risk factor is strongly associated with early age of disease onset. We performed a similar analysis for LCE3C_LCE3B-del, which indicated that it is not associated with 
Haplotype Controls Psoriasis p OR [95% CI]Haplotypes consists of 4 variants with the order: rs10888502, rs4112788, rs4845456, LCE CN. p-value indicating distribution of haplotypes: 9.31*10-5.G G A Del 35.7 39.4 0.011 1.17 [1.04-1.32]C A G Non-Del 32.4 27.1 1.1*10-4 0.78 [0.68-0.88]C A G Del  0.4 1.0 0.021 2.69 [1.17-6.18]C G A Del 1.8 1.2 NS NAC G G Del 26.2 27.7 NS NAG A G Non-Del 2.6 2.1 NS NA
(B)
Haplotype Controls Psoriasis p OR [95% CI]Haplotypes consists of two variants with the order: rs4112788, LCE CN. p-value indicating distribution of haplotypes: 1.80*10-6.G Del 64.5 69.3 0.0010 1.24 [1.10-1.41]A Non-Del 35.0 29.2 3.4*10-5 0.77 [0.68-0.87]A Del 0.5 1.5 2.7*10-4 3.19 [1.54-6.57]
Table 3. Frequencies of A 4- and B 2-marker haplotypes, results of association statistics and 
ORs [95% CIs] in 1,354 psoriasis patients and 937 control probands.
(A)
Abbreviations: CI, confidence interval; CN, copy number; LCE, late cornified envelope; NS, not significant; NA, not applicable; OR, odds ratio.
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Regarding possible interaction(s), we have to consider limited power due to study size, and this limit does not allow 
a final conclusion. In general though, no evidence for interaction is not a wholly 
unexpected finding as interaction in Crohn’s disease -a disease in which many more loci/risk factors have been 
identified in total- has been observed for only single risk factors [24, 25] and 
evidence for replication of these finding is scarce. 
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early disease onset. But confirming previous results from the European study [17], we observed a dosage effect of the LCE3C_LCE3B-del at genotype level. The major risk allele for psoriasis has been found to be epistatic to LCE3C_
LCE3B-del in the subgroup of Dutch individuals [17], but not in the other subgroups. We observed only marginal evidence for interaction in the German 
cohorts which remained not significant after correcting for multiple interactions by Bonferroni. A large multicenter meta-analysis on the possible interaction between PSORS1 risk allele and 
LCE3C_LCE3B-del is underway (Riveira 
et al., chapter 4). The meta-analysis will provide more generalizable data regarding this possible interaction and might show differences in various European populations. We did not observe evidence for interaction of 
LCE3C_LCE3B-del with the β-defensin CNV nor with a variant of the IL12B locus, while we did not test interaction 
to newly identified risk alleles in the genes TNIP1 and TNFAIP3 [9]. 
LCE3C_LCE3B-CN IL12B DEFB-CN
LCE3C_LCE3B-CN x 0.55 0.22
IL12B 0.55 x 0.80
DEFB-CN 0.22 0.80 x
(B) German individuals
LCE3C_LCE3B-CN PSORS1 IL12B DEFB-CN
LCE3C_LCE3B-CN x 0.02* 0.49 0.32
PSORS1 0.02* x 0.98 0.66
IL12B 0.49 0.98 x 0.56
DEFB-CN 0.32 0.66 0.56 x
Table 4. Uncorrected results (p-values) of interaction analyses in case control cohorts. 
(A) Dutch and German individuals
Abbreviations: CN, copy number; LCE, late cornified envelope; PSORS, psoriasis 
susceptibility locus. *P-value did not remain significant when corrected for number of interaction analyses performed. P-values for interaction of two risk factors can be found in a square, with the corresponding risk factors above and on the left-hand side.
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Recent genome-wide association studies have identified several genetic risk factors for psoriasis, but data on their association with age of onset are lacking. The goal of this study was to compare the association between known risk alleles and psoriasis in well-defined cohorts of pediatric and adult onset psoriasis. Based on previous studies we selected seven genes and loci associated with psoriasis. Psoriasis patients with pediatric (< 18 years) and adult 
onset psoriasis (≥ 18 years) and controls were genotyped. Genotype frequencies were compared between controls (n=450) and all cases (n=217), and between controls and cases stratified for confirmed age of onset (pediatric onset n=85, adult onset n=80). Pediatric onset psoriasis showed a significant association with single nucleotide polymorphisms (SNPs) in the ERAP1 (P=0.042) and in the IL23R locus (P=0.042), LCE3C_LCE3B deletion (P=0.003) and HLA-C*06 (P=1.72*10-19) when compared with the control group. A significant association of these four genes was also demonstrated when all psoriasis cases were compared with controls. In adult onset psoriasis a significant association was found for HLA-C*06 (P=5.11*10-6) and for LCE3C_LCE3B deletion (P=0.042). No associations were found for the 
IFIH1, IL12B and TRAF3IP2 loci. Notwithstanding the small cohort sizes, we could demonstrate an association with established and recently discovered genetic risk factors in pediatric onset psoriasis including genes involved in epidermal barrier function and adaptive immunity. Our data suggest that heritable factors may play a more important role in pediatric onset psoriasis than in adult onset psoriasis. 
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Introduction Psoriasis is a common, chronic skin disorder, affecting around 2% of the population. The disease is caused by both environmental and genetic factors, like HLA-C*06 [1]. In recent years, independent genome-wide association studies (GWAS) and candidate gene 
approaches identified other genetic susceptibility factors for psoriasis. These were mainly single nucleotide polymorphisms (SNPs) [2-6].Previous studies already demonstrated a strong association with HLA-C*06 
in type I psoriasis, which is defined as disease onset before the age of 40 and a positive family history [7]. Recently, Xu 
et al. [8] demonstrated an association between LCE3C_LCE3B-del and type I psoriasis. These studies were based on the observed age of onset peaks in psoriasis. The occurrence of such a distribution, however, has recently been discussed [9]. Besides two studies on HLA-C*06, limited data about the association of psoriasis risk genes and age of disease onset are available [7, 10]. Therefore, we investigated the possible association of known psoriasis risk genes in pediatric onset (<18 years) 
and adult onset (≥ 18 years) psoriasis. We analyzed seven genetic risk factors 
for psoriasis in well-defined cohorts of pediatric onset and adult onset psoriasis. We chose variants that play a (putative) role in the various pathways underlying the pathophysiology of psoriasis. Several studies showed that variants in the innate (IFIH1) and adaptive immune system (HLA-C*06 and 
ERAP1), the Th17 pathway (TRAF3IP2, 
IL23R and IL12B) and the skin barrier function (LCE3C_LCE3B-del) are 
genetically linked with psoriasis [2, 3, 5, 6, 8, 11-13]. 
Materials and Methods 
Sample collectionDNA samples from psoriasis patients (n=217) were obtained from individuals referred to the outpatient clinic of the Department of Dermatology of the Radboud University Nijmegen Medical Centre. Only patients with psoriasis vulgaris were included in this study. The 450 control samples were obtained from the Nijmegen Biomedical Study (NBS) [14]. For the LCE and HLA analysis, we used another control group consisting of 386 samples, which were used in our previous studies [2, 15]. Only self-reported data were available for all controls, and individuals reported to have psoriasis were excluded from this study. All patients and controls were of European descent. Patients 
were stratified by age of onset of their 
disease. Eighty patients were classified as having pediatric onset psoriasis, 
defined as a dermatologist confirmed psoriasis diagnosis before the age of 18. 
Eighty-five patients were categorized 
as having adult onset psoriasis, defined 
as having a dermatologist confirmed psoriasis diagnosis at the age of 18 or later. For 52 patients reliable information about psoriasis onset was not available. The local ethical committee approved the study. All participants (for patients under 18, their parents) gave written informed consent. For cohort characteristics see Table 1.
GenotypingSNP genotyping was performed using 
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Taqman® SNP genotyping assays (assay IDs C_920306_20, C_1272298_10, C_3056837_10, C_34244955_10 and C_29927086, for SNPs rs240993, rs11209026, rs27524, rs17716942 and rs3213094 respectively) according to the manufacturer’s recommendations (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). As quality control on the SNP typing 5% of the samples were analyzed in duplicate; all genotypes were concordant. The SNPs were successfully genotyped in the psoriasis and control samples with genotyping success rates between 98.4% and 99.6%. Genotype cluster plots were evaluated prior to analysis to ensure satisfactory assay performance. For the LCE3C_LCE3B-del genotyping a polymerase chain reaction (PCR) using three different primers was performed 
as earlier described [2]. Briefly, 10 
ng DNA template was amplified with one universal forward primer and two different reverse primers, one spanning the breakpoint of the deletion and one located in the possible deleted region generating PCR products of 199 and 240 bp, respectively. These were visualized on an agarose gel. HLA-C*06:02 was determined by PCR with sequence 
specific primers for C*06:02 [2]. Using this method the HLA-C*06 gene itself 
is identified rather than a tagging SNP. This method does not allow distinction between homozygotes and heterozygotes.  
Statistical analysisThe observed genotype frequencies were compared with the expected 
Hardy-Weinberg distribution by a χ2- test, for none of the variants deviations from Hardy-Weinberg equilibrium were found both in the control and the psoriasis group. Logistic regression analyses were performed in SPSS software 16.0 (SPSS Inc., Chicago, IL, U.S.A.) using additive models. Because of subgroup differences, models were adjusted for sex by adding sex as a covariate. The Odds Ratio (OR) and 95% 
Confidence Intervals (95%CI) were calculated using homozygosity for the non-risk variant (from previous studies) as a reference. Power calculations were performed using the Genetic Power Calculator [16]. Input for the power calculations, like allele frequency and genotypic relative risk per genotype, were derived from previous studies [2, 12, 13]. Powers shown in Table 2 were derived from the values given for additive models, except for HLA-C*06 in which numbers derived from dominant models were used.
Controls All psoriasis
Pediatric 
onset  
psoriasis
Adult
onset 
psoriasisNumbers 450 217 80 85Male, N (%) 176 (39.1) 118 (54.2) 29 (36.2) 58 (68.2)Age, years (SD) 49.6 (14.1) 40.1 (24.6) 14.9 (9.7) 60.7 (12.2)Age of onset psoriasis, years (SD) - 21.3 (15.4)* 8.2 (3.8) 33.5 (12.5)
Table 1 Cohort characteristics.
* Data were available for 165 subjects
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Results In our complete psoriasis cohort, we 
found significant associations between the G allele of SNP rs11209026, 
IL23R (Ptrend=0.007), the A allele of SNP rs27524, ERAP1 (Ptrend=0.019), with LCE3C_LCE3B-del (Ptrend=0.001) and HLA-C*06 (Ptrend=3.94*10-19) and psoriasis (Table 2). All found associations were in the same directions as previously reported. 
Next, we stratified our data into pediatric and adult onset psoriasis and performed subgroup analyses. Logistic regression models showed that in the pediatric onset psoriasis cohort all found associations in the full cohort were still present. Pediatric 
onset psoriasis was significantly associated with IL23R (Ptrend=0.042), 
ERAP1 (Ptrend=0.042) LCE3C_LCE3B-del (Ptrend=0.003) and HLA-C*06 (Ptrend=1.72*10-19). Adult onset psoriasis was only associated with the 
LCE3C_LCE3B-del (Ptrend=0.042) and 
HLA-C*06 (P=5.11*10-6).Moreover, when comparing the pediatric onset psoriasis cohort with the adult onset psoriasis cohort, we 
found a significant difference for 
HLA-C*06 (P=2.3*10-6), but not for the other genes. 
Lastly, we confirmed the known genetic interaction between HLA-C*06 and LCE3C_LCE3B-del in our full cohort (P=0.017) [2, 13]. Furthermore, 
specifically the pediatric onset 
psoriasis group significantly differed 
from the control group when stratified for HLA-C*06 and LCE3C_LCE3B-
del (χ2-test; p=0.001). The logistic regression model, however, showed 
no significant contribution of the 
interaction term (P=0.174), probably due to the large effect of the HLA-C*06-component in pediatric onset psoriasis. 
Discussion In this study, we showed in a small cohort that pediatric onset psoriasis 
is significantly associated with SNPs in ERAP1 (rs27524) and IL23R (rs11209026) loci, and LCE3C_LCE3B-
del and we confirmed the association for HLA-C*06. Previous studies have reported a genetic interaction of ERAP1 and LCE3C_LCE3B-del with HLA-C*06 [13, 17]. Given the high HLA-C*06 allele frequency in our pediatric onset patients, it is not surprising that the associations with ERAP1 and 
LCE3C_LCE3B-del were detected in such a modestly sized cohort. In adult 
onset psoriasis significant associations were only found for LCE3C_LCE3B-del and HLA-C*06. In our study we used a relatively small number of samples compared to large GWAS. It should be noted, however, that the subgroup analysis had between 12% and 100% power to detect an association. The power in pediatric and adult onset psoriasis groups was equal owing to similar group sizes (Table 2). In the current study, we have chosen the cut-off point at 18 years of age, which is an accepted cut-off point for adulthood in clinical investigations of medicinal products in the pediatric population, based on developmental biology and pharmacology [18].
ERAP1 encodes an amino peptidase, which regulates the quality of peptides bound to MHC class I molecules, such as HLA-Cw6 [19]. Activation of the interleukin 23 receptor (IL23R) 
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rs11209026
IL23R
G/A
All psoriasis
0.04
0.08
0.007
2.19 (1.23 to 3.91)
Adult onset psoriasis
0.06
0.08
0.279
1.49 (0.72 to 3.10)
Pediatric onset psoriasis
0.03
0.08
0.042
2.59 (1.03 to 6.49)
rs3213094
IL12B
T/C
All psoriasis
0.16
0.17
0.344
0.85 (0.62 to 1.19)
Adult onset psoriasis
0.17
0.17
0.956
1.01 (0.64 to 1.60)
Pediatric onset psoriasis
0.14
0.17
0.237
0.75 (0.46 to 1.21)
rs27524
ERAP1
A/G
All psoriasis
0.40
0.33
0.019
1.34 (1.05 to 1.72)
Adult onset psoriasis
0.39
0.33
0.079
1.38 (0.96 to 1.96)
Pediatric onset psoriasis
0.42
0.33
0.042
1.43 (1.01 to 2.03)
rs17716942
IFIH1
T/C
All psoriasis
0.11
0.14
0.615
1.09 (0.77 to 1.55)
Adult onset psoriasis
0.13
0.14
0.887
0.97 (0.59 to 1.58)
Pediatric onset psoriasis
0.12
0.14
0.726
1.09 (0.67 to 1.78)
rs240993
TRAF3IP2
T/C
All psoriasis
0.32
0.27
0.057
1.28 (0.99 to 1.65)
Adult onset psoriasis
0.32
0.27
0.210
1.25 (0.88 to 1.78)
Pediatric onset psoriasis
0.33
0.27
0.132
1.32 (0.92 to 1.88)
direct PCRLCE3C_LCE3BDEL/WT All psoriasis
0.30
0.40
0.001
1.53 (1.19 to 1.97)
Adult onset psoriasis
0.31
0.40
0.042
1.44 (1.01 to 2.05)
Pediatric onset psoriasis
0.27
0.40
0.003
1.77 (1.21 to 2.57)
direct PCRHLA-C*06**POS/NEG All psoriasis
0.54
0.17
3.94*10 -19
5.09 (4.02 to 8.80)
Adult onset psoriasis
0.40
0.17
5.11*10 -06
3.36 (2.00 to 5.65)
Pediatric onset psoriasis
0.78
0.17
1.72*10 -19
18.5 (9.81 to 34.8)
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stimulates CD4+ T cells into IL-17 producing Th17 cells instead of Th1 cells 
[20]. The late cornified envelope 3 (LCE3) genes have a role in skin barrier repair [21]. The deletion of LCE3C_LCE3B may lead to a compromised barrier repair response upon barrier disruption, which could lead to the penetration of exogenous agents. Against a genetic background of HLA-C*06 positivity, these could evoke a response of the adaptive immune system. It should be noted, however, that for all associated variants a nearby functional variant in linkage disequilibrium with the genotyped variant could also contribute to psoriasis. Our data suggest that at least genes involved in epidermal barrier function and adaptive immunity play a role in pediatric onset psoriasis. We hope that this study will stimulate other centers to evaluate their psoriasis 
patient cohorts and define patient 
groups with reliable and definite age of onset, in order to replicate and extend our current study. In conclusion, an association of known genetic risk factors with pediatric onset psoriasis, even in a relatively small cohort, was established and our data suggest that heritable factors may play a more important role in pediatric onset psoriasis than in adult onset psoriasis. Further elucidation of genetic factors and triggering environmental factors in an early stage may lead to a better understanding of the pathogenesis of psoriasis and could contribute to the development of more targeted therapies or even preventive measures for pediatric onset psoriasis.
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rs11209026
IL23R
G/A
All psoriasis (208)
0.04 (17)
0.08 (71)
Adult onset psoriasis (81)
0.06 (9)
0.08 (71)
Pediatric onset psoriasis (78)
0.03(5)
0.08 (71)
rs3213094
IL12B
T/C
All psoriasis (214)
0.16 (67)
0.17 (155)
Adult onset psoriasis (82)
0.17 (28)
0.17 (155)
Pediatric onset psoriasis (80)
0.14 (22)
0.17 (155)
rs27524
ERAP1
A/G
All psoriasis (215)
0.40 (172)
0.33 (295)
Adult onset psoriasis (85)
0.39 (67)
0.33 (295)
Pediatric onset psoriasis (78)
0.42 (65)
0.33 (295)
rs17716942
IFIH1
T/C
All psoriasis (217)
0.11 (49)
0.14 (121)
Adult onset psoriasis (85)
0.13 (22)
0.14 (121)
Pediatric onset psoriasis (80)
0.12 (20)
0.14 (121)
rs240993
TRAF3IP2
T/C
All psoriasis (216)
0.32 (139)
0.27 (241)
Adult onset psoriasis (85)
0.32 (55)
0.27 (241)
Pediatric onset psoriasis (79)
0.33 (52)
0.27 (241)
direct PCRLCE3C_LCE3BDEL/WT All psoriasis (215)
0.30 (128)
0.40 (308)
Adult onset psoriasis (85)
0.31 (53)
0.40 (308)
Pediatric onset psoriasis (78)
0.27 (42)
0.40 (308)
direct PCRHLA-C*06**POS/NEG All psoriasis (214)
0.54 (115)
0.17 (63)
Adult onset psoriasis (85)
0.40 (34)
0.17 (63)
Pediatric onset psoriasis (77)
0.78 (60)
0.17 (63)
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A multicenter meta-analysis including data from 9,389 psoriasis patients and 9,477 control subjects was performed to investigate the contribution of the deletion of genes LCE3C and LCE3B, involved in skin barrier defense, to psoriasis susceptibility in different populations. The study confirms that the deletion of LCE3C and LCE3B is a common genetic factor for susceptibility to psoriasis in the European populations (OROverall=1.21 (1.15–1.27)), and for the first time directly demonstrates the deletion’s association with psoriasis in the Chinese (OR=1.27 (1.16–1.34)) and Mongolian (OR=2.08 (1.44–2.99)) populations. The analysis of the HLA-Cw6 locus showed significant differences in the epistatic interaction with the LCE3C and LCE3B deletion in at least some European populations, indicating epistatic effects between these two major genetic contributors to psoriasis. The study highlights the value of examining genetic risk factors in multiple populations to identify genetic interactions, and indicates the need of further studies to understand the interaction of the skin barrier and the immune system in susceptibility to psoriasis.
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IntroductionPsoriasis is a common chronic 
inflammatory disease of the skin with a variable worldwide prevalence, being common in European descent individuals and less frequent in Asian ancestry populations [1]. To date, several loci have been underlined as psoriasis risk susceptibility factors, with psoriasis susceptibility region 1 (PSORS1), a major histocompatibility complex class I region on chromosome 6p21, being the locus with the largest 
effect identified to date [2]. Within PSORS1, the HLA-Cw06 allele has been pinpointed as the risk variant that confers the strongest susceptibility to psoriasis [3]. In a previous study we reported the association of the deletion of two late 
cornified envelope (LCE) genes, LCE3C and LCE3B (LCE3C_LCE3B-del), with psoriasis in 1,426 unrelated psoriatic patients and 1,406 controls from four populations of European ancestry. The 
LCE3C_LCE3B-del involves a 32.2-kb deletion, removing genes LCE3C and 
LCE3B of the LCE cluster, which is part of the epidermal differentiation complex on chromosome 1q21.3. Association with rs4112788, a tag single-nucleotide polymorphism (SNP) for the biallelic 
LCE3C_LCE3B-del copy number variant, located 584 nucleotides downstream of LCE3D, was also found. Interaction analysis showed epistatic effects between LCE3C_LCE3B-del and HLA-
Cw06 allele only in the Dutch population [4]. At the time of publication, an independent genome-wide association 
scan in a Chinese cohort also identified association of rs4112788 with the disease, indicating a major role of the 
LCE locus in psoriasis susceptibility [5]. Furthermore, this locus was replicated in a German case–control study of psoriasis vulgaris [6] and in a Spanish case–control study of chronic plaque-type psoriasis vulgaris [7]. Since these initial studies in psoriasis, the LCE3C_
LCE3B locus has been evaluated in other and psoriasis-related phenotypes. Hüffmeier et al. [8] found no association of this locus with susceptibility to psoriatic arthritis in the German samples, whereas association with this phenotype has been detected in the British and Irish [9] and in the Spanish [10] patients. Finally, Bergboer et al. [11] have found negative association of the LCE3C_LCE3B locus with atopic dermatitis.The aim of this meta-analysis with individual patient data was to further investigate the contribution of LCE3C_
LCE3B-del to psoriasis susceptibility and its possible interaction with the PSORS1 locus. In total 13 cohorts from 12 populations, nine of European ancestry (Finland, France, Germany, Ireland, Italy, Spain, The Netherlands, 
United Kingdom, and United States (US-California (US-CA) and US-Michigan (US-MI)), and three of Asiatic origin (China, Mongolia, and Japan), were included in the study (see Supplementary Methods for sample description). Overall, 9,389 psoriasis cases and 9,477 control samples were analyzed for the association of LCE3C_LCE3B-del with psoriasis. Association of rs4112788 was also investigated in 11 of the 13 data sets included. A possible relationship between PSORS1 and LCE3C_LCE3B-del and its tag SNP was assessed through interaction analysis using directly typed 
LCE3C_LCE3B-del and psoriasis risk
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and 3 of the HLA-C gene, as previously described [3].
Statistical analysis of LCE3C_LCE3B-del 
and SNP associationLogistic regression models assessed the genetic effect of the LCE3C_LCE3B-del and SNPs on psoriasis risk. Calculations for genotype frequency differences were performed by regression analysis for co-dominant, dominant, recessive, and log-additive models. The best genetic model was selected using the Akaike information criteria. Heterogeneity among populations was assessed using the Woolf test that evaluates the homogeneity of odds ratios (ORs). Overall values were calculated when the homogeneity assumption among populations was plausible, and were adjusted by population according to a logistic model that introduces population as a confounding variable. Potential interaction between LCE3C_
LCE3B-del or rs4112788 and HLA-Cw06 or rs130076 was evaluated from the log-likelihood ratio test between a model that includes both the additive effect and the interaction term against a model that only includes additive effects.
Results and DiscussionAssociation analyses of the genotyping 
data confirmed that the deletion of both LCE3C and LCE3B genes is that rs4112788 is a close proxy of the 
LCE3C_LCE3B-del allele in the Chinese population also (Table 1). This is the 
first direct indication that the strong association of psoriasis with rs4112788, detected in the initial analysis in Chinese samples [5], is also associated with the 
HLA-Cw06 when available, or rs130076, a SNP in linkage disequilibrium with it [12].
Materials and Methods
GenotypingTyping of the LCE3C_LCE3B copy number variant was performed by direct PCR using a four-primer or three-primer assay as previously described [4], allowing the simultaneous detection of intact and deleted alleles. Genotyping rates for LCE3C_LCE3B-del ranged from 92.5 to 100% in all European ancestry populations and from 97.3 to 100% in Asian populations. With regard to rs4112788, genotyping rates ranged from 93.7 to 99.6% in the European ancestry populations, whereas it reached 99.2% in the Chinese population. SNP assays in Spain, Netherlands, Italy, and US-CA were genotyped as previously described [4]. In the Ireland data set, genotyping of SNPs was performed 
using competitive allele-specific PCR at 
Kbiosciences (Hoddesdon, Herts, UK), and in Finnish data set using matrix-assisted laser desorption/ionization time-of-light mass spectrometry (Sequenom, San Diego, CA). In the remaining populations, genotyping of SNPs was conducted using TaqMan assays (Applied Biosystems, Foster City, CA). HLA allele discrimination in sample collections from The Netherlands and Italy were performed as described [4]. In the Japanese and Mongolian cohorts, HLA typing was conducted with LABType SSO typing test (One Lambda, Canoga Park, CA) and LABScan 
100 flow analyzer. HLA-Cw06 genotypes in the US-MI sample were determined by genotyping seven SNPs in exons 2 
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LCE3C_LCE3B-del allele.
Interestingly, we observed a significant negative correlation between the frequency of LCE3C_LCE3B-del among controls and the corresponding OR for psoriasis for the eight populations from Europe examined—the more common the risk allele, the smaller its effect on psoriasis risk (Supplementary Figure 1). Allele frequency, and the correlated effect strength, appears to follow an approximate north–south gradient pattern. Even though this observation could be because of sampling error, and additional European populations would need to be studied, a genuine 
significance of this phenomenon on the genetic predisposition to psoriasis cannot be ruled out.Direct typing of HLA-Cw06 in The Netherlands, Italy, Japan, Mongolia, and the US samples allowed the estimation of a potential interaction between the 
LCE3C_LCE3B deletion, or its tag SNP 
rs4112788, with PSORS1 locus. Apart from the already known interaction observed in the Dutch population alone, evidence for interaction was also observed in the US-MI data set, but not in the Italian sample. The existence of heterogeneity among the cohorts with European ancestry prevented the analysis of the interaction in those cohorts as a whole. Evidence of interaction between either LCE3C_
LCE3B-del or rs4112788 with HLA-
Cw06 was not observed in the Japanese and Mongolian data sets (Table 2). In the remaining populations, interaction with PSORS1 was assessed through its proxy marker rs130076. No evidence for interaction was seen with LCE3C_LCE3B-del or its tag SNP in any of the populations interrogated (Supplementary Table 3). To investigate whether the association of rs130076 with psoriasis (Supplementary Table 4) is independent or secondary to 
LCE3C_LCE3B-del and psoriasis risk
Figure 1. Meta-analysis of (A) LCE3C_LCE3B-del and (B) rs4112788 for association with 
psoriasis across populations of European ancestry. Squares show the point estimate of the 
odds ratio (OR) and its 95% confidence (95%CI) intervals with regard to genotype frequencies. 
Diamonds show the summary effect by fixed (Overall-Fix) and random (Overall-Ran) effects model. Different square sizes represent different weights of each population.
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In summary, we have confirmed that the deletion of genes LCE3C and 
LCE3B is a common genetic factor for susceptibility to psoriasis in European 
populations, and for the first time directly demonstrated the deletions association with psoriasis in some Asian groups. Interestingly, we detected 
significant differences in the epistatic interaction of the deletion with HLA-
Cw06, with a positive interaction in the Dutch and US-MI samples but no interaction with other European cohorts. This study highlights the value of examining genetic risk factors in multiple populations, and suggests that further studies in experimental models of disease are needed to understand the interaction of the skin barrier and the immune system in susceptibility to psoriasis.
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HLA-Cw06, the effect of this SNP was 
analyzed in a stratified analysis that 
defined strata by carriage of HLA-
Cw06 in the Italian data set (as the Italian was the only population in which both rs130076 and HLA-Cw06 were genotyped). In the subset of samples that does not contain an HLA-
Cw06 allele, rs130076 was no longer 
significantly associated with psoriasis (OR=4.64 (2.74–7.84), P=3.61*10−09 in HLA-Cw06-positive samples vs. OR=1.05 (0.73–1.50), P=0.7938 in HLA-
Cw06-negative samples). This suggests that the association of rs130076 is dependent on HLA-Cw06, but also that this SNP is an imperfect surrogate for HLA-Cw06, at least in the Italian population. Therefore, although it is valid to perform interaction analyses using rs130076, these analyses will likely have less power than those that use directly typed HLA-Cw6. Hence, it 
may not be coincidental that significant interaction was detected in two of the 
five data sets with HLA-Cw06 typing, but in none of the eight data sets with rs130076 typing. The existence of a potential epistasis found only in the Dutch and US-MI data sets, but in none of the remaining data sets in which 
HLA-Cw06 was typed, might be because 
of population-specific effects, different genetic backgrounds, or varying environmental exposures among data sets. The fact that no interaction was observed between LCE3C_LCE3B-del and HLA-Cw06 in the Chinese data set is probably because of the fact that despite 
HLA-Cw06 being a major risk allele for psoriasis in the Chinese population, it does not explain by itself the full linkage evidence of the PSORS1 locus in that 
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Supplementary MethodsA total of 9,389 psoriatic samples and 9,477 unrelated controls belonging to thirteen different data sets from twelve different populations were included in the present study. Patients were referred by a general physician or a dermatologist and informed consent was obtained for all the participants after ethical approval from the relevant committee in each participating center. Collections from Spain, The Netherlands, Italy, US California and Germany have been described elsewhere [4, 16]. France dataset: A case-control sample collection was constructed from a familial dataset consisting of 119 families using PEDSTATS [17]. In total, 141 psoriatic cases and 164 unrelated control individuals were used in the analysis. The study was conducted in accordance with the Declaration of Helsinki Principles and approved by the 
Ethics Committee of Le Kremlin-Bicêtre 
Hospital in 1995 (CCPPRB). UK dataset: A total of 1010 British patients of self-reported North-European descent were recruited through St John’s Institute of Dermatology (London) and Glasgow 
Western Infirmary. All patients were affected by early onset psoriasis vulgaris (disease onset occurring before 40 years of age). The control group included 1,025 unrelated individuals randomly sampled from the 1958 Birth Cohort, 
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University of Michigan Medical Center, the Ann Arbor Veterans Affairs Medical Center, and Henry Ford Hospital of Detroit. Individuals were considered to be affected if chronic plaque or guttate psoriasis lesions covered more than 1% of the total body surface area or if at least two skin, scalp, nail or joint lesions were clinically diagnostic of psoriasis. Individuals with psoriasis only of palms and soles were excluded. Normal controls were 18 years of age or older with no blood relatives affected with psoriasis. Informed consent was obtained for all subjects under protocols adherent to the Declaration of Helsinki Principles and approved by the Institutional Review Boards of the University of Michigan. Chinese dataset: The total of psoriasis patients and healthy controls used in the study were recruited from the Chinese Han population through collaboration among multiple hospitals in China, including 1,995 cases with a mean age of 32.67 years (range from 3 to 86 years) and 1,897 controls with a mean age of 32.69 years (range from 5 to 81 years). Type I psoriasis was diagnosed in 94.6 percent of the patients and 57.6 percent were males. Clinical diagnosis 
of all psoriasis patients was confirmed by at least two dermatologists. All the controls used were individuals without psoriasis, any autoimmune disorders systemic disorders and any family 
history of psoriasis (including first-, second- and third- degree relatives). They were from the same areas as cases. The age and gender were both matched with cases. Japanese and Mongolian dataset: A total of 561 individuals affected with psoriasis (426 males and 
a nationally representative dataset, including individuals prospectively ascertained in 1958, in England, Wales and Scotland [18]. This study was approved by the Guy’s and St Thomas’ 
Hospitals Ethics Committee of Kings College London and the North Glasgow University Hospitals NHS Trust Local Research Ethics Committee. Ireland dataset: Psoriasis patients, 55.6% of whom were male, were recruited at several centres in Dublin (St Vincent’s University Hospital, Dublin, St James’s Hospital, Dublin and The Adelaide and Meath Hospital, Dublin Incorporating the National Children’s Hospital, Dublin) and Galway (University College Hospital, Galway), Ireland. The overwhelming majority (>99%) had onset of symptoms  before age 40. Controls were randomly selected blood donors, 30% of whom were male. All cases and controls were unrelated individuals of uniform ethnic Irish origin. Finland dataset: A case-control sample collection was constructed from a familial dataset consisting of 254 families using PEDSTATS. The families were recruited from all over Finland and inclusion criteria for probands were age of under 40 years and presence of chronic plaque psoriasis. Fifty-eight percent of patients were males and the average age of onset was 23 years. In total, 135 psoriatic cases and 335 unrelated control individuals were used in the analysis. US Michigan dataset: A total of 2,132 cases and 1,937 controls were recruited. All individuals were of European Caucasian ancestry, and most were from southeast Michigan. 
Affected individuals were identified through the dermatology services of the 
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135 females) and an equal number of healthy unrelated individuals (428 males and 133 females) of Japanese origin participated in this study. Japanese cases were hospitalized for diagnosis and treatment at the multiple hospitals in Japan. A total of 102 unrelated Mongolian patients (50 males and 52 females) with psoriasis vulgaris were investigated in the present study. All patients were being diagnosed and treated at the National Centre for Dermatology and Mycology, Ulaanbaatar, Mongolia. A total of 168 healthy unrelated individuals (84 males and 84 females) of Mongolian origin from the region of Ulaanbaatar, Mongolia participated in the current study.
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Supplementary Figure 1. Correlation between ORs (y-axis) and LCE3C_LCE3B-del allele 
frequencies (x-axis) in the eight studied European populations (P=0.0045).
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Dataset Status del/del del/Intact Intact/Intact
ORa 
(95%CI) P-valueSpain C 107 (28.0) 206 (53.9) 69 (18.1) 1.56 (1.19-2.08) 0.0014PV 66 (37.5) 95 (54.0) 15 (8.5)Italy C 159 (35.3) 198 (44.0) 93 (20.7) 1.28 (1.06-1.54) 0.0079PV 186 (41.3) 201 (44.7) 63 (14.0)France C 73 (44.5) 65 (39.6) 26 (15.9) 1.27 (0.91-1.75) 0.155PV 68 (48.2) 60 (40.6) 13 (9.2)Netherlands C 102 (36.4) 130 (46.4) 48 (17.1) 1.49 (1.14-1.96) 0.0033PV 95 (46.6) 91 (44.6) 18 (8.8)Germany C 391 (41.8) 433 (46.3) 112 (12.0) 1.30 (1.15-1.50) 0.0333PV 678 (50.5) 543 (40.5) 121 (9.0)
UK C 460 (45.1) 450 (44.1) 111 (10.9) 1.16 (1.02-1.33) 0.0285PV 454 (48.2) 415 (44.1) 72 (7.7)Ireland C 463 (48.9) 385 (40.7) 99 (10.5) 1.06 (0.89-1.28) 0.466PV 195 (49.7) 164 (41.8) 33 (8.4)Finland C 150 (44.8) 136 (40.6) 49 (14.6) 1.33 (0.99-1.79) 0.0547PV 72 (53.3) 50 (37.0) 13 (9.6)US CA C 113 (38.4) 152 (51.7) 29 (9.9) 1.41 (1.12-1.75) 0.0025PV 292 (49.0) 263 (44.1) 41 (6.9)US MI C 809 (42.3) 860 (45.0) 244 (12.8) 1.10 (1.00-1.21) 0.0579PV 936 (44.1) 963 (45.4) 224 (10.6)Overall C 2827 (42.0) 3015 (44.9) 880 (13.1) 1.20 (1.15-1.28)b 1.42*10-13bPV 3042 (46.8) 2845 (43.8) 613 (9.4) 1.21 (1.15-1.27)c 1.48*10-12cJapan C 187 (34.8) 257 (47.9) 93 (17.3) 1.18 (0.99-1.39) 0.0658PV 216 (39.3) 257 (46.7) 77 (14.0)Mongolia C 44 (26.2) 78 (46.4) 46 (27.4) 2.04 (1.41-2.94) 9.38*10-05PV 44 (44.0) 46 (46.0) 10 (10.0)China C 624 (32.9) 926 (48.8) 347 (18.3) 1.28 (1.16-1.41) 1.41810-07PV 781 (39.1) 956 (47.9) 258 (12.9)
Supplementary Table 1. Association of LCE3C_LCE3B-del genotypes with psoriasis.
aORs and P-values are derived from the log-additive model, with homozygotes for the deleted allele (LCE3C_
LCE3B-del) at higher risk for psoriasis. Overall values for the European ancestry populations adjusted by population according to a logistic model in which population was introduced as a confounding variable (based on 
fixed effects modelb and a random effects modelc) after no significant evidence of heterogeneity based on allelic frequencies was detected by population.
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Dataset Status C/C (%) C/T (%) T/T (%) ORa (95%CI) P-valueSpain C 117 (30.6) 193 (50.5) 72 (18.8) 1.61 (1.23-2.13) 4.92*10-04PV 72 (41.1) 89 (50.9) 14 (8.0)Italy C 155 (34.8) 200 (44.8) 91 (20.4) 1.37 (1.14-1.64) 0.00101PV 189 (42.1) 205 (45.7) 55 (12.2)France C 76 (45.8) 64 (38.6) 26 (15.7) 1.27 (0.91-1.75) 0.155PV 71 (49.7) 60 (42.0) 12 (8.4)Netherlands C 102 (36.7) 129 (46.4) 47 (16.9) 1.47 (1.12-1.92) 0.00461PV 94 (46.5) 90 (44.6) 18 (8.9)Germany C 368 (41.4) 415 (46.7) 106 (11.9) 1.22 (1.08-1.39) 0.00208PV 616 (47.3) 567 (43.6) 118 (9.1)
UK C 437 (44.5) 429 (43.7) 115 (11.7) 1.12 (0.98-1.28) 0.0862PV 472 (46.8) 446 (44.2) 90 (8.9)Ireland C 466 (48.0) 403 (41.5) 101 (10.4) 1.18 (0.99-1.41) 0.0698PV 222 (51.4) 180 (41.7) 30 (6.9)Finland C 149 (45.2) 135 (40.9) 46 (13.9) 1.33 (0.98-1.79) 0.0602PV 71 (54.6) 46 (35.4) 13 (10.0)US-CA C 115 (38.9) 149 (50.3) 32 (10.8) 1.41 (1.14-1.75) 0.00229PV 286 (48.6) 263 (44.7) 40 (6.8)US- MI C 811 (42.6) 850 (44.7) 241 (12.7) 1.10 (1.00-1.21) 0.0515PV 940 (44.6) 948 (45.0) 221 (10.5)Overall C 2795 (42.1) 2967 (44.7) 878 (13.2) 1.20 (1.15-1.27)b 1.81*10-12bPV 3033 (46.4) 2894 (44.3) 611 (9.3) 1.21 (1.15-1.27)c 1.92*10-12cChina C 625 (33.1) 923 (48.9) 339 (18.0) 1.35 (1.22-1.47) 3.62*10-10PV 794 (40.2) 955 (48.4) 224 (11.4)
Supplementary Table 2. Association of rs4112788 genotypes with psoriasis.
aORs and P-values are derived from the log-additive model, with homozygotes C/C at higher risk for psoriasis. Overall values for the European ancestry populations were adjusted by population according to a logistic model 
in which population was introduced as a confounding variable (based on a fixed effects modelb and a random effects modelc) after no significant evidence of heterogeneity based on allelic frequencies was detected by population.
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Dataset Status
rs130076 
HWE
OR (95%CI)
P-value
C (%) T (%) T vs. CSpain C 651 (85.2) 113 (14.8) 0.54 2.58 (1.91-3.49) 6.82*10-10PV 243 (69.0) 109 (31) 0.05Italy C 718 (81.0) 168 (19.0) 0.54 1.79 (1.43-2.24) 3.56*10-07PV 595 (70.5) 249 (29.5) 0.41Germany C 1478 (80.6) 356 (19.4) 0.83 3.01 (2.62-3.46) <2*10-16PV 1537 (58.0) 1115 (42.0) 4.19*10-09France C 277 (82.4) 59 (17.6) 0.30 3.52 (2.44-5.09) 1.88*10-11PV 160 (57.1) 120 (42.9) 0.06Ireland C 1368 (70.4) 574 (29.5) 1 1.55 (1.31-1.83) 3.50*10-07PV 524 (60.6) 340 (39.4) 0.02Finland C 533 (82.3) 115 (17.7) 0.45 2.02 (1.45-2.82) 3.26*10-05PV 181 (69.6) 79 (30.4) 0.30US-CA C 362 (80.8) 86 (19.2) 0.40 2.25 (1.72-2.93) 1.95*10-09PV 759 (65.2) 405 (34.8) 0.006China C 3317 (89.0) 409 (11.0) 0.72 6.43 (5.70-7.25) <2e*10-16PV 2178 (55.8) 1726 (44.2) 2.9*10-153
Supplementary Table 4. Association of rs130076 in the PSORS1 locus in individuals 
from different populations.
Overall values for European ancestry populations are not presented since the Woolf-test on homogeneity of odds 
ratios based on allelic frequencies of rs130076 showed statistical significant heterogeneity among them (P = 1.851*10-08).
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Atopic dermatitis (AD) and psoriasis are common skin diseases characterized by cutaneous inflammation and disturbed epidermal differentiation. Genome-wide analyses have shown overlapping susceptibility loci, such as the epidermal differentiation complex on chromosome 1q21. Recently, a deletion on 1q21 (LCE3C_LCE3B-del), comprising LCE3B and LCE3C, two members of the late cornified envelope (LCE) gene cluster, was found to be associated with psoriasis. Although the mechanistic role of LCE proteins in psoriasis has not been identified, these proteins are putatively involved in skin barrier formation and repair. Considering the potential genetic overlap between the two diseases and the recent finding that mutations in the skin barrier protein filaggrin are associated with AD, we investigated a possible association between LCE3C_LCE3B-del and AD. Evaluation of four different cohorts of European ancestry, containing a total of 1,075 AD patients and 1,658 controls, did not provide evidence for such an association. Subgroup analysis did not reveal an association with concomitant asthma. Our data suggest that the potential roles of skin barrier defects in the pathogenesis of AD and psoriasis are based on distinct genetic causes. 
Chapter 5
77
IntroductionAtopic dermatitis (AD) and psoriasis are 
clinically distinct, chronic inflammatory skin diseases with a strong genetic basis [1-3]. Several genome-wide analyses have been performed to discover genetic factors contributing to AD and psoriasis [4]. These analyses have revealed chromosomal regions harboring possible susceptibility loci for both diseases, including chromosomal regions 1q21, 3q21, 17q25 and 20p12. 
These findings suggested that AD and psoriasis could share some contributing genetic factors, but none of these have 
been identified to date [5].Although both diseases are generally regarded as immune-mediated conditions, recent genetic studies have indicated the importance of inherited abnormalities of epidermis-expressed genes as a primary cause [4, 6-10]. 
These findings are in line with the 
concept of inflammatory epithelial disease, which was coined previously for a number of conditions that were associated with epithelium-expressed genes and immunological mechanisms [4]. The shared locus on chromosome 1q21 overlies the epidermal differentiation complex (EDC), a cluster of genes encoding proteins found in the uppermost layers of the epidermis, which are of great importance for keratinocyte differentiation and skin barrier maintenance [11]. Genes located in the EDC include loricrin (LOR), involucrin (IVL), filaggrin (FLG), the small proline rich protein (SPRR) genes, the S100 genes and the late 
cornified envelope (LCE) genes. Null mutations in the FLG gene have been 
identified as a remarkably strong and 
widely replicated risk factor for AD and led to a paradigm shift, placing the barrier function of the skin into the center of the pathogenetic concepts [10, 12-16]. Interestingly, also the cytokine environment associated with AD (Th2 cytokines) appears to contribute to compromised skin barrier function, as interleukin-4 and interleukin-13 suppress FLG gene expression [17]. In 
contrast to the genetic findings for AD, no associations of FLG null alleles with psoriasis could be shown [18, 19]. Although FLG mutations account for 13% of the population attributable risk (PAR) in AD [20], they only partially explain the linkage signal of AD to the EDC [21]. In addition, in a recent large-scale genome-wide association study (GWAS) evidence for additional AD risk factors in the EDC apart from prevalent 
FLG mutations was obtained [22].Apart from SNPs, DNA copy number variation (CNV) represents a considerable source of human genetic diversity [23-25]. De Cid and colleagues [7] discovered that the deletion of two genes of the LCE gene family, LCE3B and LCE3C (annotated as LCE3C_LCE3B-del), located in the 
EDC, was significantly associated with psoriasis in individuals of European 
ancestry. This finding has recently been replicated by an independent study in German psoriasis patients [26]. In addition, in an independent GWAS of a Chinese cohort, association with SNPs in strong LD with the deletion were 
identified as risk factors for psoriasis [27]. LCE proteins are incorporated 
in the cornified envelope during epidermal differentiation, as shown by Marshall et al. [28]. The work by De Cid 
AD not associated with LCE3C_LCE3B-del
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the Netherlands: The medical ethics committee of the University Medical 
Center Groningen and “Commissie Mensgebonden Onderzoek Arnhem-
Nijmegen”; for Germany: “Bayerische 
Landesärtzekammer” Munich and the ethics committee of the University of Bonn; for Italy: the medical ethics 
committee “Policlinico Tor Vergata”. and for Ireland: The Research Ethics Committees of Our Lady’s Children’s Hospital Crumlin (cases) and Trinity College Dublin (Trinity Biobank controls). The investigations were conducted according to the Declaration of Helsinki principles.
GenotypingThe Dutch, German and Irish cohort were genotyped by using the direct PCR-based method described by De Cid et al. [7]. The Italian cohort was genotyped by analyzing SNP rs4112788, which was shown to be in strong LD with the deletion (r2=0.93 and D’=0.99) [7]. Genotyping was successful in 98.1% of probands. We did not observe 
and colleagues [7] suggests that one of the psoriasis-associated genes, LCE3C, is involved in repair of skin barrier function, as its expression is only induced upon epidermal activation. These observations together with the role of skin barrier maintenance in both diseases, prompted us to investigate a possible genetic association between the LCE3C_LCE3B-del allele and AD. Our analysis of four European case-control cohorts, a total of over 2,500 samples, however, did not support such an association.
Materials and Methods
Study populations A total of 1,075 patients and 1,658 controls of European origin from four cohorts was investigated. Basic characteristics of the study cohorts are shown in Table 1, and a detailed description of the study population is given in the Supplementary text. In all studies informed consent was obtained, and all studies have been approved by the local ethical committees. For 
Population Phenotype N (%) Ratio Mean age (SD) % Male
The Netherlands Control 386 48 (16) 56AD 295 1.3 34 (9.3) 33AD+asthma 172 (58) 2.2 34 (8.8) 30
German replicate Control 248 39 (13) 36AD 258 1.0 38 (16) 38AD+asthma 83 (32) 3.0 36 (15) 36
Irish replicate Control 578 36 (3.5) 30AD 314 2.1 4.0 (3.8) 64AD+asthma 98 (31) 5.9 7.8 (4.3) 64
Italian replicate Control 446 42 (15) 62AD 208 1.5 8.9 (6.2) 60AD+asthma 38 (18) 11 13 (6.5) 79AD+asthma is a subgroup of the AD cohort. (%) is the percentage of the total AD cohort which is present in the AD+asthma cohort. Ratio, control / case ratio; SD, standard deviaton.
Table 1. Cohort characteristics.
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Chicago, IL, U.S.A.). Power calculations were performed using Stata Software 10.0 (StataCorp LP, College Station, TX, U.S.A.) assumptions in the power analysis (OR of 1.7) were derived from our previous study [7].
Results
Analysis of association of LCE3C_LCE3B-
del with AD To investigate a possible association of AD with the deletion of the LCE3B and LCE3C genes, we genotyped four European case-control cohorts, consisting of adult cases from The Netherlands and Germany and children with AD from Ireland and Italy (see Table 1 and supplementary text for cohort summaries and description). The Dutch, German and Irish cohort were genotyped by using the direct PCR-based method described by De Cid et al. [7]. The Italian cohort was genotyped by analyzing SNP rs4112788, which can be used as a proxy for the deletion as it is in strong linkage disequilibrium with the deletion (r2=0.928 and D’=0.988) [7]. In the different control groups, frequencies of the LCE3C_LCE3B-del allele varied between 59 and 66%. This heterogeneity of the control groups in different ethnic backgrounds was already known from our previous study (de Cid et al., 2009). In the Dutch 
cohort, we found a significantly higher frequency of the LCE3C_LCE3B-del allele in AD patients (66%) compared to healthy controls (59%) (Supplementary Table 1). Further analysis were performed by using logistic regression models in which the wt/wt genotype (homozygous for the undeleted LCE3C_
LCE3B allele) was used as reference-
significant evidence for deviation from Hardy-Weinberg equilibrium in any of the study groups. 
Statistical analysisDescriptive statistics for quantitative values are given as means ± standard deviation (SDs). The observed genotype frequencies were compared with the expected Hardy-Weinberg distribution 
by a χ2-test. Logistic regression models were used to assess the genetic effect of the LCE3C_LCE3B-del allele on AD risk: 
data from allele and genotype-specific models were calculated (for results from allelic models see Supplementary 
Tables 1 and 2). Genotype-specific models were used in the main text of this article, since these models are biologically relevant. The presented data in the main text are derived from models which are unadjusted for age and sex. Unadjusted odds ratios (OR) 
and 95% confidence intervals (95%CI) were calculated using homozygosity for the undeleted allele (wt/wt) as a reference category. Overall values present in the tables are adjusted by population. The sex adjusted analysis for the Italian and Irish cohorts are present in Supplementary Table 3. To test if the cohorts show heterogeneity, the Cochran-Mantel-Haenszel statistics were performed, for del/del compared 
to wt/wt genotypes significant differences were found (P=0.003). Values for total serum IgE levels were only available for the Dutch cohort. 
These values were first log-transformed and comparisons were made using one-way analysis of variance (ANOVA). The statistical analysis was performed using SPSS software 16.0 (SPSS Inc., 
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category. For the Dutch cohort these analyses showed only for the del/del genotype (homozygous for the LCE3C_
LCE3B deletion) a significant association with AD (P=0.022), corresponding odds 
ratio (OR) of 1.71 (95% confidence interval (95%CI): 1.08-2.70). For the del/wt genotype (heterozygous for the 
LCE3C_LCE3B deletion) no association with AD was found (P=0.420) (Table 2). In none of the other cohorts a 
significant association with AD and the del/del genotype was found (Table 2). 
For the del/wt genotype a significant association was found in the German cohort (P=0.018), which was in the opposite direction to the Dutch cohort (OR 0.52, 95%CI: 0.31-0.90). When all cohorts were combined to increase statistical power (Table 2, combined 
power is 1.0), no significant association was detected for either of the two genotypes (P=0.665 and P=0.945). It has to be noted, however, that for the del/
del analysis significant heterogeneity was found between the cohorts. 
Analysis of association of LCE3C_LCE3B-
del with AD + asthma or serum IgESubgroup analysis of the different AD cohorts revealed that the Dutch cohort, 
which showed a significant association, contained a higher percentage of patients with concomitant asthma (58% versus 18-32% in the other cohorts). 
In this cohort, we found a significantly higher frequency of the LCE3C_LCE3B-del allele in the subgroup of AD + asthma patients (66%) compared to healthy controls (59%) (Supplementary Table 2). In contrast, logistic regression models, again using wt/wt as reference, showed no association for the del/wt 
genotype with AD + asthma (P=0.350, OR 1.30, 95%CI: 0.75-2.26 Table 3). For the del/del genotype an association of 
borderline significance was found for AD + asthma (P=0.057, OR 1.71, 95%CI: 
0.98-2.98) (Table 3). Stratification for asthma in the other cohorts, however, 
did not reveal significant associations between AD + asthma and LCE3C_
LCE3B-del (Table 3). For the del/wt genotype an association of borderline 
significance for LCE3C_LCE3B-del and AD + asthma was found in the German cohort (P=0.059), which was in the opposite direction to the Dutch cohort (OR 0.50, 95%CI: 0.24-1.03). Combining all AD + asthma data from the four cohorts, to increase statistical power (see Table 3 combined power is 1.0), 
revealed no significant association of AD + asthma and the LCE3C_LCE3B-del allele (n=2,049, P=0.416 and P=0.103 for the del/wt and del/del genotypes respectively, Table 3).Since a region on 1q21 in close proximity to the LCE cluster was previously reported to be associated with total serum IgE levels [29], we further examined the association of the LCE3C_LCE3B-del allele with total serum IgE levels in our Dutch cohort. As expected, the cases (mean total IgE 115 
kU/L) had significantly higher total IgE serum levels than the controls (mean total IgE 20.7 kU/L, P<0.001). However, ANOVA did not show differences in IgE serum levels for the different genotypes within the patient groups separately and overall (P=0.351, data not shown).
DiscussionOur analysis of the association of 
LCE3C_LCE3B-del and AD showed 
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genetic basis of both AD (estimated PAR of FLG is 13% [20]) and psoriasis (estimated PAR of LCE3C_LCE3B-del is 21% [7]). For AD it is very likely that 
FLG mutations directly affect barrier function of normal skin and contribute to percutaneous antigen priming and the subsequent immunological sequelae leading to overt disease [12]. In the case of psoriasis, the role of the deleted LCE genes is less clear as they are not normally expressed in intact skin, but only induced upon 
activation. Preliminary findings from our lab indicate that this is also true for LCE3C and LCE3E expression in AD (data not shown). It was recently suggested that other genes of the EDC contribute to AD, and clearly there are many other plausible candidate genes in this region, which may on their own or through interaction with FLG lead to barrier dysfunction and AD [21]. As there was no convincing association between LCE3C_LCE3B-del and AD, we did not further investigate a possible interaction with FLG null alleles. We conclude that, despite the shared locus on chromosome 1, the psoriasis-associated deletion of LCE3 genes does not contribute to AD. Our data indicate that the potential roles of skin barrier defects in the pathogenesis of AD and psoriasis are based on distinct genetic causes.
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varying results in the different cohorts. 
A significant positive association was found in the Dutch cohort whereas a weak association in the opposite direction was found for the del/wt genotype  in the German cohort. The apparent association found in the Dutch cohort might be due to population heterogeneity, or could 
be a false-positive finding resulting from small cohort sizes. Because of the high LD between SNP rs4112788 and LCE3C_LCE3B-del (r2=0.928 and D’=0.988), although admittedly not absolute, we decided to include both the LCE3C_LCE3B-del results and the rs4112788 results (Italian data set) in our overall analysis. On the basis of the combined results, we conclude that there is no evidence for association of 
LCE3C_LCE3B-del and AD in individuals of European ancestry. These results underline the importance of replication studies. Similarly, we did not detect an association of LCE3C_LCE3B-del and AD + asthma. It has to be noted, however, that the power to detect an effect for AD + asthma was smaller than for AD alone. For the AD + asthma phenotypes the power of the individual cohorts is rather small (Table 3), however the power of combined analysis both in AD and AD + asthma is 1.0. It should be noted that for a part of the Dutch control cohort, the Irish and Italian control cohorts no information about asthma status was available, which may limit the interpretation of our analysis.Previous studies on FLG and 
LCE3C_LCE3B-del have indicated that polymorphisms and mutations in genes encoding skin barrier proteins make a sizeable contribution to the 
AD not associated with LCE3C_LCE3B-del
84
of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands) for statistical support. This work was supported by research grant 01GS0818 of the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN). Stephan Weidinger was supported by a grant of the University Hospital Rechts der Isar, Technische Universität München (C49-08), a grant from the Wilhelm-Vaillant-Stiftung, and a Heisenberg fellowship (DFG WE 2678/4-1) from the German Research Council. Dirkje Postma was supported by grants from the Dutch Asthma Foundation. The Irish collection has been established with funding from the Children’s Medical and Research Foundation, Our Lady’s Children’s Hospital Crumlin. Natalija Novak was supported by grants from the German research council NO454/5-2 and SFB704 TPA4.
Supplementary Materials and 
Methods
DNA samples
Dutch samples Samples from 295 AD patients (32 from Nijmegen, 263 from Groningen) were recruited from individuals referred to the out-patient clinic of the Department of Dermatology of the Radboud University Medical Centre by their general practitioner or dermatologist. AD was diagnosed 
using the Hanifin criteria. The 263 AD samples from Groningen were recruited from asthma and rhinitis trios. Out of these trios patients with AD, diagnosed 
by using Hanfin criteria, were selected. 
The rhinitis and asthma patients were recruited through media appeals and among out-patients in the departments of Allergology and Pulmonology of the University Medical Center Groningen and local hospitals. The control samples from the Nijmegen cohort (N=272) have been described previously [8]. Asthma status was not available for these subjects. Control samples from Groningen (N=114) were derived from a familial study of asthma [30], in which the unaffected probands  served as controls. None of the Groningen controls had asthma or AD. The mean age of the combined control groups was 48 (±16) years, with a male:female ratio of 56:44. All control patients were from native European Dutch origin. Blood was stored at -80°C and genomic DNA was isolated by standard procedures. Permission for these studies was obtained from the medical ethics committee of the University Medical 
Center Groningen and “Comissie Mensgebonden Onderzoek Arnhem-
Nijmegen”.
German samples Samples from 258 AD patients were recruited in the out-patient Department of Dermatology and Allergy of the Technische Universität München. The patients were diagnosed on the basis of a skin examination by experienced 
dermatologists using the UK Working Party diagnostic criteria for AD. The mean age of the AD population was 38 (±16) years, with a male:female ratio of 38:62. 32% of the AD patients had a concomitant diagnosis of asthma. 248 control individuals matched for age and sex were selected from the 
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Fatebenefratelli Hospital. A consensus diagnosis of the disease was assessed either by an expert dermatologist or by a pediatric allergologist. All patients 
fulfilled the diagnostic criteria of the 
UK Working Party. A written consent was obtained for all the patients or their parents. The mean age of the AD population was 8.9 (±6.2) years, with a male:female ratio of 60:40. 18% of the AD patients had a concomitant diagnosis of asthma. The 446 controls had no AD at the time of recruitment. The average age of the controls was 42 (±15) years, with a male:female ratio of 62:38. All of them were healthy blood donors. Asthma status was not available from these subjects. Permission for these studies was obtained from the local the 
medical ethics committee “Policlinico 
Tor Vergata”. 
population-based cross-sectional 
KORA S4 (Cooperative Health Research in the Region of Augsburg) survey [31]. None of the control group had asthma. Permission for these studies 
was obtained from the “Bayerische 
Landesärtzekammer” Munich and the ethics committee of the University of Bonn.
Irish samples Samples from 314 AD patients were recruited from individuals attending a secondary/tertiary AD center (Our Lady’s Children’s Hospital, Dublin, Ireland). All patients were assessed by an experienced pediatric dermatologist 
(ADI, GMO’R) and meet UK Working Party criteria. The mean age of the AD population was 4.0 (±3.8) years, with a male:female ratio of 64:36. 31% of the AD patients had a concomitant diagnosis of asthma. The 578 controls samples were collected from healthy Irish blood donors (the Trinity DNA Biobank). The mean age of the control group was 36 (±3.5) years, with a male:female ratio of 30:70. Asthma status was not available from these subjects. The DNA from the controls was extracted using the Autopure PureGene chemistry system. Permission for these studies was obtained from the Research Ethics Committees of Our Lady’s Children’s Hospital Crumlin (cases) and Trinity College Dublin (Trinity Biobank controls). 
Italian samplesSamples from 208 AD patients were recruited from individuals referred to the Operative Unit of Immunoallergology of San Pietro 
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Population Phenotype
LCE3C_
LCE3B-del
LCE3C_
LCE3B OR 
(95% CI) P value power
Alleles (%) Alleles (%)The Netherlands Control 458 (59) 314 (41) 1.36 (1.09-1.70) 0.007 0.82AD 392 (66) 198 (34)German replicate Control 311 (63) 185 (37) 0.91 (0.71-1.17) 0.465 0.70AD 312 (60) 204 (40)Irish replicate Control 762 (66) 394 (34) 0.81 (0.67-1.00) 0.045 0.89AD 384 (67) 244 (33)Italian replicate Control 523 (59) 369 (41) 1.04 (0.82-1.32) 0.736 0.75AD 248 (68) 168 (32)All* Control 2,054 (62) 1262 (38) 1.00 (0.90-1.13) 0.883 1.0AD 1,336 (65) 814 (35)
Supplementary Table 1. No association of LCE3C_LCE3B-del with AD in 2,733 subjects of 
four European populations.
LCE3C_LCE3B-del,  LCE3C_LCE3B deleted allele; OR, Odds ratio; 95%CI, 95% confidence interval; AD, atopic dermatitis. The Italian cohort was genotyped by analyzing SNP rs4112788, in all other cohorts the LCE3B/C 
deletion was directly analyzed. *In the combination of all cohorts significant heterogeneity was detected.  
Population Phenotype
LCE3C_
LCE3B-del 
LCE3C_
LCE3B OR 
(95% CI) P value power
Alleles (%) Alleles (%)The Netherlands Control 458 (59) 314 (41) 1.31 (1.02-1.73) 0.035 0.67AD + asthma 227 (66) 117 (34)German replicate Control 311 (63) 185 (37) 0.90 (0.62-1.29) 0.572 0.39AD + asthma 100 (60) 66 (40)Irish replicate Control 762 (66) 394 (34) 1.04 (0.76-1.43) 0.801 0.5AD + asthma 131 (67) 65 (33)Italian replicate Control 523 (59) 369 (41) 1.53 (0.93-2.53) 0.097 0.21AD + asthma 52 (68) 24 (32)All Control 2,054 (62) 1262 (38) 1.17 (0.99-1.38) 0.074 0.98AD + asthma 510 (65) 272 (35)
Supplementary Table 2. No association of LCE3C_LCE3B-del with AD+asthma in 2,049 
subjects of  four European populations.
LCE3C_LCE3B-del,  LCE3C_LCE3B deleted allele; OR, Odds ratio; 95%CI, 95% confidence interval; AD, atopic dermatitis. The Italian cohort was genotyped by analyzing SNP rs4112788, in all other cohorts the LCE3B/C deletion was directly analyzed.
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Population Phenotype
LCE3C_LCE3B del/wt del/del
del/del wt/del wt/wt OR (95% CI)
P 
value
OR 
(95% CI)
P 
valueIrish replicateN=892 Control 256 (0.44) 250 (0.43) 72 (0.13) 0.77 (0.49-1.22) 0.268 0.64 (0.40-1.03) 0.064AD 118 (0.38) 148 (0.47) 48 (0.15)Italian replicateN=654 Control 156 (0.35) 211 (0.47) 79 (0.18) 1.1  (0.76-1.59) 0.629 0.84 (0.50-1.41) 0.512AD 71 (0.34) 106 (0.51) 31 (0.15)
OR 95%CI, odds ratio and 95% confidence interval for del/wt and del/del LCE3C_LCE3B genotypes and AD obtained by logistic regression using wt/wt as a reference; adjusted for sex.
Supplementary Table 3.  No association of LCE3C_LCE3B-del with AD in Italian and Irish cohorts 
in analysis adjusted for sex.
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Two recent studies, in a Spanish and a Chinese population, point to an association between rheumatoid arthritis (RA) risk and the deletion of the Late Cornified Envelope (LCE) 3B and 3C genes (LCE3C_LCE3B-del), a known risk factor for psoriasis. We aimed to replicate these studies in a large Dutch cohort and to perform a meta-analysis of the combined data sets.  A total of 1,039 Dutch RA cases and 759 controls were genotyped for LCE3C_LCE3B-del. Association analysis was performed for the complete cohort and after stratification for the serologic markers anti-cyclic citrullinated peptide and rheumatoid factor. A meta-analysis was performed combining our data with the Spanish and Chinese datasets, resulting in an analysis that includes 2,466 RA cases and 2,438 controls. In the Dutch cohort we did not observe a significant association of LCE3C_LCE3B-del (p=0.093) with RA risk. A stratified analysis for the serologic positive and negative group did not show an association between the genetic variant and disease risk, either. The meta-analysis, however, confirmed a significant association (p<0.0001, OR=1.31, 95% confidence interval 1.16-1.47). Our meta-analysis confirms the association of the LCE3 deletion with RA, suggesting that LCE3C_LCE3B-del is a common risk factor for (auto)immune diseases.
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IntroductionRheumatoid arthritis (RA) is a chronic 
inflammatory joint disease affecting approximately 1% of the population. Although the causes of the disease are largely unknown, both genetic and environmental factors seem to contribute. Thus far, genome-wide association studies have revealed more than 30 risk loci explaining 16% of the disease variance.The copy number of DNA segments in the human genome varies in normal individuals and most likely this 
diversity is responsible for a significant proportion of phenotypic variation. Not much is known about the role of copy number variation (CNV) in the etiology of RA, but relevance of these common genetic variants is expected. A small number of candidate gene studies have indicated that CNVs in Chemokine ligand 3-like 1 (CCL3L1), Fc gamma receptor 3B (FCGR3B) and pre-B lymphocyte 1 (VPREB1) are associated with RA disease susceptibility [1-3]. Using a genome-wide approach the Welcome Trust Case Control Consortium (WTCCC) reported that CNVs in the 
HLA region are significantly associated with the development of RA [4]. More recently using the WTCCC dataset, 11 rare copy number variable regions 
associated with RA were identified [5]. These regions included genes that could be directly linked to the development of RA. Another potential candidate CNV is the deletion of two genes of the Late 
Cornified Envelope gene cluster, LCE3B and LCE3C (LCE3C_LCE3B-del), which was recently found associated with psoriasis in several populations [6], 
as was rs4112788, a single nucleotide polymorphism (SNP) in high linkage disequilibrium with the deletion [7]. The observation that the risk of RA is increased in the offspring of individuals affected with other autoimmune disorders, including psoriasis, prompted Docampo and colleagues [8] to investigate the association between the LCE3C_LCE3B-del and RA in two independent Spanish cohorts. In their study an association was found between RA and homozygosity for LCE3C_LCE3B-del. Recently it has been demonstrated that the deletion is also associated with RA susceptibility in a non-Caucasian (Chinese-Han) population [9]. However, 
they were unable to confirm the Spanish results that the association between 
LCE3C_LCE3B-del and RA risk was restricted to anti-cyclic citrullinated peptide (anti-CCP)-positive patients. We sought to replicate these studies in a similarly powered Dutch cohort. A total of 1,039 RA cases and 759 controls were genotyped for LCE3C_LCE3B-del, and we investigated whether this genetic variant is associated with RA. Additionally, we combined the Spanish, Chinese and Dutch data in a meta-analysis.  
Materials and Methods
Ethics statementThe ethical committee of the Radboud University Nijmegen Medical Centre 
(“Commissie Mensgebonden Onderzoek (CMO) Regio Arnhem Nijmegen) approved the study (CMO number 2004/014); all patients and controls gave written informed consent.
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Statistical analysisDescriptive statistics for quantitative values are given as mean ± standard deviation (SD). Both variants showed no deviations from Hardy-Weinberg equilibrium for either patients or controls. Co-dominant and recessive logistic regression models were used to assess the genetic effect of 
LCE3C_LCE3B-del on RA risk, using homozygosity for the allele without deletion as a reference category. These models were similar to those used in the previous studies [8, 9]. The statistical analyses were performed using SPSS software 16.0 (SPSS Inc., Chicago, IL, U.S.A.). A meta-analysis was performed in Review Manager 5 (Review Manager (RevMan) Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008) using the aggregated data from this study, Docampo et al. [8] and Lu 
et al. [9]. Heterogeneity of odds ratios (ORs) among cohorts was calculated using the Breslow-Day method, and pooled ORs were calculated under a 
fixed effects model (Mantel-Haenszel meta-analysis). A power calculation was performed using the Genetic Power Calculator [14] input values were derived from Docampo et al. [8] 
(significance level 0.05, OR=1.45, allele frequency 0.62, recessive model). 
ResultsTable 2 provides the results of the association analysis for the 
LCE3C_LCE3B-del and RA risk in the Dutch cohort. There were 1,039 RA patients and 779 controls successfully genotyped for LCE3C_LCE3B-del. The 
LCE3C_LCE3B-del and the linked SNP 
DNA samplesAll patients met the American College of Rheumatology 1987 revised criteria for RA. The patients were part of the Dutch Rheumatoid Arthritis Monitoring registry (www.dreamregistry.nl) (n=1,039) [10, 11]. The controls (n=779) were participating in the Nijmegen Biomedical Study [12]. For cohort characteristics see Table 1.
GenotypingDNA was extracted from blood using salt extraction. For the LCE3C_LCE3B-del genotyping a polymerase chain reaction was performed as earlier described [13]. 112 samples were genotyped in duplicate; error rate was 2.9% and assay failure rate was 0.3%. To validate the LCE3C_LCE3B-del genotype, we also genotyped the linked SNP rs4112788, which was performed using a Taqman® SNP genotyping assay (assay ID C__31910050_10) according to manufacturer’s recommendations (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). Five percent of the samples were analyzed in duplicate; all genotypes were concordant. The assay failure rate was 2.6%.
RA 
patients Controlsnumber 1,043 779gender (% female) 693 (66.4) 422 (54.2)age# 55.0 ± 12.7 56.3 ± 16.8age at disease onset* 45.3 ± 13.3RF positive% 736 (77.3)anti-CCP positive& 286 (63.4)Numbers are depicted as n(%) or mean ± standard deviation. Data available for #686, *717, %952, &451 patients. RA: rheumatoid arthritis; CCP: anti-cyclic citrullinated peptide; RF: rheumatoid factor.
Table 1. Demographics of the RA cohort.
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All All CCP- All CCP+ All RF- All RF+
Patientsno del/no del 149 (14.3) 18 (10.9) 43 (15.0) 24 (11.1) 112 (15.2)del/no del 460 (44.3) 85 (51.5) 130 (45.5) 96 (44.4) 326 (44.3)del/del 430 (41.4) 62 (37.6) 113 (39.5) 96 (44.4) 298 (40.5)
Controlsno del/no del 118 (15.1) 118 (15.1) 118 (15.1) 118 (15.1) 118 (15.1)del/no del 369 (47.4) 369 (47.4) 369 (47.4) 369 (47.4) 369 (47.4)del/del 292 (37.5) 292 (37.5) 292 (37.5) 292 (37.5) 292 (37.5)
Recessive P 0.093 0.982 0.546 0.064 0.231OR (95% CI) 1.18 (0.97-1.43) 1.00 (0.71-1.42) 1.09 (0.83-1.44) 1.33 (0.98-1.81) 1.14 (0.92-1.40)Codominant P 0.242 0.339 0.822 0.116 0.436
OR (95% CI) 0.99 (0.75-1.30) (del/no del) 1.51 (0.87-2.62) (del/no del) 0.97 (0.65-1.44) (del/no del) 1.28 (0.78-2.09) (del/no del) 0.93 (0.69-1.26) (del/no del)1.17 (0.88-1.55) (del/del) 1.39 (0.79-2.45) (del/del) 1.06 (0.70-1.60) (del/del) 1.62 (0.99-2.65) (del/del) 1.08 (0.79-1.46) (del/del)
Table 2. No association of the LCE3C_LCE3B deletion with RA in the Dutch cohort.
del: deletion of LCE3C and LCE3B genes; CCP-: patients negative for anti cyclic citrullinated peptide; CCP+: patients positive for anti-cyclic citrullinated peptide; RF-: patients negative for rheumatoid factor; RF+ patients 
positive for rheumatoid factor. OR: odds ratio; 95% CI: 95% confidence intervalrs4112788 were in near-perfect linkage disequilibrium (LD) with each other (r2= 0.928 and D’=0.984), confirming that LCE3C_LCE3B-del was genotyped accurately. 
In the Dutch cohort, we did not find evidence for an association between 
LCE3C_LCE3B-del and RA, at the genotypic (p=0.093, OR 1.18, 95% 
confidence interval (95%CI) 0.97-1.43 (Table 2)) nor the allelic level (p=0.147, OR 1.11 95%CI: 0.97-1.27 (data not shown)). It has been hypothesized that the LCE3C_LCE3B-del might result in a defective skin barrier repair leading to an abnormal or increased exposure to environmental antigens. This could lead to an earlier age of disease onset in carriers of LCE3C_LCE3B-del compared to non-carriers. An analysis 
for age of onset, however, did not show association with the LCE3C_LCE3B-del status (p=0.25, t-test).Docampo et al. [8] demonstrated that LCE3C_LCE3B-del showed the strongest association with RA in anti-CCP and rheumatoid factor (RF) positive patients. In the study of Lu et 
al.  [9] no associations were found in the different RA subsets, these analyses were corrected for age and gender. We performed association analyses of the anti-CCP and RF patient subsets separately, for those patients with 
information available. We did not find an association between LCE3C_LCE3B-del and RA in any of the subsets analyzed (Table 2).We performed an overall meta-analysis, using a recessive logistic regression 
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statistically significant association of the deletion with RA. This suggests that a larger population is necessary to prove whether the deletion is associated with 
RA. The contradictory findings from this study and the previous RA studies [8, 9] could also be caused by differences in the study population, e.g. disease phenotype or ethnicity. In addition, there is a discrepancy between the allele frequency of the deletion in the controls from Spain (55%) and China (54%) compared to The Netherlands (61%). This heterogeneity of LCE3C_LCE3B-del allele frequency in control groups from different ethnic backgrounds was already known from previous studies [6, 16]. Indeed, a recent meta-analysis 
confirming an association between 
LCE3C_LCE3B-del and psoriatic arthritis showed that the OR of the Spanish population was much higher than observed in an Italian population (1.66 versus 1.23) [16]. In our meta-analysis we used a recessive 
model, because this model fitted the LCE data in the psoriasis study best, based on the Akaike Information Criteria [13] which is in line with the two previous studies on LCE3 in patients with RA [8, 9]. Although we could not identify an association between the deletion and RA in the Dutch cohort, addition of the data resulted in lower p-values than without 
this dataset, showing a significant contribution of the Dutch population to the overall results. The addition of our Dutch samples leads to a lower OR and a smaller CI than previously reported. The 
other two studies may have significantly overestimated the magnitude of the odds ratio, the so-called winner’s curse [17]. Due to publication bias it 
model unadjusted for age and gender, on the combined data from this study and the studies of Docampo et al. [8] and Lu et al. [9] (Table 3). Despite the 
lack of significance of the association in the Dutch cohort, in the meta-analysis 
a significant association between 
LCE3C_LCE3B-del and RA was found (p<0.0001, OR 1.31 95%CI: 1.16-1.47). Next to the overall analysis, we performed also a meta-analysis on the anti-CCP and RF subgroups combining the Spanish, Chinese and our data (Table 3), unfortunately not for all patients these data was available. In this subgroup analysis all previously found associations [8] between LCE3C_LCE3B-
del and RA were significant, with the association apparently strongest in RF-positive subset of patients (p=0.0007 OR 1.27 95%CI: 1.11-1.45) (Table 3).
Discussion Although a previously reported association of the LCE3C_LCE3B-del 
with RA risk did not reach significance in our Dutch cohort, a meta-analysis combining our data and the previously reported Spanish and Chinese data [8, 
9] confirmed the association of LCE3C_
LCE3B-del with RA. Our study had a power of over 95% 
to find an association, although we based this calculation on the previously found OR of 1.45. When we recalculate the power using the OR of the meta-analysis (OR=1.31), the power of our study drops to 73%. A study population of 1,256 samples will be needed to reach 80% power. The ORs observed in the Dutch population are in the same direction as seen in the previous studies [8, 9] and our meta-analysis showed a 
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might be possible that some studies investigating the same subject have not been published, this information will be 
important to confirm the association between RA and the deletion as shown in this study. In our subgroup analysis, we observed the strongest association in the RF positive patients. Larger datasets will be necessary to clarify whether the observed association is patient subset 
specific. In contrast to the results from our meta-analysis, genome-wide CNV analyses using the WTCCC RA dataset did not identify association with the LCE3 region [4, 5]. One study only assessed rare CNVs (population frequency <5%) which excludes the LCE3C_LCE3B-del [5]. The other study included a probe covering the region that passed QC in their analysis (probe CNVR358.1, chr1:150,822,234-150,856,715 (UCSC genome browser hg18) [4]). It might be possible that the region is associated with RA in the WTCCC dataset at lower 
significance level than their genome-
wide significance threshold. Until now, LCE3C_LCE3B-del was found to be associated with psoriasis, psoriatic arthritis and RA in several populations [6-9, 13, 16, 18, 19], whereas no association was found for atopic dermatitis [15]. Also in one study an association with systemic lupus erythematosus was found [9], implying that LCE3C_LCE3B-del may be a common risk factor for (auto)immune diseases. The function of the LCE genes has only been studied in skin in general [20, 21] and in relation to psoriasis [22]. From these studies it is known that the LCE proteins are likely to be incorporated 
in the cornified cell envelope, which is 
an important structure in the barrier function of skin. When comparing normal and psoriasis skin, the genes of the LCE1, 2, 5 and 6 groups are mainly expressed in normal skin, whereas the LCE3 genes are predominantly expressed in psoriasis skin. Moreover, upon barrier disruption of normal skin the LCE1, 2, 5 and 6 gene-groups are downregulated, while the expression of the LCE3 genes is upregulated. Altogether, these data imply a role in barrier repair for the LCE3 proteins and a role in barrier maintenance for the other LCEs. As hypothesized by Docampo et al. (Docampo et al., 2010), the absence of LCE3B and LCE3C could compromise barrier function of the epithelia and possibly facilitate the entrance of environmental antigens or pathogens. Since the LCE genes are mainly expressed in skin and oral epithelia, these would be relevant tissues that could facilitate the entrance of antigens or pathogens, like the Epstein-Barr virus and the cytomegalovirus, thereby triggering RA. We reasoned that if this would be the case patients with 
LCE3C_LCE3B-del might be exposed more readily to common antigens and therefore would have an earlier age of onset due to easy access of pathogens/triggers through the skin. However, we did not observe such an association between the genotype and age of RA onset. Our meta-analysis showed that the 
LCE3B and LCE3C deletion is associated with RA, though the contribution of our large Dutch sample is small. Therefore it will be necessary to test even larger patient cohorts to shed more light on the possible association of the 
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deletion in specific RA patient subsets. An interesting next step would be to perform functional studies to unravel the mechanisms underlying this association.
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The late cornified envelope (LCE) genes are a group of highly homologous genes located on chromosome 1 in the epidermal differentiation complex, which is a 1.6 Mb region on the human genome containing a large number of genes involved in epidermal differentiation. The epidermal differentiation complex contains a total of 18 LCE genes, divided over 6 groups [1]. Two genes of the LCE3 group, LCE3B and LCE3C, are subject to copy number variation due to a commonly deleted segment of 32 kb [2]. Individuals can have copy number 0 (homozygous for the deletion), 1 (heterozygous for the deletion) or 2 (homozygous for the wild type ancestral haplotype). Deletion of 
LCE3B and LCE3C (LCE3C_LCE3B-del) is a strong and widely replicated risk factor for psoriasis [2-5]. Recent studies indicate that LCE3C_LCE3B-del may also be a risk factor for other (auto)immune diseases [6-8], but it is not associated with atopic dermatitis [9]. LCE proteins are expressed in a limited number of epithelia [1, 10] and we have recently shown that the genes of the 
LCE3 group, including the psoriasis-associated LCE3B and LCE3C genes, show distinct expression patterns under 
inflammatory conditions or upon skin 
injury [2, 11]. Out of all the identified psoriasis-associated risk factors, only 
LCE3C_LCE3B-del and copy number 
variation in the β-defensin cluster [12] affect expression of putative skin barrier proteins. Although the observed odds ratios (ORs) in various cohorts are smaller than those published for 
HLA-Cw6 (current notation HLA-C*06) [13, 14], the strongest known psoriasis risk factor, LCE3C_LCE3B-del has a large 
population attributable risk (23% [2]). 
Both the significant contribution to the genetic basis of psoriasis and its plausible biological function, render 
LCE3C_LCE3B-del an important risk factor that is amenable to mechanistic studies. 
In 1877, Heinrich Koebner described the appearance of psoriatic lesions in uninvolved skin of psoriatic patients as a consequence of trauma. Now, it is known that patients with other dermatological conditions can koebnerize as well [15]. Several causes for this phenomenon are known, like trauma, allergic or drug reactions and therapeutics, although the pathogenesis is not well understood [15]. In previous studies it was shown that on average 25% of psoriasis patients will koebnerize on external stimulation of the skin [15]. We hypothesized that the deletion of the LCE3B and LCE3C genes could lead to an inferior barrier function or to an impaired repair function following barrier disruption. This would make the skin more susceptible to penetration by microbial or other environmental molecules, which could trigger innate or adaptive immune responses. Based 
on our hypothesis that the Koebner reaction may be caused by breaching 
the skin barrier and/or insufficient barrier repair, we investigated a 
possible association of the Koebner phenomenon with LCE3C_LCE3B-del. In a Dutch cohort of psoriasis patients that were previously typed for LCE3C_
LCE3B-del (by PCR [2]) and HLA-C*06:02 status (by PCR [2]) we assessed their propensity to koebnerize following skin 
injury. The “Commissie mensgebonden 
onderzoek Arnhem-Nijmegen” 
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95% confidence interval (95%CI): 0.64 - 1.74). Also for HLA-C*06 we did not observe an association with the 
Koebner phenomenon (P=0.310, OR 1.43, 95%CI: 0.72 – 2.82). This is in contrast with a previously reported 
association between Koebner effect and 
HLA-C*06 in Icelandic psoriasis patients [16].  This discrepancy may have several causes such as the study design (family-based versus population-based), ethnic background, inaccurate reporting because of self-reported data or lower statistical power of our study (66%, input values were derived from Gudjonsson et al. [16] significance level 0.05, OR 2.3, allele frequency 0.28, dominant model). 
Our results suggest that the Koebner phenomenon in psoriasis is unlikely to be dependent on the LCE3B/C genotype. Therefore, the biological role of LCE3B and LCE3C deletion in development and/or maintenance of psoriasis remains to be explained. 
approved for this study. Patients/parents of the patients gave their informed consent. The investigations were conducted according to the Declaration of Helsinki principles. Adult patients were approached via written questionnaires. In the case of juvenile psoriasis patients we approached the parents by telephone. Both the patients/parents and the interviewers were unaware of the LCE3C_LCE3B-del and HLA-C*06 status of the patients. We assessed, on a 4-point scale, how often a psoriasis plaque appeared after skin damage of their non-involved skin: never, rarely, often or nearly always. The individuals that responded with often or nearly always were considered 
as Koebner positive patients and 
the others as Koebner negative. We approached 259 patients of whom 192 responded (response rate 74%). Of these, 46 patients (24%) were 
Koebner positive. This percentage is in line with the previously reported 
data [15]. We found similar figures for adults (22%, n=24) and children (27%, n=22). Table 1 shows an equal distribution over the three LCE3B/C 
genotypes for the Koebner positive and negative group. Logistic regression analysis demonstrates that there is no association between LCE3C_LCE3B-
del and the Koebner phenomenon in psoriasis patients (P=0.835, OR 1.06, 
LCE3B/C 
copy 
number
genotype Koebner positive
Koebner 
negative P OR (95% CI)0 del/del 20 (43%) 66 (45%) 0.835 1.06 (0.64 – 1.74)1 del/wt 21 (46%) 65 (45%)2 wt/wt  5  (11%) 15 (10%)
Table 1. No association between LCE3B/C copy number and koebnerization in psoriasis 
patients.
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PSORIASIS RISK GENES OF THE LATE CORNIFIED ENVELOPE 3 (LCE3) GROUP ARE DISTINCTLY EXPRESSED COMPARED TO GENES OF OTHER LCE GROUPS
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Deletion of the late cornified envelope (LCE) genes LCE3B and LCE3C has recently been identified as a risk factor for psoriasis. Here we investigated the expression of 16 LCE genes of the LCE groups 1, 2, 3, 5 and 6 in vivo and 
in vitro. Using qPCR, we found that moderate to high LCE expression was largely confined to skin and a few oropharyngeal tissues. Genes of the LCE3 group showed increased expression in lesional psoriatic epidermis, and were induced following superficial injury of normal skin. In contrast, expression of the members of other 
LCE groups was downregulated under these conditions. Immunohistochemistry and immunoelectron microscopy showed that LCE2 protein expression was restricted to the uppermost granular layer and the stratum corneum. Stimulation of in vitro reconstructed skin by several psoriasis-associated cytokines resulted in induction of LCE3 members. Our data suggest that LCE proteins of groups 1, 2, 5 and 6 are involved in normal skin barrier function, whereas LCE3 genes encode proteins involved in barrier repair upon injury or inflammation. These findings may provide clues to the mechanistic role of LCE3B/C deletion in psoriasis.
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Introduction
Psoriasis is a common inflammatory skin disease caused by both genetic and environmental factors [1-3]. In the past years, a substantial number of psoriasis 
susceptibility loci have been identified that harbor genes involved in adaptive and innate immunity, such as HLA-Cw6, 
IL12B, IL23R, TNFAIP3, TNIP1 and the 
β-defensins [3]. Recently, a deletion 
of two members of the Late Cornified Envelope genes (LCE3B and LCE3C) 
was identified as the first psoriasis risk factor with a putative role in skin barrier function [4]. In support of 
this finding, an independent genome-wide association study (GWAS) of a large Chinese cohort found that single nucleotide polymorphisms (SNPs) in strong linkage disequilibrium with the LCE3B/C deletion are associated with psoriasis [5]. This association has been widely replicated in cohorts from European and Asian origin [6, 7].The LCE genes are located on chromosome 1q21 in a region called the epidermal differentiation complex (EDC) [8]. The EDC is enriched for genes expressed during epidermal differentiation, including loricrin, 
involucrin, filaggrin, the small proline rich protein genes and the LCE genes [9, 10]. With a total of 18 members, the LCE gene family is divided into six groups, 
LCE1 to LCE6, based on similarities of amino acid sequences, genomic organization and expression patterns [9].The role of the LCE proteins in epidermal biology has, so far, not been extensively studied. In mice, it was found that members of the Lce1 group are expressed rather late in 
epithelial development, where they are 
incorporated into the cornified envelope via cross-linking by transglutaminases [11]. Other investigators used quantitative polymerase chain reaction (qPCR) to show that the human LCE1 and LCE2 genes are mainly expressed in skin, whereas LCE4 and LCE5 gene expression is largely undetectable in the human tissues they examined [9]. 
LCE3 gene expression was found absent or variable at low levels in internal and external epithelia, although it should be noted that at that time the LCE3B/C deletion was not known, which may have affected these results. Studies in cultured keratinocytes showed that 
LCE2 expression is induced by Ca2+, while UVB irradiation was found to induce the expression of LCE3E and members of the LCE1 and LCE2 group [9].In our previous study, based on the observed LCE3C induction in lesional psoriatic skin and injured skin, we hypothesized a role for the LCE3 genes in skin barrier repair [4]. Here we sought to extend these studies, in 
order to find a possible clue for the mechanistic relationship between the LCE3B/C deletion and psoriasis. We investigated the expression of 16 
LCE genes of the LCE groups 1, 2, 3, 5 and 6 in vivo and in vitro at the mRNA level as well as the protein level. Our results show that the members of the 
LCE3 group are differently expressed compared to the other LCE groups, suggesting non-redundant functions that may be relevant for psoriasis.
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lowered to allow air exposure to induce terminal differentiation. For analysis of the LCE expression during normal skin development, the constructs were cultured air-exposed for the indicated time periods. This cultured epidermis is negative for psoriasis-associated 
proteins, such as cytokeratin16, elafin and hBD-2 [12]. At this point, a mixture 
of proinflammatory cytokines (10 ng/ 
mL IL-1α, 5 ng/mL TNF-α and 5 ng/ mL IL-6) or Th17 cytokines (100 ng/mL IL-17 or 100 ng/mL IL-22) was added for 72 h (N=5 per group) to induce 
cytokine-specific gene expression. Nine different healthy donors of human keratinocytes were used.
Quantitative real-time PCREpidermal sheets from skin biopsies or skin constructs were separated from the underlying dermis as described previously [13]. The extracted and DNAse I treated RNAs from these 
epidermal sheets were used for first-strand cDNA synthesis using iScript cDNA synthesis kit (Bio-rad, Hercules, 
CA) using 1 μg RNA as input [14]. The reverse transcriptase reaction products 
were used for qPCR amplification of genes of interest using the MyiQTM Single-Color Real-Time Detection 
System for quantification (Biorad, Richmond, CA) and melting curve analysis, as described previously [15]. Expression of target genes was normalized to the expression of the house keeping gene human ribosomal phosphoprotein P0 (RPLP0) in the same sample. For the analysis of LCE1A, 
LCE1C, LCE1D&E and the complete LCE2 group, primers were used as described previously [9]. Primers for LCE1B, 
Materials and Methods
Human tissuesPatients and healthy volunteers (N=6 for both groups) were recruited by the Dermatology Clinic of the Radboud University Nijmegen Medical Centre. All diagnoses were made by a dermatologist. The study was approved by the local medical ethical committee 
“Commissie Mensgebonden Onderzoek 
Arnhem-Nijmegen” and conducted according to the Declaration of Helsinki principles. Written informed consent was obtained. Patients had moderate to severe plaque-type psoriasis. Biopsies were taken from lesional and non-lesional skin (N=4). For stratum corneum removal by tape-stripping of healthy controls (N=5), two areas on the lower back measuring 3x2 cm each were tape-stripped until the surface glistened after repeated (20-40 times) application and removal of adhesive tape. At 24 and 48 h after tape stripping, 3-mm biopsies were taken from the tape-stripped area and from healthy skin for both RNA isolation and histology, respectively. Archival autopsy material from a large number of normal human tissues was obtained from the Department of Pathology (Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands).
Three-dimensional reconstructed skinReconstructed skin was generated as described previously [12]. In brief, de-epidermized human dermis, 0.8 mm thick and 8 mm in diameter, was used as a scaffold for keratinocytes. Constructs were cultured submerged for three days in tissue culture inserts in a 24-well plate, and subsequently the medium level was 
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to expression of the same gene in the control condition (Figure 4).
LCE2 antibody productionA human pan-LCE2 antibody was raised in rabbits against the following synthetic peptide: RPRLFHRRRHQSPD. This peptide perfectly matches LCE2B, LCE2C and LCE2D and differs one amino acid for LCE2A (4th R=H in LCE2A). The antiserum was positively tested on recombinant human LCE2A from bacterial lysates on Western blot (see Supplementary Figure 1).
Immunohistochemistry
Tissues or skin constructs were fixed in a buffered 4% formalin solution (Baker Mallinckrodt, Deventer, The Netherlands) for 4 h and subsequently 
embedded in paraffin. Material was 
cut in 6 μm sections and subsequently processed for staining using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA) as previously described 
LCE1F, LCE3A, LCE3C, LCE3D, LCE3E, 
LCE5A and LCE6A were designed and PCR products were sequenced to check 
primer specificity. Primers (Biolegio, Nijmegen, the Netherlands) for qPCR 
were only accepted if their efficiency was 100 ± 10 %. For LCE3B and LCE4A none of the designed primer pairs passed this criterium and therefore these genes were not analyzed in this 
study. Primer sequences and efficiency are shown in Table 1. Because the LCE primer pairs were not intron-spanning, each primer pair was also tested with input in which, during cDNA synthesis, no reverse-transcriptase had been 
used. No specific product was found in any of these reactions. Relative mRNA expression levels were calculated with 
the ΔΔ-Ct method [16]. For graphic representation of mRNA data, all in 
vivo data are plotted relative to LCE1A expression in normal (Figures 1, 2A and 3A) or uninvolved skin (Figure 2B). The in vitro data are plotted relative 
Gene Forward primer 5’-3’ Reverse primer 5’-3’ E*LCE1A# TGCAAGAGTGGCTGAGATGC AGACAACACAGTTGGTGTCAGG 2.18LCE1B TGAGCCTAGAAGAACACAA GAAGGAGAAGGAAGACGG 1.94LCE1C# GAATCCAGGACCGCAAACTG TGGACCTGTGAGCCTCTCAG 2.03LCE1D&E# TGAATAGCTGAGAGGTTCCAGC CAGCCATGGATCTGCAGAAG 2.06LCE1F CCACACCGAAGTGCC GCTGCAGCAGGAAGAG 1.83LCE2A# GGACCTGTCCCAGAGTGATG GATCCAGGATGGGCTCTTG 2.10LCE2B# GGTTGACTAAACTCTGCCAGG CACTGGGGCAGGCATTTA 2.04LCE2C# CTTGGGACTGAATGGCCAAG GACTTGCAATTGGGGTGTTAC 1.91LCE2D# CTGCAGAAGAGCTCTGGTACTG CTCCATCAAGCACAAAGTTCTG 2.15LCE3A GAGTCACCACAGATGCC CTTGCTGACCACTTCCC 2.02LCE3C CTGAGCCACCACAGGCACTT TGTTTCCTCCAAAGATCACTTGTC 2.03LCE3D CCCCATCTTGATGCATGAG TGTGACATCCTGGACATCAG 2.07LCE3E CTGATGCTGAGACAAGCGATCTT GATCCCCCACAGGAAAACCT 2.20LCE5A CCCTCTTTATCCTGCCC ACAACACCTAGTTCTCCAA 1.87LCE6A AGAAGCAGCAATCTTGGA CCTTTGGGAACTGGAATG 2.05
Table 1. Primers for qPCR.
*Efficiency as fold-increase in fluorescence per PCR cycle. #These primers were previously described by Jackson 
et al. [9]
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[17]. LCE2 staining was performed using the primary rabbit anti-human-pan-LCE2 antibody and a goat-anti-rabbit antibody as a secondary antibody (Vector Laboratories).
Immunofluorescence analysis
Skin biopsies were fixed and cut as described in the immunohistochemistry 
section. Immunofluorescence analysis was performed as previously described [18] using the rabbit anti-human-pan-LCE2 antibody and a mouse anti-cathepsin V antibody (R&D Systems, Minneapolis, MN) as primary antibodies. The secondary reagents were Alexa-Fluor 488 goat anti-rabbit IgG highly cross-absorbed and Alexa-Fluor 594 goat anti-mouse IgG highly cross-absorbed (Molecular Probes, Eugene, OR). Nuclei were stained with 4’,6-diamide-2’-phenylindole dihydrochloride (Dako-Cytomation, Copenhagen, Denmark).
Immunoelectron microscopyPost-embedding immunoelectron 
microscopy using Lowicryl K11M resin (Chemische Werke Lowi, Waldkraiburg, Germany) was performed as described previously [19]. The secondary antibody used for immunoelectron microscopy was 5 nm gold-conjugated goat anti-rabbit IgG (BBinternational, 
Cardiff, UK).
Statistical analysisData are expressed as mean ± SD. Statistical analysis of qPCR data was 
performed on ΔCt values using SPSS software (release 16.0, SPSS, Chicago, IL). One-way analysis of variance (ANOVA), followed by Dunnett post 
hoc testing, and paired t-tests were performed. P-values of <0.05 were 
considered statistically significant. 
ResultsLCE expression in human tissuesAs quantitative information on relative expression levels of the LCE gene family in humans is limited [9, 11], we performed qPCR analysis on a large panel of tissues, including many epithelia. We analyzed the expression of all LCE genes, except LCE3B and LCE4A, 
for which validation of specific primers failed. Because of high sequence similarities between LCE1D and LCE1E these genes were analyzed together (in Figures annotated as 1D&E). Figure 1 shows the expression of the LCE3 genes in a wide range of normal human tissues, using the expression of LCE1A in skin as a reference (set at unity). The tissues originate from individuals homozygous for the LCE3B/C deletion, therefore no LCE3C data are available. The gene expression data from the other LCE genes is shown in Supplementary Figure 2. In the majority of samples very low to undetectable LCE expression was found. Moderate expression was observed in trunk skin and some oral epithelia. High 
LCE gene expression levels genes were only found in plantar skin. 
Distinct expression patterns of LCE3 
genes in normal and psoriatic skinFigure 2A shows the mRNA expression of the different LCE genes as determined in epidermal sheets of normal skin and of lesional skin of psoriasis patients (see 
Supplementary Table 1 for ΔCt values and exact P-values). The expression levels of the different LCE groups 
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the LCE3 group were hardly present 
in normal skin and were significantly induced in psoriatic skin (for LCE3C only when present in the genome), as recently reported by others [20]. In four of the psoriasis patients, we also investigated the LCE gene expression levels in uninvolved psoriatic skin, which showed a similar pattern of group-wise expression as observed for normal skin (Figure 2B and Supplementary Table 2). 
To confirm the LCE mRNA expression data at the protein level, we used an antiserum directed against all LCE2 
members to stain paraffin sections of psoriatic and normal skin. Figure 2C shows that the pan-LCE2 antibodies stained the upper granular layer and stratum corneum of normal and lesional psoriatic epidermis. No gross difference in staining intensity between normal and diseased skin was found, despite the decrease of mRNA expression observed for LCE2 members (notably 
LCE2B) in psoriasis. Colocalization 
studies, using immunofluorescence microscopy on normal skin sections, showed overlap between LCE2 and cathepsin V expression (Figure 2D). Previous studies showed that cathepsin 
V is present in the superficial granular layer and stratum corneum where it is associated with corneodesmosomes [18]. LCE2 colocalized completely with cathepsin V in the granular layer, while the expression in the stratum corneum partly colocalized. In the stratum corneum, LCE2 is more broadly expressed. We performed immunoelectron microscopy analysis to study the subcellular localization of the LCE2 protein, which was found to be present in a diffuse cytoplasmic 
LCE expression in vivo and in vitro
Figure 1. mRNA expression of LCE3 group 
members in normal human tissues. Relative mRNA expression levels of LCE3 genes in normal human tissues. Expression of target genes was normalized to that of RPLP0. For graphical representation, all values were expressed relative to LCE1A in skin, which was set at unity, to allow comparison of the expression levels between tissues and genes 
[16]. For primer sequences and efficiency of 
amplification see Table 1. For expression of the other LCE family members see Supplementary Figure 1. Normal human tissues are from one individual. Data from normal skin are from 12 individuals. Mean and SD.
appeared to be group-wise regulated. All members of the LCE groups 1, 2, 5 and 6 were significantly downregulated in psoriatic skin, whereas all genes of 
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distribution in the cells of the granular layer. In the stratum corneum and upper granular layer, LCE2 proteins 
were localized along the cornified envelopes (Figure 2E). LCE2 expression in skin appendages was limited to nail, where expression was found in the matrix, between matrix and proximal nail fold, in the proximal nail fold and 
in the hyponychium (Figure 2F). No expression was observed in hair follicles or sweat glands (not shown).
Skin injury induces specific expression of LCE3 genesWe have previously shown that the expression of the LCE3C and LCE3E genes is induced after tape-stripping 
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Figure 2. LCE expression in normal and psoriatic skin. Relative LCE gene mRNA expression levels in epidermal sheets from (A) healthy controls (NS) and psoriasis patients (PS) (N=6), (B) uninvolved and involved skin of psoriasis patients (N=4). All values were expressed relative to 
LCE1A in normal/uninvolved skin. *P<0.05 compared with normal/uninvolved skin, mean and SD. (C) Immunohistochemical staining with an anti-LCE2 antibody on normal skin (NS) and lesional psoriatic skin (PS). (D) Co-localization (merged yellow signal) of LCE2 (green) and cathepsin V (red) in the upper granular layer of normal skin. (E) Immunoelectron microscopy, 
LCE2 labels (arrow heads) are associated with the cornified envelope in the stratum granulosum. 
D; desmosome, KHG; keratohyalin granule. (F) Immunohistochemical staining for the LCE2 group 
in nail. Bar = 100 μm (C); 50 μm (D-F).
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orthokeratotic stratum corneum.  Forty-eight hours after tape-stripping LCE2 protein was completely absent in the granular layer and in the parakeratotic stratum corneum.LCE gene expression in stratifying 
epidermis in a reconstructed skin modelTo examine the dynamics of LCE gene expression during the process 
of epidermal stratification, we used reconstructed skin on de-epidermized dermis as described previously [22]. The mRNA data (Supplementary Figure 3A and Supplementary Table 4) show that the expression of the LCE genes was very low at day 0 (mean Ct-value of 31). At this time point the cells are still present as an undifferentiated layer of a few cells. After three days of air-exposure, expression of all LCE genes, except LCE3A and LCE5A, was highly induced. The LCE expression 
of normal skin [4]. Superficial skin injury in healthy volunteers leads to skin barrier disruption and induces epidermal activation as assessed by morphology, cell proliferation and gene expression [21]. Here we used qPCR analysis to investigate the expression of all LCE genes before and after tape-stripping of normal skin, as shown in Figure 3 and Supplementary Table 3. The genes of the LCE1, 2, 5 and 6 groups 
were significantly downregulated after tape-stripping, while the LCE3 genes 
were significantly upregulated. This pattern of group-wise induction and downregulation was very similar to that found in normal versus psoriatic skin, as depicted in Figure 2A. The 
mRNA data were confirmed at protein level for LCE2. Figure 3B shows that before tape-stripping LCE2 was detected in the uppermost layer of the stratum granulosum and in the entire 
LCE expression in vivo and in vitro
Figure 3. LCE expression before and after tape-stripping in normal skin. (A) Relative mRNA expression levels of LCE genes in epidermal sheets of healthy controls before and after tape-stripping (TS) (N=5). All values were expressed relative to LCE1A in skin to allow comparison of the expression levels between genes. *P<0.05 compared with before tape-stripping, mean and SDs. (B) Immunohistochemical staining with an anti-LCE2 antibody on sections of normal skin before (upper panel), before enlarged (middle panel) and 48 h after tape stripping (lower panel). 
Each picture is representative for data of five different individuals. Bar = 50 μm.
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levels continued to rise until day 6 and then stabilized until day 15 of the air-exposure phase. The qPCR results for 
LCE2 were confirmed at the protein level (Supplementary Figure 3B). LCE2 proteins were not expressed in the skin construct at day 0, but from day 3 onwards, expression gradually emerged in the stratum granulosum and later LCE2 proteins were also present in the stratum corneum. The expression data for reconstructed skin, both on the mRNA and protein level (for LCE2) were quite similar to those observed in normal human skin (Figure 2B), indicating that this is a suitable model to study LCE biology in vitro. In this model, for LCE3D and LCE3E higher expression and for LCE5A lower expression levels were found compared to expression levels of these genes in normal skin.LCE gene expression in a reconstructed 
skin model: induction by cytokinesWe used our recently developed in 
vitro psoriatic skin model to examine 
disease-specific keratinocyte gene expression levels [12]. Using this model we studied the effect of 
proinflammatory cytokines associated with psoriasis, on the expression of 
LCE genes. As shown in Figure 4 and Supplementary Table 5, a combination 
of psoriasis-associated cytokines TNF-α, 
IL-1α and IL-6 significantly induced the expression of the LCE3 genes, whereas this mixture and the Th17 cytokine 
IL-22 significantly downregulated the expression of LCE1B. IL-17 and IL-22 
showed non-significant upregulation of the LCE3 genes. The investigated 
cytokine mixtures did not significantly affect the expression of the other LCE 
members. 
DiscussionWe here report a comprehensive study on the expression of human LCE genes in vivo and in vitro. We found the highest expression of all LCE genes in skin and moderate expression in some oral epithelia. Very low to undetectable expression was found for all LCE genes in the majority of samples from a broad panel of tissues, including many epithelia. Out of 16 investigated 
LCE genes, only the expression of the 
LCE3 group members was significantly induced in psoriatic skin, whereas the genes from the other LCE groups were 
significantly downregulated. Similar group-wise expression patterns were 
found after superficial injury of normal skin by tape-stripping. Localization studies showed that the LCE2 proteins are expressed in the uppermost layer of the stratum granulosum on 
cornified envelopes. Stimulation of in 
vitro reconstructed skin with psoriasis associated cytokines demonstrated an induction of LCE3 gene expression. This 
in vitro model also showed that during 
the process of epidermal stratification the LCE gene and protein expression starts at the moment of stratum corneum formation.Tissue expression analysis suggests that all LCE genes are likely to be 
involved in skin specific processes. 
The data presented here confirmed the results of previous studies of LCE1, 2 and 5 expression. One study, however, showed that LCE3 genes were mainly expressed in the studied internal epithelia esophagus and tongue, and hardly present in skin [11]. This may be 
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We here showed that we can mimic the induction of the LCE3 gene expression observed in lesional psoriatic epidermis, 
by adding a mixture of TNF-α, IL-1α and IL-6 to our reconstructed skin model. Also the Th17 cytokines seem to have an effect on LCE3 expression; IL-22 showed a trend towards induction of especially LCE3A. The effects on 
LCE3D and LCE3E gene expression are smaller. An explanation could be that the basal expression levels of these genes in the reconstructed skin model are higher in the control situation than in normal skin, which makes induction 
of gene expression more difficult to demonstrate. Previous in vitro studies used submerged keratinocyte cultures, in which LCE2 gene expression was induced by adding Ca2+-rich medium [9]. And UVB irradiation caused induction of the LCE1 and LCE2 groups and LCE3E. The other LCE genes remained expressed at low levels in both situations. These results do not 
because only normal skin was studied, where LCE3 expression is rather low. We showed that the LCE2 proteins are 
localized in the superficial cells of the stratum granulosum and in premature 
cornified envelopes, resembling involucrin staining in normal skin [23]. In mouse embryos, similar localizations were found for Lce1 [11]. LCE2 is also present in the nail unit, at similar 
locations as involucrin, filaggrin and transglutaminase 3 [24], suggesting that LCE2 is not only involved in terminal differentiation in the epidermis but also in the nail unit. From our in vitro data in stratifying epidermis, we found that 
LCE expression starts at the moment of stratum corneum formation, which is similar to loricrin expression in our previous study [22]. Altogether these results strengthen previous observations that LCE proteins are expressed late and end up in the 
stratum corneum as part of the cornified envelope [11]. 
LCE expression in vivo and in vitro
Figure 4. Cytokine induced LCE mRNA expression in reconstructed skin. Relative mRNA expression levels of LCE genes in epidermal sheets from skin constructs after stimulation with 
different cytokine mixtures (N=5 per group): 10 ng/mL IL-1α, 5 ng/mL TNF-α and 5 ng/mL IL-6 or 100 ng/mL IL-17 or 100 ng/mL IL-22. Values for each gene were expressed relative to the control culture conditions, which was set at unity. It is not possible to compare the expression levels between genes. *P<0.05 compared with control condition, mean and SD.
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show the same group-wise expression as observed in our study. This might be caused by the use of submerged cultures, where the basal expression levels of the LCE genes are very low (data not shown).The deletion of LCE3B and LCE3C is a widely replicated risk factor for psoriasis [4-7]. Although the associated odds ratio is modest (1.21 in a recent meta-analysis [7]), compared to that of HLA-Cw6 (2.8 according to another meta-analysis [25]), the high prevalence of the deletion in psoriatic patients causes a considerable population associated risk (21% [4]). Its reported epistasis with HLA-Cw6 in at least some Caucasian populations makes it a major psoriasis risk factor [7]. As all LCE genes are very similar and would be predicted to exert similar functions, the question arises why a deletion of two genes out of 18 quite similar LCE genes could play a role in the etiology of psoriasis. 
We have shown for four out of the five 
LCE3 genes, that these are differently expressed compared to the other LCE groups. Our interpretation is that LCE3 members may function as barrier repair proteins whose expression is 
driven by proinflammatory cytokines, whereas the other LCE proteins have a constitutive role in barrier function of normal skin. Heterozygous or homozygous deletion of LCE3B and 
LCE3C, which is observed in > 90% of the psoriasis patients could potentially affect skin barrier properties (compared to the homozygous ancestral status of two intact chromosomes), particularly under stressed conditions [7]. Thus, concerning the relevance for psoriasis we are dealing with a deletion of two out 
of five LCE3 genes rather than two out of 18 LCE genes. As LCE3B and LCE3C are expressed at low levels, if at all, in normal skin, the situation is different 
from the filaggrin (FLG) gene and atopic dermatitis [26]. For atopic dermatitis, it has been suggested that a slightly leaky skin barrier could allow penetration of environmental allergens and would favor development of atopy [27]. In case of LCE3B and LCE3C, expression is only induced after barrier disruption. Although 18 LCE genes are present 
on the genome, only five genes from this family appear to have a function following skin barrier disruption or 
inflammation. We hypothesize that due to the deletion of LCE3B and LCE3C, in combination with other unknown factors, an incomplete skin barrier repair response could occur after minor skin injury. Speculatively, the presence of only the LCE3A, 3D and 3E proteins 
is not sufficient for a complete barrier repair response. A consequence could be an increased permeability for environmental stimuli (e.g. microbial components) leading to activation of innate immune mechanisms and subsequent recognition by the adaptive immune system in predisposed (e.g. 
HLA-Cw6+) individuals. This is a testable hypothesis which merits further investigation. 
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LCE expression in vivo and in vitro
HUGO
symbol
mRNA in 
vivo Ratio 
Rel Q4
P 
value5
 dCt
1 
NS2
dCt 
PS3LCE1 groupLCE1A 4.1 6.8 0.30 0.020LCE1B 5.5 8.7 0.18 0.007LCE1C 3.9 6.9 0.21 0.008LCE1D&E 5.0 7.6 0.18 0.012LCE1F 7.7 10.7 0.23 0.006LCE2 groupLCE2A 4.8 6.4 0.58 0.110LCE2B 4.3 7.9 0.13 0.005LCE2C 5.3 7.4 0.45 0.074LCE2D 5.2 7.9 0.29 0.050LCE3 groupLCE3A 14 6.3 185 0.000LCE3C 14 9.4 51 0.024LCE3D 6.5 3.6 8.6 0.001LCE3E 8.1 5.2 7.9 0.009LCE5 groupLCE5A 6.1 10 0.13 0.003LCE6 groupLCE6A 6.8 9.6 0.25 0.028
Supplementary Table 1. qPCR data on 
LCE gene expression in epidermis of 
normal and psoriatic skin.
1dCt: Delta PCR cycle time. mRNA expression data from epidermal cells of 2normal skin (NS) (N=6), 3psoriatic plaques (PS) (N=6), 4Ratio relative quantitiy PS/NS, 5P-values of t-test. Bold: p-value < 0.05.
Supplementary Table 2. qPCR data 
on LCE gene expression in epidermis 
of uninvolved (un) and involved (in)
psoriatic skin.
1dCt: Delta PCR cycle time. mRNA expression data from epidermal cells of 2uninvolved psoriatic skin (un) (N=4), 3involved psoriatic skin (in) (N=4),4Ratio relative quantitiy involved/uninvolved, 5P-values of paired t-test. Bold: p-value < 0.05.
HUGO
symbol
mRNA in 
vivo Ratio 
Rel 
Q4
P 
value5 dCt1 
un2
dCt 
in3LCE1 groupLCE1A 5.0 6.4 0.46 0.171LCE1B 4.6 8.6 0.08 0.016LCE1C 4.1 6.6 0.19 0.021LCE1D&E 6.5 7.8 0.58 0.307LCE1F 7.0 10.8 0.11 0.042LCE2 groupLCE2A 5.0 6.2 0.68 0.345LCE2B 3.8 7.8 0.05 0.033LCE2C 5.2 7.3 0.29 0.076LCE2D 4.6 7.9 0.19 0.066LCE3 groupLCE3A 9.5 6.0 6.2 0.053LCE3C 13.9 9.7 57 0.114LCE3D 4.3 3.4 2.3 0.158LCE3E 6.1 5.0 3.5 0.295LCE5 groupLCE5A 6.4 10.3 0.10 0.018LCE6 groupLCE6A 6.4 9.6 0.17 0.053
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Supplementary Table 3. qPCR data on LCE gene expression in epidermis of normal skin 
before (pre) and after (post) tape-stripping. 
HUGO
symbol
mRNA in 
vivo Ratio
Rel Q4
P 
value5 dCt1 
pre2
dCt 
post3LCE1 groupLCE1A 4.7 8.1 0.14 0.002LCE1B 4.8 8.5 0.11 0.002LCE1C 4.4 7.3 0.17 0.002LCE1D&E 6.8 9.7 0.06 0.093LCE1F 8.2 11.4 0.12 0.001LCE2 groupLCE2A 4.7 7.4 0.19 0.006LCE2B 5.0 8.6 0.09 0.000LCE2C 5.0 7.8 0.18 0.002LCE2D 5.2 8.4 0.14 0.006LCE3 groupLCE3A 11.5 6.5 12 0.015LCE3C 12.4 8.2 20 0.078LCE3D 5.5 2.5 5.8 0.044LCE3E 7.2 4.6 5.3 0.046LCE5 groupLCE5A 5.4 11.3 0.03 0.001LCE6 groupLCE6A 7.6 10.9 0.13 0.0011dCt: Delta PCR cycle time. mRNA expression data from epidermal cells of 2normal skin before tape-stripping (pre) (TS) (N=5), 3after tape-stripping (post) (N=5), 4Ratio relative quantitiy post/pre tape-stripping, 5P-values of paired t-test. Bold: p-value < 0.05.
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LCE expression in vivo and in vitro
HUGO
symbol
mRNA in vitro (dCt day) Ratio Relative Quantification (day x/day x)
02 33 64 95 126 157 3/0 6/0 9/0 12/0 15/0LCE1 groupLCE1A 13 7.2 6.4 5.2 5.6 5.4 56 74 172 137 181LCE1B 13 9.1 6.9 5.3 6.2 5.3 16 56 172 114 190LCE1C 9.5 7.2 5.0 3.5 4.1 3.8 6.2 21 61 42 69LCE1D&E 14 9.6 7.9 6.6 8.0 6.7 22 53 130 59 136LCE1F 15 11 9.5 8.9 9.6 8.2 11 33 48 39 101LCE2 groupLCE2A 13 7.8 6.2 5.2 6.1 5.2 48 107 218 139 256LCE2B 13 7.8 6.7 5.7 6.0 5.2 52 104 217 201 424LCE2C 16 9.0 7.1 5.8 6.7 5.8 163 461 1148 664 1489LCE2D 12 8.6 6.8 5.3 6.3 5.6 15 42 121 68 131LCE3 groupLCE3A 15 15 12 11 12 11 1.9 8.6 16 14 23LCE3C ND ND ND ND ND ND ND ND ND ND NDLCE3D 9.6 6.1 4.4 4.3 4.3 4.4 16 37 39 38 43LCE3E 11 5.9 4.6 4.4 5.2 5.2 51 96 106 70 72LCE5 groupLCE5A 16 14 12 10 12 8.5 2.6 11 38 17 128LCE6 groupLCE6A 13 8.2 7.6 5.5 5.4 5.9 42 58 252 272 249
Supplementary Table 4. qPCR data on LCE gene expression in stratifying epidermis in 
reconstructed skin.
1dCt: Delta PCR cycle time. 2mRNA expression data from keratinocytes in reconstructed skin 0 days air-exposed (N=1), 33 days air-exposed (N=2), 46 days air-exposed (N=1), 59 days air-exposed (N=2), 612 days air-exposed (N=2), and 715 days air-exposed (N=2), because of the low N no statistics were performed. ND; not determined, because the used cells were homozygous for the LCE3B/LCE3C deletion.
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LCE1 group
LCE1A
5.5
6.1
6.5
7.8
0.93
0.90
0.53
0.406
0.344
0.100
LCE1B
4.9
5.8
6.1
7.2
0.56
0.86
0.44
0
.0
1
0
0.350
0
.0
4
9
LCE1C
3.5
5.1
5.3
6.5
0.41
0.72
0.40
0.054
0.190
0.075
LCE1D&E
5.7
6.2
7.7
8.6
0.98
0.81
0.73
0.478
0.334
0.243
LCE1F
8.2
8.5
9.0
9.9
1.5
0.99
0.76
0.805
0.718
0.308
LCE2 group
LCE2A
4.6
4.9
4.9
5.9
1.2
1.3
0.94
0.697
0.977
0.364
LCE2B
5.6
6.6
6.8
7.6
1.0
1.1
0.72
0.448
0.623
0.230
LCE2C
5.8
6.6
7.3
8.0
0.82
0.96
0.74
0.355
0.476
0.224
LCE2D
5.3
6.2
6.8
8.0
0.75
1.3
0.84
0.296
0.734
0.237
LCE3 group
LCE3A
10
5.7
8.9
8.2
40
9.8
15
0
.0
0
4
0.127
0.071
LCE3C
11
9.1
11.8
13
8.5
2.3
28
0.356
0.635
0.866
LCE3D
3.1
1.4
2.3
3.1
3.3
1.6
1.4
0
.0
0
4
0.143
0.832
LCE3E
3.6
2.0
3.4
3.9
3.5
1.1
1.1
0
.0
0
6
0.989
0.568
LCE5 group
LCE5A
11
11
13
13
0.90
1.5
0.63
0.371
0.503
0.177
LCE6 group
LCE6A
6.2
7.4
7.9
9.2
0.52
0.74
0.39
0.050
0.264
0.054
1dCt: Delta PCR cycle time. 2mRNA expression data from keratinocytes in reconstructed skin with addition of 1control medium (N=14), 2a m
ixture of T
N
F-α
, 
IL-1α
 and IL-6 cytokines (N
=5), 3IL-17 cytokine (N=5), 4IL-22 cytokine (N=5), 5P-values of repeated measurements ANOVA and Dunnett post hoc test. Bold: 
p-value < 0.05.
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LCE expression in vivo and in vitro
Supplementary Figure 1. Validation anti-LCE2 antibody on bacterial lysates expressing 
recombinant human His6-Flag-LCE2A. The anti-LCE2 antibody was raised in a rabbit against a synthetic peptide. This peptide perfectly matches LCE2B, C and D and differs one amino acid from LCE2A. Validation of 2 different bleeds (#73 and #74) on bacterial lysates 
expressing human His6-Flag-LCE2A showed a band at about 20-25 kDa which was specific. This band was detected by both anti-Flag and anti-LCE2A antibodies. Antibodies 74 give 
higher specific signal than antibodies 73 but also higher background. Both bleeds were used in immunohistochemistry and showed similar results.
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LCE expression in vivo and in vitro
Supplementary Figure 3. LCE expression in stratifying epidermis in reconstructed skin. 
(A) Relative mRNA expression levels of LCE genes in epidermal sheets from skin constructs. Adult human keratinocytes were seeded on a de-epidermized dermis, and cultured for three days submerged, followed by 0, 3, 6, 9, 12 or 15 days culturing at the air-liquid interphase. All values were expressed relative to LCE1A at day 0, which was set at unity, to allow comparison of the expression levels between genes (mean and SD). (B) Immunohistochemical staining with an anti-LCE2 antibody on sections of reconstructed skin at different time points during 
the process of epidermal stratification. Bar = 50 μm.
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Deletion of two members of the Late Cornified Envelope (LCE) family, LCE3B and LCE3C (LCE3C_LCE3B-del), has been identified as a risk factor for psoriasis with a possible role in skin barrier function. Moreover, genetic interaction between LCE3C_LCE3B-del and HLA-C*06, located in the psoriasis susceptibility regions 4 and 1 (PSORS4 and 1), respectively, has been reported in several populations. Because of high linkage disequilibrium between the PSORS1 genes HLA-C*06 and corneodesmosin (CDSN), both genes are potentially involved in psoriasis. As corneodesmosin and LCE proteins are both constituents of the stratum corneum, we investigated a potential direct protein-protein interaction between LCE proteins (LCE1E, LCE2A, LCE3B, LCE3C, LCE3E, LCE5A) and two corneodesmosin sequence variants. Partial co-localization of LCE2 and CDSN was observed in normal and psoriasis skin using immunofluorescence microscopy. Co-expression of eCFP-LCE and mRFP-CDSN proteins in COS-1 cells and human primary adult keratinocytes, and GST pull-down results did not provide evidence for direct interactions between LCE proteins and CDSN variants. Further research will be necessary to explore the function of LCE proteins in general, and the role of the LCE3 risk genes in psoriasis.
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Introduction
Psoriasis is a common inflammatory skin disease that affects about 2% of Western societies [1]. It is a complex disease meaning that it has both environmental and genetic factors to its etiology [2]. One of the known psoriasis genetic risk factors is deletion 
of the Late Cornified Envelope (LCE) 
3B and 3C genes (LCE3C_LCE3B-del) on chromosome 1q21 [3, 4]. As early as 1999 this region was linked to psoriasis, based on family studies, and was termed psoriasis susceptibility region 4 (PSORS 4) [5, 6]. The LCE gene family consists of 18 members divided over six groups LCE1 to LCE6 [7]. Not much is known about the exact function of the proteins of the LCE family. In mice, an Lce1 group member was found 
to be cross-linked to the cornified envelope by transglutaminases [8]. Also human LCE6A protein was shown to be a transglutaminase substrate [9]. Furthermore, in our previous study we showed that LCE2 proteins are 
localized along the cornified envelope [10]. We demonstrated that LCE3 group members are distinctly expressed, compared to the expression levels of other LCE genes in normal and psoriasis skin, and in normal skin before and after minor skin injury [10].PSORS1, the major genetic determinant for psoriasis susceptibility, is located on chromosome 6 [11, 12]. This region harbors HLA-C*06, which was already known to be associated with psoriasis in the 1970s [13]. It also contains several other genes including CDSN and CCHCR1 [14]. 
HLA-C encodes a class I MHC molecule involved in antigen presentation to 
CD8+ T cells [15]. CCHCR1 encodes a protein of unknown function, which is overexpressed in lesional psoriatic skin [16]. CDSN encodes corneodesmosin, an extracellular adhesive protein 
covalently linked to the cornified envelope [17].Like many other genes of the PSORS1 region, CDSN is highly polymorphic with approximately 1 polymorphism per 100 
bp [18, 19]. Polymorphisms identified within the coding sequence of CDSN have been grouped in several different single nucleotide polymorphisms (SNPs) haplotypes, initially described as CD1-CD6 [20]. These polymorphisms, causing synonymous and non-synonymous substitutions as well as single amino-acid deletions, result in six different protein variants. Association studies have shown strong linkage disequilibrium (LD), the tendency of two genes to be inherited together more often than would be predicted by chance, between polymorphisms in the CDSN gene and the HLA-C locus [20, 21]. More importantly, this strong association is only present when the SNPs are grouped as CDSN haplotypes, with the 
strongest significant association for the CD2 variant [19, 20]. Studies of Orru et al. [22] suggest that CDSN is the susceptibility gene, whereas Nair et al. [23] reported that HLA-C*06 is the most likely susceptibility gene in the PSORS1 region. Alternatively it might even be possible that both HLA-C*06 and CDSN contribute to psoriasis susceptibility [24].Previous studies from our group and others, showed genetic interaction between LCE3C_LCE3B-del and 
HLA-C*06 in populations from the 
Interaction between CDSN and LCEs
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primer sequences). By using Gateway technology (Invitrogen, Carlsbad, Ca) cDNAs encoding the proteins of interest were cloned into the pDONR201 vector. To study the psoriatic and neutral variant of CDSN (see below) four SNPs (position 619, 1236, 1243, 1593) in exon 2 of the CDSN gene were mutated in the original pDONR201-CDSN using sets of oligonucleotides (Table 2) (Biolegio, Nijmegen, the Netherlands). In a DNA thermal cycler (T Gradient, Biometra, Göttingen, Germany) PCR-based mutageneses reactions were performed using 1 ng of DNA template (adequate pDONR201-CDSN clone), 0.5 µM of each oligonucleotide, 0.2 mM of each dNTP (Promega Corporation, Madison, WI), 1X Phusion HF Buffer (Finnzymes, 
Thermo Fisher Scientific Inc., Vantaa, 
Netherlands, USA and China [3, 4, 25]. In addition, epistasis between PSORS1 and PSORS4 loci has been reported in an Italian cohort [6]. Given the LD between CDSN variants and HLA-C*06 and assuming the biological role of LCE proteins in skin barrier function, we hypothesized a direct protein-protein interaction between CDSN and the LCE proteins, which upon disturbance might have pathophysiological consequences.
Materials and Methods
Immunofluorescence analysisTissues were embedded in Tissue-Tek (Sakura Finetek, Zoeterwoude, the Netherlands), snap frozen in liquid nitrogen and stored at -80°C. Sections 
were sliced 6 μm thick on superfrost-plus coated slides (Menzel, Germany) 
air dried and fixed in cold acetone 
for 10 min. Immunofluorescence analysis was performed by using the rabbit anti-human-pan-LCE2 antibody 1:1000 and a mouse anti-CDSN G36-19 antibody 1:200. The secondary reagents were Alexa-Fluor 488 goat anti-rabbit IgG highly cross-absorbed 1:200 and Alexa-Fluor 594 goat anti-mouse IgG highly cross-absorbed 1:200 (Molecular Probes, Eugene, OR). Nuclei were stained with 4’,6-diamide-2’-phenylindole dihydrochloride (Dako-Cytomation, Copenhagen, Denmark).
VectorsSix different LCE proteins were studied; LCE1E, LCE2A, LCE3B, LCE3C, LCE3E and LCE5A. The cDNAs coding these LCE 
proteins were amplified by PCR using genomic DNA as a template. The CDSN vector was constructed using human cDNA as a template (see Table 1 for 
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Gene Primer sequence (5’ to 3’)LCE1E FOR TCCTGCCAGCAGAGCCAGCAGREV TCAGCAGCAGCCTCCAGAGTGCLCE2A FOR TCCTGCCAGCAAAACCAGCAGREV CTGTGATGTTCGAGGTCTGGLCE3B FOR TCCTGCCAGCAGAACCAGREV GTTAATTAGCATGTCTAAGLCE3C FOR TCCTGCCAGCAAAACCAGCAGREV TCAGCAGCAGCCCCCAGAGCCALCE3E FOR TCCTGCCAGCAGAACCAGREV TCTCAGCATCAGGATCTGGALCE4A FOR TCCTGCCAGCAGAACCAAREV TGCTGCTCCTGGTCCAGGLCE5A FOR TCCTGCCAGCAGAGCCAGCAGREV CGTGCTCCTCATGGCCCAGGCDSN FOR GGCTCGTCTCGGGCACCC TGGREV TTATGGACTGTTGAGTAACT CTCCTT
Table 1. Primers used to amplify the 
different human LCEs and CDSN cDNA.
All primers contain additional sequence for Gateway cloning: FW primers 5 ’ - G G G G A C A A G T T T G TA C A A A A A A G C A G G C TTC-3’, Rev primers 5’-GGGGACCACTTTGT ACAAGAAAGCTGGGTG-3’. 
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LCE genes were cloned from pDONR201 constructs into pDEST501 and pPalm-Myr-Dest vectors using Gateway technology (Invitrogen), resulting in N-terminally fused enhanced cyan 
fluorescent protein (eCFP) with or without palmitoylation site for membrane anchoring, respectively. The two cDNA variants of CDSN (neutral and psoriatic, see below) were cloned into the pDEST733 using the Gateway cloning technology (Invitrogen) resulting in N-terminally fused monomeric red 
fluorescent protein (mRFP) CDSN proteins. COS-1 cells, seeded on coverslips, were co-transfected with pDEST733-CDSN, neutral or psoriatic variant, and pDEST501-LCEs or pPalm-Myr-LCEs by using Lipofectamine2000 (Invitrogen) according to manufacturer’s instructions. Primary human adult keratinocytes, seeded on coverslips coated with type 1 rat-tail collagen (BD Biosciences, Bedford, MA), were co-transfected with pDEST733-CDSN, neutral or psoriatic variant, and pDEST501-LCEs or pPalm-Myr-LCEs by using FuGENE HD Transfection 
Finland), and 0.02 U Phusion HF DNA Polymerase (Finnzymes) in a 20 µL reaction. Conditions were 95°C for 2 min, 10 cycles of 95°C for 30 s, 55°C for 30 s and 72°C for 2 min. The last cycle was followed by an elongation step of 5 min at 72°C. Next, 1 U of DpnI restriction enzyme (Roche Diagnostics GmbH, Mannheim, Germany) was added and incubated at 37°C for 1 h. Two µl of resulting product was transformed into one shot chemically competent TOP10 
E. coli bacteria (Invitrogen) according to manufacturer’s instructions. 
Mutagenesis was confirmed by sequence analysis. LCE3B cDNA was cloned from pDONR201 into pDest15 to produce glutathione S-transferase (GST)-tagged LCE3B. To produce FLAG-tagged CDSN-P (see below) this cDNA was cloned from pDONR201 into pDest3xFLAG.
Co-localization in COS-1 cells and in 
primary human keratinocytesTo determine the cellular localization of human full-length LCE proteins and CDSN, cDNAs encoding the different 
Interaction between CDSN and LCEs
polymorphic 
position change Oligonucleotide sequence (5’ to 3’)619 T to C FOR CTC TTC CCA AAC CTC TGG GGT ATC CAG CAG TGREV CAC TGC TGG ATA CCC CAG AGG TTT GGG AAG AG
1236 G to T FOR TAG CAT TTC CAG CAG CTC CGG TTC ACC CTA CCA TCCREV GGA TGG TAG GGT GAA CCG GAG CTG CTG GAA ATG CTA
1243 C to T FOR CAT TTC CAG CAG CGC CGG TTT ACC CTA CCA TCC CTG CREV GCA GGG ATG GTA GGG TAA ACC GGC GCT GCT GGA AAT G
1593 A to G FOR GTT TTC CTA CCC CAA GGA GAG TTA CTC GAC AGT CCA TAAREV TTA TGG ACT GTC GAG TAA CTC TCC TTG GGG TAG GAA AAC
Table 2. Oligonucleotides used to introduce single nucleotide mutations in CDSN cDNA.
* Nucleotides set in bold indicate the polymorphic positions.
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Reagent (Promega) according to manufacturer’s instructions. Twenty-four hours after transfection, cells 
were washed with PBS, fixed with 3.7% paraformaldehyde (Merck Chemicals, Darmstadt, Germany) and mounted with Vectashield containing DAPI (Vector Laboratories, Inc., Burlingame, CA). Images were taken with an Axioskop 2 mot plus microscope (Carl Zeiss, Oberkochen, Germany) coupled to AxioCam MRc5 camera or Zeiss Axio 
Imager Z1 fluorescence microscope. Images were processed using AxioVision 4.3 (Zeiss) and ImageJ software.
GST pull-down assayIn order to produce glutathione S-transferase (GST)-fused LCE3B, BL21-DE3 bacteria (Invitrogen) were transformed with pDest15-LCE3B. Cells were induced at 32°C for 2 hours with 0.5 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG, 
Thermo Scientific, Rockford, IL) 
and subsequently lysed with lysis buffer (2% Triton X-100 (Bio Rad laboratories, Hercules, CA), 1 mM 
phenylmethanesulfonylfluoride (PMSF, 
Thermo Scientific), 1mM dithiothreitol (DTT, Sigma-Aldrich, St Louis, MO) in PBS). Lysates were precleared 
and purified using glutathione Sepharose 4B beads according to the manufacturer’s instructions (GE Helathcare, Bio-Science, Uppsala, Sweden) and dialysed against PBS. A 
total of 250 µg purified GST-LCE3B was incubated with glutathione Sepharose 4B beads at 4°C for 2 h. Beads with bound proteins were washed three times with PBS. The amount of bound 
GST-fusion protein was verified on a 4-12% SDS-PAGE gel stained with Coomassie Brilliant Blue solution (data 
not shown). 3xflag-tagged CDSN/P was produced in polyethylenimine (PEI) 
transfected COS-1 cells. In brief, 25 μg pDest3xFLAG-CDSN/P was dissolved in 2.5 mL of Opti-MEM medium 
Figure 1. Partial co-localization of CDSN and LCE2 protein in human skin. LCE2 (green signal) and CDSN (red signal) expression in normal skin (upper panels) and psoriasis skin (lower panels). In the merged panels, the yellow signal represents overlap of the LCE2 and CDSN signal, which is partly present in the stratum granulosum. Scale bar = 50 µm.
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vitro colocalization and protein-protein interactions between LCE proteins and CDSN. 
Co-localization of LCE2 and CDSN in 
normal and psoriasis skin
As there are no specific antibodies available against individual LCE proteins, we used a polyclonal antiserum known to recognize LCE2 family members. Previous studies in mice and humans have shown that LCE proteins are expressed in the stratum granulosum cells of the epidermis. 
Using immunofluorescence, normal and psoriasis lesional skin sections were double-labeled for LCE2 and CDSN (Figure 1). As shown, both proteins partially co-localize in the upper granular layer. In psoriasis skin CDSN is expressed in more skin layers than LCE2. Careful examination of the staining in these skin sections reveals that CDSN is merely present at the cell periphery, whereas LCE2 is more prominent in the cytoplasm. At the cell periphery, however, still some overlap is present.
Co-localization studies of LCE and CDSN 
in COS-1 cells and primary human 
keratinocytesTwo different CDSN variants were studied (Table 3), corresponding to different CDSN haplotypes distinguished on the basis of SNPs in exon 2 of the 
CDSN gene. CDSN/P (CDSN/Psoriasis) contains all SNPs associated with psoriasis, whereas CDSN/N is the neutral variant; it contains at these positions the four non-associated nucleotides. To visualize a possible co-localization of 
(Invitrogen). 36 μg PEI (Sigma-Aldrich, 1 mg/mL) was added to the plasmid DNA 
solution, vortexed briefly and incubated at RT for 10 min. Subsequently, medium was exchanged for 2% DMEM complete growing medium with addition of the transfection solution to cells. After 24 hours the cells were lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Triton X 100 containing complete mini protease inhibition cocktail (Roche) in de-mineralized 
water) and five times passed through a needle. The precleared lysates were incubated 2 hours with the beads 
coupled to GST-LCE3B. After five washes with lysis buffer, the beads were boiled in 1xSDS loading buffer. Protein complexes were resolved on a 4-12% NuPage gradient gel (Invitrogen). Western blot analysis was performed with anti-FLAG (Sigma) and horseradish peroxidase (HRP)-linked rabbit anti-mouse IgG (Cell signaling Technology, Beverly, MA) antibodies.
ResultsBased on a presumed genetic interaction between the LCE3C_LCE3B-del and PSORS1, we investigated in vivo and in 
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Table 3. List of the four studied SNPs at exon 
2 of the CDSN gene with the corresponding 
amino acids.
position CDSN/P CDSN/NT619C Phe SerT1236G Ser AlaC1243T Ser LeuG1593A Asp AsnAmino acids set in italic refer to the SNPs for which association with psoriasis has not been shown. The underlined amino acids, however, were found to be associated with psoriasis, as they are part of CD2, the haplotype showing the strongest association with the disease. CDSN/P represents the haplotype grouping psoriasis-associated SNPs whereas CDSN/N comprises the neutral variants of the SNPs.
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LCE proteins and CDSN/N or CDSN/P, we used N-terminally fused eCFP and mRFP fusion proteins. Recombinant CFP-LCEs and RFP-CDSN proteins were initially co-expressed in COS-1 cells as, in contrast to human primary keratinocytes, these cells are easily transfected allowing for rapid and 
efficient expression of recombinant proteins. Next, the engineered proteins 
were expressed in human primary keratinocytes, a more physiologically relevant environment.As shown in the Figures 2 and 3, upon co-expression, both proteins demonstrated a cytoplasmic localization, visible as yellow stained cells in the overlay pictures of Figure 2 and 3. Similar results were observed for all tested LCE proteins (LCE1E, LCE2A, LCE3B, LCE3C, 
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Figure 2. LCE3C and LCE5A proteins co-localize with CDSN upon co-expression in COS-1 
cells. mRFP-CDSN (red signal in A, D, G, J) and eCFP-LCE (green signal in B, E, H, K) co-localized in the cytoplasm (yellow signal in overlays C, F, I, L, highlighted by yellow arrows). The same results were obtained for LCE1E, LCE2A, LCE3B and LCE3E proteins upon co-expression with either neutral or psoriatic variants of CDSN protein (data not shown).
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LCE3E, LCE5A), with both CDSN/N as well as CDSN/P (not shown). Furthermore, no differences in protein localization were observed when different cell types were used, as similar results were obtained in both COS-1 cells and human primary keratinocytes. These data, although consistent with our hypothesis, obviously did not prove a direct interaction between LCE 
proteins and CDSN. This was addressed using a strategy that would allow us to monitor interaction of the proteins by forced translocation of one of the putative interaction partners.To this end, the LCE cDNAs were cloned into the pPalm-Myr vector. Expression of the pPalm-Myr vector results in an N-terminally fused eCFP protein that contains palmitoylation 
Interaction between CDSN and LCEs
Figure 3. LCE1E and LCE3C proteins co-localize with CDSN upon co-expression in human 
primary keratinocytes. mRFP-CDSN (red signal in A, D, G, J) and eCFP-LCE (green signal in B, 
E, H, K)  co-localized in the cytoplasm (yellow signal in overlays C, F, I, L). The same results were obtained for other LCE family members (LCE2A, LCE3B, LCE3E, LCE5A; data not shown) upon co-expression with both neutral and psoriatic variant of CDSN.
142
and myristoylation sites. Expression of this fusion protein leads to membrane targeting of the fusion protein [26]. Therefore, in case of direct protein-protein interaction, CDSN should ‘follow’ LCE and localize along the cell membrane in a similar pattern.When both recombinant proteins were co-expressed in COS-1 cells or in 
human primary keratinocytes, however, translocation of CDSN and subsequent co-localization was not observed: eCFP-LCE fusion proteins localized along cell membranes, as anticipated, but mRFP-CDSN remained in the cytoplasm (Figure 4 and 5). These results were obtained for all LCE proteins tested (LCE1E, LCE2A, LCE3B, LCE3C and LCE5A), 
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Figure 4. Membrane translocated LCE3B and LCE5A proteins do not co-localize with CDSN 
upon co-expression in COS-1 cells. eCFP-LCE (green signal in B, E, H, K) is localized at the cell membranes due to the Palm-Myr tag fused to the N-terminus of the protein. However, mRFP-CDSN (red signal in A, D, G, J) remained in the cytoplasm suggesting lack of direct protein-protein interaction. In contrast to the previous results, a yellow signal could not be observed in overlays (C, F, I, L). For LCE1E, LCE2A, LCE3C proteins similar results were obtained (data not shown).
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both when co-expressed with CDSN/P or CDSN/N. From these translocation/co-localization studies we conclude that none of the tested LCE proteins is likely to interact directly with CDSN.
GST pull-down with GST-LCE3B and 
3xFLAG-CDSN/P 
In order to confirm the previous results obtained in a cellular system 
by a biochemical method, a GST pull-down assay was performed. LCE3B was N-terminally fused to GST and recombinant 3xFLAG-CDSN/P protein, expressed in COS-1 cells, was used as a potentially interacting protein. As shown in Figure 6, FLAG-tagged-CDSN/P was present in the input. CDSN/P, however, did not interact with 
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Figure 5. Membrane translocated LCE1E and LCE3C proteins do not co-localize with CDSN 
upon co-expression in human primary keratinocytes. eCFP-LCE (green signal in B, E, H, K) was localized at the cell membranes due to the Palm-Myr tag fused to the N-terminus of the protein. However, mRFP-CDSN (red signal in A, D, G, J) remained in cytoplasm. A yellow signal could not be observed in overlays (C, F, I, L) indicating lack of direct protein-protein interaction. For LCE2A, LCE3B, LCE5A proteins similar results were obtained (data not shown).
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immobilized LCE3B protein as FLAG-tagged CDSN/P was not detectable in the pulled-down fraction. 
DiscussionIn this study we found no direct protein-protein interactions between LCE proteins, including LCE3B and LCE3C, and two CDSN variants, encoding the ‘neutral’ and ‘psoriatic’ variant of the protein. Although many of the proteins 
of the cornified envelope are covalently cross-linked, reversible protein-protein interactions are also relevant for 
cornified envelope assembly as was recently shown by Yoneda et al. [27]. This appears not to be the case for CDSN and LCE proteins studied here. We demonstrated that LCE2 and CDSN partially co-localize in human skin. Studies using immunoelectron analysis demonstrate that both proteins are 
present along cornified envelopes, however their exact localization differs. CDSN is mainly localized at the desmosomal region, whereas LCE2 is 
present along the cornified envelope 
and not specifically at desmosomes [10, 28]. Since no LCE3-antibodies are available and LCE2 and LCE3 genes show distinct expression patterns in normal versus psoriasis skin [10], it is, until now, unknown if LCE3 proteins co-localize with LCE2 proteins. Moreover, it has been postulated that the different LCE groups have distinct functions [8], which may complicate the story for LCE3 in the aforementioned LCE2 and CDSN co-localization. Due to our study design, indirect protein-protein interactions between the proteins cannot be ruled out. In this study, we also used primary human keratinocytes, however, we overexpressed our proteins of interest. Therefore possible linker proteins may be present, nevertheless in a too low concentration to have any effect. In addition, it should be taken under consideration that the employed tags 
may have influenced the results. These tags may negatively affected protein folding and function, for example domains that mediate the interaction may be disrupted by sterical hindrance, or these may be buried inside the protein. Especially for LCE proteins, which are small 12 kDa-proteins, the use of relative large mRFP, eCFP and GST tags (over 25 kDa in size) may have negative effects. We used N-terminally fused proteins, it might be possible that C-terminally fused proteins would, to some extent, behave differently. To overcome obstacles connected with application of large epitope tags the implementation of other systems that could shed some light on LCE function, such as yeast two-hybrid and tandem 
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Figure 6. In vitro GST pull-down assay with 
GST-LCE3B and 3xFLAG-CDSN/P expressed 
in COS-1 cells. FLAG-tagged CDSN (57 kDa) was detected in input but not in the pull-down fraction proving lack of direct interaction between recombinant LCE3B and CDSN/P proteins.
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affinity purification (TAP)-approach, should also be considered for future studies [29, 30].In conclusion, we could not demonstrate direct protein-protein interactions between LCE proteins and CDSN in this study. Further research will be necessary to explore the function of the different LCE proteins in general and in relation to psoriasis.
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TOWARDS IDENTIFICATION OF LATE CORNIFIED ENVELOPE 3 
(LCE3) PROTEIN INTERACTION PARTNERS USING TANDEM 
AFFINITY PURIFICATION (TAP) ASSAY IN PRIMARY HUMAN 
KERATINOCYTES
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Deletion of two genes of the Late Cornified Envelope (LCE) family, LCE3B and LCE3C, is an established risk factor for psoriasis. On the human genome 18 LCE genes are localized, divided over six groups, which have a putative role in skin barrier function. In the literature, no information about LCE3 protein function is available so far. Tandem affinity purification (TAP) is an unbiased approach to purify protein complexes and analyze these using mass-spectrometry. Here we optimized the experimental conditions to perform TAP-tagging in primary human adult keratinocytes using TAP-LCE3 proteins as bait. We showed that lentiviral delivery of the TAP construct and blasticidin selection are required to get sufficient number of TAP-protein producing keratinocytes. We determined that addition of phorbol 12-myristate 13-acetate (PMA) or coal tar to the culture medium during the last days of culture significantly increased the number of LCE positive keratinocytes. These findings will enhance the success rate of finding interaction partners of LCE proteins in primary human keratinocytes.
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Introduction
The deletion of the Late Cornified Envelope 3B and 3C (LCE3C_LCE3B-del) genes is an established risk factor for psoriasis [1, 2]. To our knowledge, four studies have been published presenting LCE protein data [3-6]. In mice, Marshall et al. [3] showed that Lce1d, which is homologous to human LCE1 group proteins [7], is expressed late during skin differentiation. In addition, they showed that Lce1d is a transglutaminase substrate and 
part of the cornified envelope (CE). Steinert et al. [5] found that a Late Epidermal Protein (LEP, now known as LCE) is cross-linked to involucrin and trichohyalin in murine CEs. Jonca and colleagues [6] demonstrated that also human LCE6A could act as a transglutaminase substrate. In our previous study, we indicated that LCE2 proteins are expressed along the CE in human skin [4]. Interestingly, each human LCE group has different amino acid sequences that may confer distinct properties to the protein. To gain more insight into LCE3 protein function, we optimized 
the tandem affinity purification (TAP) method for use in adult human 
primary keratinocytes to find possible interaction partners for LCE3. TAP is an unbiased, generic approach for the 
purification of protein complexes [8]. Although this strategy was originally developed in yeast, it is now also adapted for other systems, including insects [9], mammalian cells [10], plants [11] and bacteria [12]. TAP involves the 
fusion of two affinity modules to the protein of interest and introduction 
of the construct into the host cell or organism. Once expressed in cells, the TAP-tagged protein forms a complex with its endogenous partners. The dual-
affinity tag allows purification of the expressed target protein along with its interacting partners from cell extracts in two consecutive steps, which reduces 
non-specific background compared 
to single-step purification [13]. The method has proven to be better than the yeast-two-hybrid approach because it is more sensitive, less error-prone and capable of revealing interacting complexes [8, 14, 15]. In combination with mass spectrometry for protein 
identification, TAP technology constitutes a powerful tool for the characterization of protein complexes associated with a given target [16]. Depending on the (putative) function of the protein of interest, a suitable cell type needs to be selected for the TAP experiments. When proteins involved in general processes, e.g. mitosis or cytoskeletal processes, are studied 
COS-1 or HEK293 cell lines could be used. These cells are easily cultured 
in large quantities and are efficiently transfected. In our study we investigated 
a cell-type specific process, therefore we used primary human keratinocytes. The use of primary cells, which are notoriously hard to transfect, gives rise 
to specific problems, which needed to be solved before the TAP-experiments could be performed. Here we established and optimized the TAP protocol for use in primary human keratinocytes, which now can be 
applied to find interaction partners for 
LCEs and other skin specific proteins.
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plate using keratinocyte growth medium 
(KGM), consisting of KBM (0.15 mM Ca2+ BioWhittaker, Verviers, Belgium) supplemented with ethanolamine (0.1 mM; Sigma, St Louis, MO), phosphoethanolamine (0.1 mM, Sigma), bovine pituitary extract (0.4% vol/vol; BioWhittaker) epidermal growth 
factor (10 ng/ml; Sigma), insulin (5 μg/
ml; Sigma), hydrocortisone (0.5 μg/ml; Collaborative Research, Lexington, MA), penicillin, and streptomycin, supplemented with 10 µM Y-27632 (Sigma) as described previously [17, 19, 20]. Subsequently, each well was 
incubated with 2 μg of lentivirus for 4 hours. Next, cells were washed three times with PBS. After 48 hours of 
recovery in KGM supplemented with 10 
μM Y-27632, cells were harvested with trypsin-EDTA (Life Technologies). Cells 
were either prepared for flow cytometry 
analysis or grown to confluency in KGM 
supplemented with 10 μM Y-27632 and blasticidin (Sigma). To determine the optimal concentration of blasticidin, pLenti6.2-NTAPe5/V5-GFP transduced 
cells were grown to confluency in KGM 
supplemented with 10 μM Y-27632 and various concentrations of blasticidin (ranging from 0.5-2.5 µg/mL) and 
prepared for flow cytometry analysis.
Flow cytometryAfter harvesting with trypsin-EDTA, cells were washed with PBS. Next, cells were 
fixed using 3.7% paraformaldehyde (Merck chemicals, Darmstadt, Germany) for 30 min at room temperature. Cells were washed three times with PBS 
and finally resuspended in PBS + 2% fetal calf serum (FCS). All assays were 
run on an Epics Elite flow cytometer 
Materials and Methods
Lentiviral TAP vectorA lentiviral construct was produced: pLenti6.2-NTAPe5/V5-GFP, resulting in N-terminally fused TAP GFP protein. The 
GFP cDNA was amplified by PCR using pDest501 (Life Technologies, Carlsbad, CA) as a template. By using Gateway technology (Life Technologies) GFP was cloned into the pDONR201 vector and further cloned into pLenti6.2-NTAPe5/V5-Dest.
Lentivirus productionFor generation of recombinant lentiviral particles, the third-generation self-inactivating transfer vector pLenti6.2-NTAPe5/V5-GFP was used. Packaging of VSV-G pseudotyped viruses was performed by transient transfection of 293T cells as previously described [17]. 48 hours post transfection the 
virus was purified, concentrated to 1.5 ml, and dialyzed against sterile 
PBS using an Amicon filter (MWCO 100 kDa, Millipore, Cork, Ireland). Viral stocks are aliquoted and stored at -80 °C. Viral concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) kit 
(Murex Biotech Limited, Dartford, UK) targeting the viral envelope protein p24 and expressed as ng p24/µl.
Lentiviral transduction of adult 
keratinocytesPrimary human keratinocytes obtained from biopsies of healthy volunteers were cultured following the Rheinwald–Green system [18] and stored in liquid nitrogen until use. Liquid nitrogen-stored primary adult keratinocytes were 
grown to 40% confluency in a 6 wells 
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real-time PCR amplification of genes of interest using the MyiQ Single-Color Real-Time Detection System 
for quantification with SYBR Green and melting curve analysis (Bio-Rad). Expression of the target genes LCE2A, 
LCE2B, LCE2C, LCE2D, LCE3A, LCE3C, 
LCE3D and LCE3E was normalized to that of the housekeeping gene human ribosomal phosphoprotein P0 (RPLP0). 
Primer sequences and efficiencies were previously published [4].
Immunocytochemistry
After fixation slides were washed twice in PBS for 5 min, and further processed for LCE2 staining according to a previously published protocol [4]. Slides were mounted with glycerol-gelatin solution (Sigma) and examined using an Axioxkop 2 mot plus microscope (Carl Zeiss, Germany) coupled to AxioCamMRc5 camera.
Statistical analysisData are expressed as mean ± SD. Statistical analysis of qPCR data was 
performed on ΔCt values using SPSS software (release 16.0, SPSS, Chicago, IL). One-way analysis of variance (ANOVA), followed by LSD post hoc testing were perdformed, P-values of <0.05 were considered statistically 
significant.
Results
Optimization of transduction and 
number of TAP-protein producing cellsTo our knowledge, no TAP tag experiments have been performed using primary human adult keratinocytes. Primary human keratinocytes have a 
relative short life span and are difficult 
(Beckman Coulter, Cytomics FC500, Miami, FL, USA) equipped with an argon 
ion laser emitting at 488 nm. The flow cytometer was calibrated routinely, as recommended by the manufacturer. List mode data were acquired and analyzed using CXP Software (Version 2.1, 2005, Miami, FL, USA). A regional gate was set on forward versus side scatter to gate for viable cells in the sample being studied. At least 10,000 gated events were acquired per sample.
Submerged keratinocyte culturesPrimary adult keratinocytes were 
cultured to confluency in KGM supplemented with Y-27632. Cells were induced to differentiate by depletion of growth factors (bovine pituitary extract, epidermal growth factor, hydrocortisone, and insulin) 
in KGM (called KGM-)  as previously described [21, 22]. Differentiating cell cultures were stimulated with 1.8 mM CaCl2 (Sigma) or 250 ng/mL Phorbol 12-myristate 13-acetate (PMA, Sigma) or 2% coal tar (pix lithanthracis, BUFA, IJsselstein, The Netherlands) 
all in KGM-. Cells were harvested after 48 hours either for mRNA isolation or cells seeded on coverslips were 
fixed with 70% ethanol at -20°C for immunocytochemistry.
Quantitative real-time PCRRNA extracted from cultured human 
keratinocytes was used for first-strand cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) according to the manufacturer’s 
recommendation with an input of 1  μg of RNA. The reverse transcriptase product was used as a template for quantitative 
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to transfect [23]. Here we studied the 
efficiency of lentiviral delivery of the TAP-GFP construct and optimized the conditions to increase the number of TAP-GFP protein producing cells. Another advantage of the use of a lentiviral delivery system is that it leads to sustained expression without clonal selection [23]. Previous experiments in our lab showed that addition of the rho kinase inhibitor Y-27632 to cell culture medium prolonged the life span of adult human keratinocytes [17]. Moreover, the addition of Y-27632 enhanced lentiviral 
transduction efficiency [17]. To study the 
efficiency of TAP-transduction, primary human keratinocytes were infected with TAP-GFP virus and evaluated for the percentage of positively transfected 
cells over time by flow cytometry (Table 1). Both a amount and a time dependent effect were observed. Increasing the concentration of TAP-GFP virus led to more GFP-positive cells. Furthermore, a longer culture period after TAP-GFP 
transduction positively influenced the percentage of GFP-positive cells to a maximum of 38%.
Unfortunately, transduction efficiency, using 2 µg virus, of different batches TAP-GFP virus varied between 1.5 - 40.2 % at 2 days after transduction. This might be caused by suboptimal production of the virus in the 293T cells, nevertheless the exact reason is still unclear. To increase the number of positively transduced cells, the effect of blasticidin addition to the culture medium was studied. In pLenti6.2-NTAPe5/V5-vectors a blasticidin resistance cassette is present, which allows for blasticidin selection of transduced cells. Figure 1 shows the 
beneficial effect of the addition of blasticidin to the culture medium on the percentage of GFP-positive cells. Already at 0.5 µg/mL a large positive effect can be observed, which stabilizes when the concentration is further increased. Addition of 0.5 µg/mL blasticidin to culture medium of non-transduced primary keratinocytes did not lead to increased cell death after three days of culture (data not shown), which is in line with the results of Bento et al. [24]. Blasticidin could possibly inhibit cell growth of the non-transduced cells. In future experiments the keratinocyte culture medium will be supplemented with 0.5 µg/mL blasticidin starting at two days after transduction.
Optimizing the expression of LCE genes 
and proteins in submerged cultureIn submerged culture, LCE genes are not highly expressed [4]. Hypothetically, the interaction partners of LCE proteins could only be present, when 
LCE genes are expressed at sufficient levels. Alternatively, the LCE proteins might be part of a dynamic network, of which the composition changes during keratinocyte differentiation. 
Chapter 10
virus 
(µg)
% green cells (day x)
2 3 7 11 141 9.2 15.9 22.9 26.5 32.81.5 20.7 ND ND ND ND2 23.4 ND ND ND ND4 38 ND ND ND ND
Table 1. Concentration and time affect 
percentage of positively transduced 
primary adult human keratinocytes.
Day x represents number of days after transduction. Values after 2 and 3 day of culture derived from independently infected wells. Values from 7, 11, 14 
days derived from P1 cells: cells confluent at 3 days were passaged and seeded in different densities. 
Confluent and near confluent wells were analyzed for GFP expression. ND, not determined.
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experiments because of high costs of 
the final TAP-tag experiments. Next, we analyzed the expression of the LCE2 genes in the same samples, which were 
also significantly induced by coal tar and PMA (Figure 3 and supplementary table 1). Subsequently, we used our pan-LCE2 antibody, which recognizes a common part present in all LCE2 proteins, to stain stimulated submerged cells for the presence of LCE2 proteins (Figure 3B). Also at the protein level, coal tar and PMA strongly induce the LCE2 expression in submerged cultured keratinocytes. To obtain high LCE3 expression levels we suggest a two day stimulation of transduced keratinocytes with coal tar or PMA at the moment the 
cells are confluent.
DiscussionThe present study was designed to optimize the conditions to use the TAP-tag technique in primary human keratinocytes. We showed that blasticidin selection after transduction of the primary human keratinocytes 
is beneficial for the number of TAP-protein producing cells. In addition, we demonstrated that both PMA and coal tar stimulation induced LCE protein expression levels in submerged keratinocyte culture.The expression of the TAP-GFP protein was rather low. Strikingly, the percentage of GFP-positive primary keratinocytes transduced with SIN-GFP virus, using the same protocol, reaches >90% [17]. We also noticed that the TAP-GFP transduced cells are less intense GFP-positive, indicating a lower GFP expression. This might be a 
promoter effect; GFP is driven by a PGK 
Therefore we evaluated the potency of several stimuli to increase the LCE3 gene expression levels in vitro (Figure 2). These stimuli are known to induce terminal differentiation in submerged keratinocyte culture: depletion of 
growth factors (KGM-) [21], switch to high calcium [21], addition of coal tar (unpublished data) and addition of phorbol 12-myristate 13-acetate (PMA) [25]. We also used a psoriasis associated cytokine mixture, containing 
IL-1α, TNF-α and IFN-γ, which induces expression of psoriasis associated genes [26].
Both coal tar and PMA significantly induced LCE3 expression levels in submerged keratinocyte cultures 
compared to the KGM- condition (Figure 2 and Supplemental Table 1 for dCT and p-values). Also the psoriasis-associated cytokine mixture induced the expression of the LCE3 
genes, though not significantly. This stimulus was excluded from further 
Towards TAP-tag from keratinocytes
Figure 1. Positive effect of blasticidin 
addition to culture medium. A total of 1 µg virus was used to transduce primary adult human keratinocytes derived from two different donors (D21 and D24). Transduction was performed independently for each condition tested. Two days after transduction, cells were harvested from wells, seeded in 
new wells and grown to confluency while blasticidin was added to the culture medium. 
Confluent and near confluent wells were analyzed for GFP expression.
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promotor and a CMV promoter in SIN-GFP and TAP-GFP viruses, respectively. Although it is generally regarded that 
CMV promoters are stronger than PGK promoters, CMV promoter strength also depends on cell type [27]. The rather low expression of TAP-GFP protein by the transduced keratinocytes might be 
beneficial for the subsequent TAP-tag experiment, because overexpression of the tagged protein can result in isolation of large quantities of chaperones and heat shock proteins [13].The TAP-tag used in our study is the streptavidin-FLAG tag (SF-tag) developed by Gloeckner and colleagues [28]. It consists of a tandem Strep II and FLAG tag and is 4.6 kDa in size. In 
both purification steps, proteins bound 
to the corresponding affinity matrix, e.g. Strep-Tactin resin and anti-FLAG 
agarose, can be efficiently released via competitive elution under naive conditions. The estimated recovery rate for this particular TAP tag ranges from 27 to 48% [28] which is among the highest recovery rates found for any of the existing TAP tags [13]. One 
of the advantages of the SF-tag is its small size. The LCE proteins are only 12 kDa and a large tag may interfere with its function. Important controls for the TAP-tag technique are the use of both N and C-terminally tagged proteins and use of an empty TAP vector or unrelated TAP-protein as control to identify false positive hits in the mass-spectrometry.In submerged culture, PMA and coal tar induced high LCE protein expression levels. Switching to high Ca2+ medium had no effect on LCE gene and protein expression levels. Jackson and colleagues [29] showed that high Ca2+ levels specifically induced LCE2 gene expression levels. No effect was observed for LCE3 expression. In their study human foreskin keratinocytes were used, which may react differently to high calcium levels than primary human keratinocytes. In addition, they also showed that LCE expression levels 
in vivo differ at various body sites. Penile skin has lower LCE2 expression levels than abdominal skin, which could also explain the differences found in the two studies. 
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Figure 2. LCE3 mRNA expression levels are significantly induced by PMA and coal tar in 
submerged culture. Five different stimuli were tested, KGM- (without growth factors), a psoriasis 
associated cytokine mixture containing IL-1α, TNF-α and IFN-γ, KGM- supplemented with 1.8 mM Ca2+, 2% coal tar, or 250 ng/mL PMA. Expression was normalized to RPLP0 expression in the 
same sample. For graphic representation, values for each gene were expressed relative to KGM- condition of the same donor, which was set at unity (dotted line in graph). * P<0.05 compared to 
KGM- condition. N=3 biological replicates. Mean ± SD.
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be confirmed using independent techniques, like yeast two-hybrid, GST-pull down, co-immunoprecipitation, and co-localization studies. 
The confirmed interaction partners will provide information about LCE function. Moreover, the genes encoding the interaction partners, especially the interaction partners of LCE3B and LCE3C, could be considered as new candidate genes for psoriasis.
AcknowledgementsWe would like to thank Dr. E. van Wijk (department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands) for providing Gateway destination vectors. Also thanks to Dr. J. Schepens and Dr. W. Hendriks (department of Cell Biology, Radboud University Nijmegen Medical 
The induction of sufficiently high LCE expression levels is likely to be necessary 
in order to find LCE interaction partners, because we are interested in 
processes in a specific state of a specific cell type: differentiated keratinocytes. The LCE interaction partners might only be present under these conditions. 
The TAP-tag method identifies non-covalently protein interactions. LCE3 proteins may be covalently linked to the CE, however, CE proteins also could interact non-covalently as was 
recently shown for loricrin and filaggrin using the yeast two-hybrid method [30]. Another problem could be that the untagged endogenous protein can compete with the tagged one for incorporation into protein complexes [13]. Finally, the results obtained using the TAP-tag method need to 
Towards TAP-tag from keratinocytes
Figure 3. LCE2 mRNA and LCE2 protein expression levels after several stimuli in submerged 
culture. (A) LCE2 mRNA expression levels are highly induced after coal tar and PMA stimulation. 
Four different stimuli were tested, KGM-, addition of 1.8 mM Ca2+, 2% coal tar and 250 ng/mL PMA. Expression was normalized to RPLP0 expression in the same sample. For graphic representation, 
values for each gene were expressed relative to KGM- condition, which was set at unity (dotted 
line in graph). * P<0.05 compared to KGM- condition. N=3 biologically replicates. Mean ± SD. (B) LCE2 protein data corresponds to LCE2 mRNA data. Primary human keratinocytes were grown on 
coverslips and stimulated. At the protein level, KGM- and Ca2+ showed hardly any LCE2 expression, whereas the expression of LCE2 proteins was strongly induced by the coal tar and PMA stimuli.
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The main function of skin is to provide a barrier between inside and outside 
of the body. The cornified envelope and embedding lipid layers are the main structures that provide skin barrier function in mammals. During epidermal differentiation these two structures are assembled in a tightly 
controlled process. The cornified envelope comprises over 20 proteins. The majority of genes encoding 
cornified envelope proteins are located on chromosome 1q21, in a region called the epidermal differentiation complex (EDC). One of the gene families 
present in the EDC are the late cornified envelope (LCE) genes, consisting of 18 highly homologous members, which are divided over six groups. Atopic dermatitis and psoriasis are common 
inflammatory skin diseases that have both environmental and genetics factors to their etiology. In 2006, mutations 
in filaggrin (FLG), an EDC gene, were shown to be major predisposing factors 
for atopic dermatitis [1]. This finding and the follow-up studies led to a paradigm shift addressing a defective skin barrier function as primary cause for atopic dermatitis. For psoriasis, over 20 genetic risk factors are known. Only two of these, however, involve genes that are mainly expressed in keratinocytes and not in the cells of the immune system: high copy number 
of the β-defensin gene cluster [2] and 
deletion of Late Cornified Envelope 3B and 3C genes (LCE3C_LCE3B-del) [3] (chapter 1). The goal of this thesis was to explore the role of LCE3C_LCE3B-del in psoriasis and other complex diseases and to investigate the function of the LCE proteins in the epidermis 
Chapter 2 reports the first replication 
study that confirmed the association between LCE3C_LCE3B-del and psoriasis in a German case-control cohort. The additional interaction analyses of known genetic risk factors for psoriasis (HLA-C*06, LCE3C_LCE3B-del, IL23R) revealed no interactions. In this study no relation between LCE3C_LCE3B-del genotype and age of psoriasis onset was observed. In a close collaboration with our clinical colleagues, which ensures detailed registering of patient data, we could demonstrate that not only HLA-C*06 but also LCE3C_LCE3B-del, and psoriasis-associated single nucleotide polymorphisms (SNPSs) in 
ERAP1 and IL23R are more frequently present in pediatric onset psoriasis. This is described in chapter 3. The differences between these data and the study presented in chapter 2 might be the result of careful registering of patient data and the used statistical methods. These data imply that in pediatric onset psoriasis genetic factors play an even more important role than in adult onset psoriasis. We hope that these data will motivate other centers to carefully register their patient characteristics, and to extract more information out of the large genome wide association studies. The large meta-analysis, presented in chapter 4, shows that LCE3C_LCE3B-del is a risk factor for psoriasis in 12 populations, including three Asian ones. Untill now, LCE3C_LCE3B-del is associated with psoriasis in over 15 populations [3-9]. Therefore LCE3C_LCE3B-del is regarded as an established genetic risk factor for psoriasis. Moreover, the meta-analysis showed that epistasis 
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[14, 15], whereas two others did not show an association [16, 17]. The meta-analysis, combining the four studies, demonstrated that LCE3C_LCE3B-del is also associated with psoriatic arthritis [15]. Furthermore, LCE3C_LCE3B-del was also shown to be associated with systemic lupus erythematosus [13] and with allergic contact dermatitis susceptibility [18], however, these studies have to be replicated before conclusions can be drawn. We did not 
find association between LCE3C_LCE3B-del and allergic contact dermatitis in a Dutch cohort (unpublished data). Overall these genetic studies imply that LCE3C_LCE3B-del may be a common risk factor for multifactorial 
inflammatory diseases. We found, by analyzing the expression of two LCE3 genes in different conditions, that 
LCE3C (when present on the genome) and LCE3E were hardly detectable in normal skin. In lesional psoriatic skin, however, expression of these LCE3 genes was induced, which also was the case after minor skin injury. We therefore hypothesized that a compromised skin barrier function plays a role in psoriasis susceptibility. Such a scenario might 
also explain the Koebner phenomenon, the appearance of psoriasis lesions after damage of the uninvolved skin, which is seen in approximately 25% of all psoriasis patients [19]. Therefore we investigated the possible association 
between the Koebner phenomenon in psoriasis patients and LCE3C_LCE3B-del, as described in chapter 7. After a survey among 192 psoriasis patients, we concluded that there is no association between LCE3C_LCE3B-
del and the Koebner phenomenon in 
between HLA-C*06 (located in psoriasis susceptibility region 1 (PSORS1)) and 
LCE3C_LCE3B-del (located in PSORS4), initially found in the Dutch cohort [3], was present in an American cohort as well. In an independent study, similar results were also found in a Chinese cohort [9]. Epistasis was not observed in the other cohorts studied in chapter 4, which might be due to population heterogeneity. To explore the association between LCE3C_LCE3B-
del and other inflammatory diseases, association studies were performed for atopic dermatitis (chapter 5) and rheumatoid arthritis (chapter 6). Although the linkage signal of atopic dermatitis to chromosome 1q21 is only partially explained by FLG mutations [10], we showed in chapter 5, by analyzing four independent European cohorts, that the remaining linkage is not explained by associations with 
LCE3C_LCE3B-del. Consequently, there are still unknown variants present in the EDC associated with atopic dermatitis. Recently, a copy number variant in the SPRR3 gene was shown to be associated with atopic dermatitis, which was independent of FLG status [11]. In case of rheumatoid arthritis (chapter 6), we detected a suggestive, 
but not significant, association with 
LCE3C_LCE3B-del in our Dutch cohort (P=0.093). Though, when combining our data with the previously published Spanish and Chinese data sets [12, 13] in a meta-anlysis, we could show a 
significant association. This illustrates the importance of replication of genetic 
findings in independent cohorts. For psoriatic arthritis two studies reported an association with LCE3C_LCE3B-del 
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psoriasis. Although this analysis was performed in a single group of patients, the P-value of 0.84 suggests that it is unlikely that analysis of another study population will lead to a different conclusion. Actually, it is not known if, 
at all, the Koebner phenomenon has a genetic component. Moreover, there are studies suggesting that the presence of 
the Koebner phenomenon is not an ‘all or nothing’ event [20], but depends on disease progression [21]. The last part of this thesis deals with the function of the LCE genes and proteins in epidermal biology. Chapter 
8 presents expression data of all LCE genes in vivo and in vitro, under normal and diseased skin conditions. As the LCE genes share a high degree of homology at the DNA and protein level, the choice 
of specific primers for quantitative PCR was limited. Nevertheless, we could analyze 16 out of 18 LCE genes. This study demonstrated that all LCE genes are mainly expressed in skin and oral epithelia. Furthermore, when comparing normal versus psoriasis skin and psoriasis non-lesional versus lesional skin, the LCE3 genes are differently expressed in contrast to the other LCE genes. The expression of 
LCE3 genes was induced in psoriasis, whereas the expression of the members of other LCE groups was downregulated. To investigate if skin barrier disruption might be a pathophysiological stimulus for LCE3 upregulation, LCE gene expression levels were compared before and after minor skin injury, induced by tape stripping. Under these conditions similar expression patterns emerged; 
LCE3 gene expression was induced, 
while the expression of the other LCE genes was downregulated. However, not only barrier disruption appeared to be a stimulus for LCE3 induction, as we also showed that cytokines associated 
with psoriasis, TNF-α, IL-1, IL-6, IL-17 and IL-22, induce LCE3 gene expression in human skin equivalents in vitro. Strikingly, we found that expression of 
LCE3 genes was already significantly increased in uninvolved skin of psoriasis patients compared to controls (unpublished data). Expression of other psoriasis-associated genes, for example 
DEFB4 (hBD2) and P13 (SKALP/elafin), were not increased in uninvolved skin. As the LCE3 genes are induced by psoriasis-associated cytokines in vitro and the knowledge that circulating cytokines are increased in psoriasis patients [22], we hypothesize that non-lesional skin is already in an activated state which includes an altered LCE3 expression pattern, and possibly altered skin barrier properties. Future studies will be necessary to test this hypothesis. Although interindividual heterogeneity is present, clear trends can be observed when analyzing LCE gene expression levels in different conditions. When comparing normal skin with atopic dermatitis skin, the expression of the 
LCE3 genes was also induced, while expression of the other LCE genes was downregulated. In addition, cluster analysis of LCE gene expression levels in normal, psoriasis and atopic dermatitis skin demonstrates a distinct cluster for the LCE3 genes (unpublished data). These data suggest a group-wise regulation of the LCE genes, with a distinct regulation for the LCE3 genes. 
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LCE3 gene expression is differently regulated. TALE (three amino acid loop extension) family of homeodomain transcription factors bind strongly to 
LCE1 and LCE2 promoters, whereas LCE3 promoters are weakly bound [27]. The TALE family of proteins are important regulators during development [28]. It was postulated that the epigenetic 
triMeK27-H3 marks control TALE access to LCE promoters in differentiating keratinocytes, because TALE proteins are more broadly expressed than LCE proteins [27] (Figure 1). Overall, the regulation of expression of the epidermal differentiation genes is a complex process. Besides the protein coding parts, also sequences functioning as transcriptional insulators or as transcription factor binding sites (Figure 2) are present in the EDC. Cooperative effects of 
epigenetically modified chromatin and factors may regulate LCE gene expression. Future studies will be necessary to explore these mechanisms.
In the study of Ezhkova et al. [23] it was shown that Ezh2, a polycomb repressor complex element, is involved in the regulation of LCE expression. Polycomb group genes form chromatin-remodeling complexes that regulate gene expression at the epigenetic level. Ezh2 catalyzes H3 trimethylation 
on lysine 27 (triMeK27H3) [24], which leads to gene silencing. Of the genes present in the EDC, especially the region harboring the LCE genes 
is enriched for triMeK27H3. Ezh2 expression was shown to be highest in proliferative undifferentiated basal cells. During differentiation Ezh2 expression diminishes, and in the stratum granulosum no Ezh2 is present [23]. Using Ezh2 conditional knock out mice, it was shown that Ezh2 prevents premature recruitment of AP1 transcriptional activator to the EDC genes [23]. The transcription factor family AP1 was previously shown to regulate loricrin and FLG promoter activity [25, 26]. Jackson and colleagues [27] showed that the LCE1, LCE2 and 
Summary and Discussion
Figure 1. Regulation of LCE expression. Left panel: schematic overview of the human epidermis. Middle panel: Expression of LCE proteins, Ezh2 polycomb repressor element, AP1 proteins and TALE proteins are represented by black boxes. TALE transcription factors are highly expressed in the terminally differentiating keratinocytes, although some TALE proteins are also expressed in basal, proliferating keratinocytes (dashed box). Rigt panel, mechanism by which the combination of Ezh2, AP1 and TALE factors might regulate LCE expression in skin.
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Next to the LCE genes, the SPRR and 
S100 gene families are located in the EDC on chromosome 1q21. The presence of multiple highly similar genes suggests evolution via gene 
amplification and then diversification, which was shown to be true for the S100 family [29, 30]. For example, S100A7 functions as a chemotactic agent and 
S100A10 is cross-linked to the cornified envelope [30]. For the SPRR gene family 
diversification was not demonstrated, though the highly homologous SPRR genes do show differential expression at distinct anatomical sites and in response to environmental stimuli, such as ultraviolet (UV) irradiation [31-33]. This implies that evolution of promoter or regulatory diversity has been more 
important then diversification of SPRR protein sequences and that protein dosage is important for function [32, 34]. Hence, conserved groups within the SPRR cluster could constitute an ‘extended promoter’ permitting far greater sensitivity to cellular and environmental stimuli than possible to achieve with a single or few genes [35]. We can transfer this knowledge to the 
LCE genes. LCE protein dosage may be important for function. In addition, the presence of multiple LCE1, LCE2 and 
LCE3 genes warrant a sensitive system. Moreover, in line with the S100 proteins, the function of LCE3 proteins may be distinct from the function of the other LCE proteins. For a mouse Lce1 protein and human LCE2 and LCE6A proteins it was shown that these proteins are likely 
to be incorporated into the cornified envelope [36-39]. This structure, together with the lipid envelope, provides the actual skin barrier function 
[40]. To our knowledge, no data about LCE3 protein function is available. Therefore we explored the function of LCE3 proteins in chapter 9 and chapter 
10. Based on the epistasis between 
LCE3C_LCE3B-del and HLA-C*06 and the high linkage disequilibrium between 
HLA-C*06 and corneodesmosin (CDSN), 
an important cornified envelope protein, we investigated the possible interaction between LCE proteins and corneodesmosin, which is described in chapter 9. Using molecular biology approaches, co-localization studies and GST-pull down, we could not demonstrate a direct interaction between corneodesmosin and the studied LCE proteins. Chapter 10 describes the optimization of an 
unbiased approach, tandem affinity 
purification (TAP), for use in adult human primary keratinocytes to identify LCE3 protein interaction partners. Lentiviral delivery of the TAP-LCE3 construct and blasticidin selection of the positively transduced cells are necessary to obtain 
sufficient TAP-protein producing cells. We evaluated several stimuli that induce 
LCE expression levels, which may be important for future experiments. Upregulation of LCE proteins was achieved by addition of phorbol 12-myristate 13-acetate (PMA) or coal tar to the culture medium. The TAP-tag method, along with for example yeast-two-hybrid, might identify interaction partners for the LCE3 proteins. These partners will provide insight into LCE3 gene function. Moreover, genes encoding these interaction partners might be interesting candidate genes for psoriasis. Another interesting question that will provide information about 
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CTCF binding sites are known isolators, which regulate the expression of neighboring genes. Different mechanisms about the blocking mechanism are proposed. The enhancer-blocking model is suggested, in which a CTCF site located between an enhancer and a promoter prevents the enhancer from activating the promoter [41]. Furthermore, recent research demonstrated that interactions between two (distinct) CTCF sites mediate chromatin looping with separate regulation of the genes within and outside the loop [42]. The transcription start sites of LCE3C and LCE3D, the two CTCF-site adjacent genes, are located at approximately 13 and 4 kb from the CTCF site, respectively. Also a conserved non-coding element which 
functions as an epidermal specific enhancer [43] is located in the deleted region. The loss of this enhancer, the Rad21 binding site and the CTCF site in individuals harboring LCE3C_LCE3B-del may function as contributing factors in disease by affecting global transcription of the EDC genes. Further research will be necessary to elucidate the roles of these non-coding elements.  For 
LCE3 function is: Are LCE3 proteins transglutaminase substrates? If so, then it is likely that the LCE3 proteins are incorporated into the CE. If not, and preliminary data suggest this, then LCE3 proteins have other, still unknown, functions. Future results will elucidate the function(s) of the LCE3 proteins.
How does LCE3C_LCE3B-del lead 
to increased risk of complex 
diseases?We now know that the deletion of the 
LCE3B and LCE3C genes is a risk factor 
for psoriasis and other inflammatory diseases. As mentioned above this does not merely involve the removal of the coding regions of the LCE3B and 
LCE3C genes. Detailed analysis of the 32.2 kb deleted segment reveals that in this region, next to the LCE3B and 
LCE3C genes, a CTCF binding site, which overlaps a Rad21 transcription binding site, is localized (Figure 2). Moreover, the deletion of LCE3B and LCE3C brings the LCE3A and LCE3D genes in close proximity. This altered positional 
configuration of regulatory and coding sequences may also have consequences on transcription rates.
Summary and Discussion
Figure 2. Detail of LCE3 region on chromosome 1q21. Red bar indicates LCE3C_LCE3B-del region. Transcription factor binding sites (black characters) and CTCF binding sites in normal 
human epidermal keratinocytes (NHEK) (pink peaks) are shown. The deletion of the LCE3B and 
LCE3C genes also deletes a Rad21 binding site and a CTCF binding site (NCBI36/hg18). 
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example, we could study the effect of 
LCE3C_LCE3B-del by analyzing gene expression levels of the other LCE genes, or EDC genes, in skin biopsies from healthy individuals that are either homozygous for the deleted or non-deleted LCE3C_LCE3B haplotype. Because of the known heterogeneous 
LCE gene expression levels between individuals a lot of volunteers need to be tested, before conclusion could be drawn. Another option would be to use cultured cells instead of skin biopsies. We could culture keratinocytes, either homozygous for the deleted or non-deleted LCE3C_LCE3B haplotype, and compare the expression levels of all other LCE genes. An advantage of using cells is that the effect of different stimuli could be tested and to analyze their effects on gene expression levels in the different LCE3C_LCE3B genotypes. Our data suggest a role for the LCE3 genes in skin barrier function. Though a direct relation has not yet been established. For involucrin and loricrin, which are also located in the EDC, it was shown, using knock-out mice, that deletion of these genes had little effect on CE formation and skin barrier function [44, 45]. Possibly other EDC genes compensate loss of these genes. Loss of corneodesmosin, however, was shown to be lethal [46]. To study the direct relationship between LCE3C_
LCE3B genotype and barrier function, transepidermal water loss (TEWL) after tape stripping of healthy individuals, with known LCE3C_LCE3B genotypes, could be analyzed in time. In addition, 
penetration of fluorescent dyes could be tested in in vitro human skin equivalents 
derived from donors, which are either homozygous for the deleted or non-deleted LCE3C_LCE3B haplotype. These skin equivalents could be stimulated towards a psoriasis-like phenotype to induce LCE3 gene expression levels. We can only speculate on the role of the deletion of LCE3B and LCE3C in the development of psoriasis, psoriatic arthritis and rheumatoid arthritis. The frequency of the deletion is high in the general population (about 60-70%) and is in fact more prevalent than the undeleted allele. As the intact LCE3B and LCE3C genes are ancestral and the deletion is a derived state, there might be a possible evolutionary pressure to lose these genes. As LCE3B and LCE3C are generally expressed at low levels in normal skin, the situation is different 
from filaggrin and atopic dermatitis. With respect to atopic dermatitis it has been suggested that a slightly leaky skin barrier could allow penetration of microbial antigens and would favor natural vaccination thereby protecting against pathogens [47]. In the case of LCE3B and LCE3C expression is only induced after barrier disruption. Speculatively, incomplete barrier repair after minor injury might lead to antigen penetration and natural immunization against pathogens. The downside is explained in Figure 3 demonstrating our hypothesis about the role of LCE3C_
LCE3B-del in the etiology of psoriasis. Similar mechanisms with respect to the role of LCE3C_LCE3B-del in psoriasis, could be expected in the other diseases linked to LCE3C_LCE3B-del. Any model that tries to explain a disease should take clinical, pharmacological, cell 
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SKALP/elafin and members of the LCE3 group). Under normal steady state 
conditions, superficial skin injury and exposure to PAMPs will quickly lead to keratinocyte activation, elimination of infectious agents, barrier repair and restoration of homeostasis. In genetically predisposed individuals, minor injury and exposure to PAMPs and cytokines could lead to enhanced 
inflammatory responses [51], to 
increased production of β-defensins in individuals with high copy numbers 
[52], and insufficient or delayed skin barrier repair in individuals that are heterozygous or homozygous for 
LCE3C_LCE3B-del [3, 36]. This will affect the innate and adaptive immune system in several ways. First, the secretion of mediators like IL-8, CXCL10 and 
β-defensins will attract neutrophils, T-cells and dendritic cells (DC) to the epidermal compartment. Secondly, incomplete barrier repair will allow sustained penetration of PAMPs or even larger (protein) antigens that will be taken up by Langerhans cells and DCs, and presented to T-cells. At this point, T-cell activation will be initiated, which could be facilitated by genetic predispositions such as HLA-C*06 or polymorphisms in genes of the IL-23 pathway and other factors. The observed epistatic interaction between 
LCE3C_LCE3B-del and HLA-C*06 could be explained in the context of such a mechanism. Sustained penetration of proteins antigens with HLA-Cw06 restricted immunodominant epitopes 
could cause antigen-specific activation of CD8+ T-cells, leading to secretion 
of TNF-α and interferon-γ (IFN-γ). 
This is compatible with the TNF-α and 
biological and genetic data into account. On basis of the available genetic data we propose that candidate genes with a presumed or proven role in the innate and adaptive immune system are 
important. In figure 3 we have tried to put these genetic factors into place, in relation to biological and clinical data.
A model for the pathogenesis of 
psoriasisThe epidermis is continuously exposed to mechanical trauma and subclinical infections. Therefore, environmental antigens and microbial components collectively named pathogen associated molecular patterns (PAMPs) will enter the epidermis. These PAMPs can be derived from resident commensal microorganisms, or from sources elsewhere in the body (throat, gut, lungs). PAMPs can activate keratinocytes and immunocompetent cells via pattern recognition receptors (PRRs) like the Toll-like receptors (TLR), NOD-like receptors (NLR), C-type lectin receptors (CLR) and RIGI-like helicases (RLH) [48, 49]. These PAMPs activate the epidermal innate immune system and drive expression and secretion of antimicrobial proteins (defensins, SLPI, S100 proteins and LL-37) and chemokines/cytokines such 
as IL-8, CXCL10, IL-1β and TNF-α [50]. Minor disturbances of the skin barrier will also initiate a repair response which includes upregulation of regular skin barrier proteins (involucrin, transglutaminase-1) but will also induce de novo expression of structural proteins putatively involved in repair, regeneration and temporal barrier recovery (e.g. keratins 6 and 17, SPRRs, 
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IFN-γ keratinocyte gene expression signature found in psoriatic epidermis. In a similar way, the observed epistasis of HLA-C*06 and ERAP1 [53] can be explained by preferred trimming of immunogenic HLA-Cw06 restricted peptides from relevant antigens by the ERAP1 protease. So far, no T-cells 
specific for a defined HLA-Cw06 restricted peptide have ever been 
identified in psoriasis. It is therefore not clear whether a regular adaptive immune response to foreign proteins is relevant in this disease. Similarly, no convincing evidence for an autoreactive response has been obtained so far. 
Assuming that HLA-C*06 is the true causative gene of PSORS1, it remains to be proven if HLA-Cw06 is a classical MHC allele involved in presentation of self peptides, or crosspresentation of non-self peptides leading to (cross)priming of T-cells. Similarly, a role of HLA-Cw06 
in the interaction with NK-cells via killer immunoglobulin receptors cannot be ruled out. Whatever the mechanism of T-cell activation may be, either antigen-driven or not, large numbers of activated CD4+ and CD8+ cells are present in the lesion. CD8+ cells in particular also invade the epidermis and are in close contact with 
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Figure 3. Tentative model of psoriasis based on genetic and cell biological data. Polymorphisms of genes involved in skin barrier and immune function will cooperatively determine the exposure, handling and response to environmental stimuli (PAMPs, antigens). Depending on the host 
genotype this may lead to increased penetration of antigens, low-grade inflammation caused by keratinocyte activation and chemotaxis of immunocompetent cells. Ultimately, this could lead to activation of adaptive immunity in genetically predisposed individuals that respond to hitherto 
unidentified external antigens, or auto-antigens through molecular mimicry. The ensuing, (HLA-Cw6-restricted) immune response which includes secretion of Th1 and Th17 cytokines will in 
turn cause activation of keratinocytes, resulting in a vicious cycle and chronicity of inflammation. Reprinted from [36] with permission from Elsevier.
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keratinocytes or from immunocytes, and has indeed proven to be an effective therapy [54]. Retinoids suppress cytokine-induced keratinocyte activation and will decrease defensin and cytokine secretion [55]. Vitamin D3 derivatives will inhibit keratinocyte proliferation [56] and normalize epidermal differentiation thereby and promoting skin barrier restoration. In addition, both retinoids and vitamin D3 derivatives may also act on the immune system by stimulating the expansion of regulatory T-cells or suppressing Th17 function [57, 58]. Various other successful antipsoriatic therapies such as corticosteroids, dithranol and methotrexate may act on many points in the vicious circle as they are found to be immunosuppressive but can also affect keratinocyte proliferation and differentiation [59, 60]. Even the 
observed moderately beneficial effects of skin occlusion as a monotherapy could be explained by decreasing the exposure to exogenous stimuli using an 
artificial skin barrier [61]. In summary, there are now more than 25 psoriasis risk genes known, and two of them (HLA-C*06 and LCE3C_LCE3B-del) 
contribute a significant proportion of the population attributable risk. At least three different biological pathways (adaptive immunity, innate immunity and skin barrier) are known to be involved, and their potential mode of interaction is illustrated in Figure 3. We believe that this model generates testable hypotheses which may uncover the pathobiological mechanisms of psoriasis, and could contribute to prevention and therapy for psoriasis.
keratinocytes and Langerhans cells. These activated T-cells will secrete 
Th1 and Th17 cytokines (IFN-γ, TNF-α, IL-17, IL-23, IL-22) which will further 
activate the keratinocytes. IFN-γ and Th17 cytokines will also synergize 
with IL-1 and TNF-α, e.g. derived from keratinocytes, to further enhance expression of antimicrobial proteins and chemokines by keratinocytes. This scenario creates a vicious circle: activated keratinocytes produce chemokines and antimicrobial proteins that attract immunocompetent 
cells. Keratinocytes will continue to proliferate, and differentiate incompletely, thereby expressing genes that make a provisional skin barrier, which may be inferior in individuals carrying heterozygous or homozygous deletions of the LCE3B and LCE3C genes. At the same time the expression of some genes involved in normal 
cornification (e.g. FLG and loricrin) is suppressed. The resulting incomplete barrier of lesional psoriatic skin will continuously allow PAMPs and protein antigens to enter the skin and activate immunocompetent cells. As there is no negative feedback in the process once initiated (depicted in Figure 3), this could explain chronicity of a lesion. From the scheme in Figure 3 it is also evident that the vicious circle can be interrupted at any point, using the appropriate medication. T-cell directed therapies will suppress secretion of Th1 and Th17 cytokines, resulting in a decrease of keratinocyte activation and a concomitant suppression of keratinocyte-derived chemokine secretion. Anti-TNF will act on secreted or membrane bound TNF, either from 
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De huid, en met name de opperhuid (epidermis), vormt de barrière tussen de binnen- en buitenkant van ons lichaam. De barrièrefunctie van de huid wordt met name bepaald door de bovenste laag van de opperhuid, de hoornlaag, die bestaat uit dode cellen (corneocyten). Deze cellen bevatten 
een eiwitschild (de ‘cornified envelope’) welke omgeven wordt door vetten. 
Tezamen vormen de cornified envelope en de vetten een effectieve fysische- en waterbarrière. De vorming van de 
cornified envelope is een nauwkeurig gereguleerd proces, waarbij vele verschillende eiwitten betrokken zijn. De meeste van de genen die voor deze eiwitten coderen liggen bij elkaar op het genoom, op chromosoom 1q21. Deze regio op het genoom wordt dan ook wel het ‘epidermale differentiatie complex’ (EDC) genoemd. Een familie van genen aanwezig in het EDC zijn de ‘Late 
Cornified Envelope’ (LCE) genen. Deze familie bestaat uit 18 sterk homologe genen en is verdeeld over zes groepen: 
LCE1-LCE6. De meest voorkomende ontstekings-ziekten van de huid zijn eczeem en psoriasis.  Beide worden veroorzaakt door een combinatie van genetische en omgevingsfactoren. In 2006 zijn 
mutaties in filaggrine (FLG), een gen gelegen in het EDC, gevonden als belangrijke genetische risicofactor voor het krijgen van eczeem. Deze vinding heeft geleid tot een veranderde kijk op eczeem. Tot dan toe werd een verstoord immuunsysteem gezien als belangrijkste oorzaak, maar de 
FLG mutaties lieten zien dat ook een verminderde huidbarrière functie 
een belangrijke rol speelt bij het krijgen van eczeem. Meer dan 25 verschillende genetische risicofactoren voor psoriasis zijn inmiddels bekend. Slechts twee van deze risicofactoren zijn genen die tot expressie komen in de huidcellen, de keratinocyten, en niet in het immuunsysteem: een hoog kopie-aantal (‘copy number’) van de 
β-defensin genen en deletie van de 
Late Cornified Envelope (LCE) 3B en 3C genen (LCE3C_LCE3B-del) (hoofdstuk 
1). Het doel van mijn onderzoek was om de rol van LCE3C_LCE3B-del in psoriasis 
en andere inflammatoire aandoeningen te onderzoeken en om de functie van de verschillende LCE eiwitten in de epidermis te achterhalen.
Hoofdstuk 2 beschrijft de eerste studie waarin de initiële vondst van de associatie tussen LCE3C_LCE3B-del en psoriasis wordt bevestigd in een groot Duits psoriasis cohort. De analyse van interacties tussen bekende genetische risicofactoren voor psoriasis (HLA-C*06, LCE3C_LCE3B-del en IL23R) 
liet geen significante bijdrage van de onderzochte interacties zien, op het krijgen van psoriasis. In hoofdstuk 3, waarbij we nauw hebben samengewerkt met onze clinici om zo goed gedocumenteerde patiënten data te verzamelen, laat zien dat verschillende genetische risicofactoren voor psoriasis (HLA-C*06, LCE3C_LCE3B-del, IL23R, 
ERAP1) vaker voorkomen in patiënten met psoriasis vanaf de kinderleeftijd. Deze data impliceren dat bij psoriasis vanaf de kinderleeftijd (psoriasis die 
ontstaat ≤ 18 jaar) genetische factoren een belangrijkere rol spelen dan bij psoriasis die op latere leeftijd ontstaat. Een grote meta-analyse, gepresenteerd 
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in hoofdstuk 4, laat zien dat in 12 verschillende populaties, waaronder drie Aziatische, LCE3C_LCE3B-del een risicofactor is op het krijgen van psoriasis. De genetische interactie tussen HLA-C*06 en LCE3C_LCE3B-del, welke al was gevonden in de eerste 
LCE3C_LCE3B-del studie voor het Nederlandse cohort, werd ook gevonden in een Amerikaans cohort. In de andere cohorten was deze genetische interactie niet aanwezig, wat zou kunnen komen door populatieverschillen. We hebben ook onderzocht of LCE3C_
LCE3B-del een genetische risicofactor is 
op het krijgen van andere inflammatoire aandoeningen zoals atopisch eczeem en reumatoïde artritis. In hoofdstuk 5 hebben we vier verschillende Europese cohorten van patiënten met eczeem onderzocht en concludeerden we dat 
LCE3C_LCE3B-del geen risicofactor is op het krijgen van eczeem. Voor reumatoïde artritis hebben we in hoofdstuk 6 ons Nederlandse cohort bestudeerd. In dit 
cohort vonden we geen significante relatie tussen LCE3C_LCE3B-del en het krijgen van reuma. Echter, in de literatuur waren ook data van twee andere cohorten beschikbaar, en bij het combineren van de drie cohorten in een meta-analyse vonden we dat 
LCE3C_LCE3B-del een risicofactor is op het krijgen van reumatoïde artritis. In onze vorige studie vonden wij dat de expressie van de LCE3C (indien aanwezig op het genoom) en LCE3E genen in normale huid zeer laag was. Desalniettemin nam de expressie van deze genen in aangedane psoriasishuid toe. Dit was ook het geval na lichte beschadigding van de huid. Hierop baseren wij onze hypothese dat een 
verminderde barrièrefunctie van de huid een oorzaak van psoriasis zou kunnen zijn. Dit zou ook een verklaring kunnen 
vormen voor het zogenoemde ‘Koebner fenomeen’ dat in 25% van de psoriasis patiënten voorkomt. Dit fenomeen is het ontstaan van psoriasisplekken na beschadiging van de onaangedane huid. Om die reden hebben wij in hoofdstuk 
7 de relatie tussen LCE3C_LCE3B-del en 
het optreden van het Koebner fenomeen in psoriasis patiënten onderzocht. Na een onderzoek onder 192 psoriasis patiënten hebben we geconcludeerd dat 
LCE3C_LCE3B-del het optreden van het 
Koebner fenomeen in deze patiënten niet verklaart. Het laatste deel van dit proefschrift behandelt de studies naar de functie van de LCE genen en eiwitten in de epidermis. Hoofdstuk 8 presenteert expressie data van vrijwel alle humane 
LCE genen in vivo en in vitro. Deze studie laat zien dat de LCE genen voornamelijk een rol spelen in de huid en het mondepitheel. Opvallend was dat wanneer de expressie van de verschillende LCE genen wordt vergeleken in gezonde huid versus psoriasis huid, en in onaangedane versus aangedane huid van psoriasis patiënten, de LCE3 genen anders tot expressie komen dan de rest van de LCE genen. De expressie van de LCE3 genen is verhoogd in psoriasishuid vergeleken met gezonde huid, terwijl de expressie van de andere LCE genen juist verlaagd is. Ook na lichte beschadiging van de huid zijn dezelfde expressiepatronen zichtbaar; expressie van de LCE3 genen is verhoogd, terwijl de expressie van de andere LCE genen is verlaagd. Beschadiging van de huid is dus een 
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stimulus voor LCE3 genexpressie. Ook cytokines die betrokken zijn bij 
psoriasis (TNF-α, IL-1, IL-6, IL-17 en IL-22) kunnen de LCE3 genexpressie omhoog brengen hetgeen we hebben gedemonstreerd in 3D huidconstructen 
in vitro.Voor een muizen Lce1 eiwit en de humane LCE2 en LCE6A eiwitten is aangetoond dat deze hoogstwaarschijnlijk 
worden ingebouwd in de cornified envelope. Er zijn nog geen eiwitdata beschikbaar ten aanzien van de LCE3 eiwitten. Daarom hebben we in de laatste twee hoofdstukken de functie van de LCE3 eiwitten onderzocht. In 
hoofdstuk 9 hebben we de directe interactie tussen de LCE eiwitten en corneodesmosine (CDSN) onderzocht. Deze studie was gebaseerd op de reeds bekende genetische interactie tussen 
LCE3C_LCE3B-del en HLA-C*06. We weten dat HLA-C*06 vaak samen op het genoom voorkomt met bepaalde varianten van het CDSN gen, coderend voor corneodesmosine, en dat het eiwit corneodesmosine een onderdeel is van 
de cornified envelope. Om die reden zou een directe interactie tussen de LCE eiwitten en corneodesmosine voor de hand liggen, hetgeen we hebben onderzocht door middel van moleculair biologische technieken, zoals co-lokalisatie studies en GST pull-down. Met behulp van deze methodes konden we de directe interactie tussen de LCE eiwitten en corneodesmosine echter niet aantonen. Hoofdstuk 10 beschrijft de optimalisatie van een techniek om LCE3 interactiepartners te vinden in primaire humane keratinocyten om zo meer te leren over LCE3 eiwit functie. Met behulp van deze techniek: ‘tandem 
affinity purification’ (TAP) kan zonder een vooraf opgestelde hypothese op zoek worden gegaan naar interactiepartners van het eiwit van interesse. Doordat we primaire cellen gebruiken zullen we ons moeten wenden tot lentivirale overbrenging van het TAP-LCE3 construct in de cel. We hebben gevonden dat selectie van positief geïnfecteerde cellen door toevoeging van het antibioticum blasticidine aan het kweekmedium het aantal TAP-eiwit producerende cellen positief beïnvloedt. Verschillende stimulatiemiddelen zijn getest op het verhogen van LCE gen- en eiwitexpressie, wat van belang zou kunnen zijn voor het vinden van LCE3 interactiepartners. Mogelijkerwijs zijn deze alleen aanwezig als LCE genen ook tot expressie komen. De   genen en eiwitten kwamen het hoogst tot expressie na toevoeging van phorbol 12-myristate 13-acetate (PMA) of koolteer. De interactiepartners van de LCE3 eiwitten die wij in de toekomst hopen te vinden, zullen inzicht verschaffen in LCE3 eiwitfunctie. De genen die coderen voor deze interacterende eiwitten kunnen interessante nieuwe risicofactoren zijn voor psoriasis. Ook zal deze data informatie verschaffen over de rol van de LCE3C_LCE3B deletie in psoriasis. Hetgeen nieuwe handvatten voor therapie zou kunnen bieden.  
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DankwoordEn dan is het zover: het werk is gedaan, je boekje is zo goed als af en je kunt het dankwoord gaan typen… Want ook voor dit proefschrift telt: dat alleen mijn naam op de voorkant staat, betekent niet dat ik alles alleen gedaan heb. Sterker nog, zonder hulp was dit proefschrift er niet eens geweest. Allereest wil ik natuurlijk Joost Schalkwijk bedanken. Je hebt me geïnspireerd en gestimuleerd om een goede en kritische wetenschapper te worden. Ik heb veel van je geleerd. Dankjewel voor je begeleiding en dat je deur altijd open stond. Ook Patrick Zeeuwen heeft me begeleid en geholpen met allerlei praktische zaken op het lab. Bovendien is hij ooit begonnen met de LCEs: niet te geloven toch dat uit de samenwerking met de Spaanse groep zoveel onderzoek in Nijmegen is voortgevloeid. Ik hoop dat ik ooit nog net zo goed georganiseerd word als jij! 
Ook wil ik Peter van de Kerkhof graag bedanken dat hij altijd zo enthousiast was over mijn onderzoek, daar kreeg ik altijd veel positieve energie van. Ook legde hij vaak de link naar de patiënt, waar we het uiteindelijk allemaal voor doen. Ik ben ook veel dank verschuldigd aan mijn collega’s van het lab, voor jullie hulp, de dingen die ik van jullie heb geleerd en ook zeker voor alle gezelligheid. Vanaf dag 1 zat ik bij Patrick J op de kamer en je hebt me naast veel praktische dingen ook andere nuttige zaken bijgebracht zoals de complete play-list van skihut-radio en 
hoe leuk de Kuukse kroegentocht wel niet is! Voor jou zal het nu toch ook niet lang meer duren? Ook Jeroen hoorde bij mijn vaste kamergenoten: bedankt voor het oneindig vaak uitlenen van de lab-faqs, het meedenken en je pep-talks. Ik vind het 
nog steeds jammer dat ik geen golf-talent blijk te hebben! Heel veel succes met je nieuwe carrière op de HAN! Ik ben heel blij dat jullie me niet alleen tijdens mijn promotietraject, maar ook vandaag zullen bijstaan als mijn paranimfen! Ook met Marijke (respect voor je combi van werk en gezin), Sandra (altijd vroeg op) en Ferry (LCE rules! succes met alle 18) was het erg gezellig op de kamer. Mijn andere labgenoten mag ik niet vergeten: Ivonne (lang leve immunohistochemie, kijk maar naar de voorkant...), Mieke (geniet van je pensioen in het hoge noorden), Diana (keratinocyten kweken, 
inclusief de gezelligheid achter de flow-kast, heb ik toch echt van jou geleerd) Heleen (medische termen, ze blijven ingewikkeld), Ellen (mede-AIOer, met jouw inzet krijg je zeker een superboekje, en hoe gaat moet het nu verder met de AEDB?), Roelie (samen via genetica gekomen en ook tegelijk weer vertrekken, wat een toeval), Hanna (nieuwste lid van het LCE clubje: Viel Glück mit Ihrem Doktorarbeit) en Piet (mede-mac’er, en 
wat fijn dat ik nu ook zelf kan FACsen). En dan moet ik ook zeker Manon, Eelke, Diny, Els en Wendy vermelden voor hun hulp bij allerhande zaken (faxen blijft toch een fascinerend iets...).Mijn onderzoek leende zich uitstekend voor samenwerken, onder andere met collega’s binnen de afdeling. Het project met Annet en Marieke was volgens mij voor iedereen een win-win situatie! Bovendien is het combineren van de kliniek en het lab niet alleen heel waardevol maar ook nog eens heel gezellig. Natuurlijk wil ik ook graag de andere klinische onderzoekers 
Romy, Anke, Karlijn, Kim, Inge, Esther, Malou, Haike, Rieke, Michelle, Paula, Juul, Anne, Renée en Margit bedanken voor hun belangstelling voor mijn onderzoek. Mijn vijf jaren bij Dermatologie waren 
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leuk, en dat kwam mede doordat het 
in de koffiekamer vaak gezellig was. En dit kwam dan weer door de mix van de aanwezige mensen: de mensen van het lab, van de verpleging, van de administratie, de fotografen, en soms ook de artsen. Ik hoop dat dit nog lang zo zal blijven!Samenwerken gebeurde ook binnen het ziekenhuis. Als je genetische studies wilt doen, is het heel erg prettig dat de Nijmeegse Biomedische Studie bestaat, voor het verkrijgen van de controle DNAs. Voor de HLA-C*06 bepalingen kunnen we altijd een beroep doen op 
Kjeld van Houwelingen en Irma Joosten, erg handig. De reuma studie was niet mogelijk geweest zonder de mensen van Genetica, met name Marieke en Maša. De kinderpsoriasis data was niet compleet geweest als ik niet had leren Taqmannen van Marlies. De afdeling Genetica kende ik al van mijn stage. Erwin heeft me niet alleen enthousiast gemaakt voor het doen van onderzoek toen ik nog student was, maar ook nu heb je me met van alles, inclusief benodigde materialen geholpen. Bedankt! Voor al mijn TAP en Gateway gerelateerde vragen kon ik ook bij Sylvia, Lisette en Stef terecht. En ook Jan en Wiljan van Celbiologie waren altijd bereid om me te helpen bij praktische problemen. Hannie mag ik zeker niet vergeten, je was niet alleen mijn mentor, dankzij jou ben ik in 2007 bij dermatologie terechtgekomen!Binnen Nederland ben ik nog een aantal mensen dank verschuldigd en dan met name degene die met hebben geholpen door het beschikbaar stellen van hun DNA cohorten: de eczeem studie was niet mogelijk geweest zonder Dirkje Postma 
en Gerard Koppelman. Ook al konden 
we onze initiële β-defensin studie niet vervolgen, ik ben heel blij dat we jullie DNAtjes ook voor de LCE typeringen mochten gebruiken. Samples heb ik ook 
gekregen van Sanja Kezic, jammer genoeg hebben we uit onze samenwerking geen publicatie verkregen. I did not only got DNA from The Netherlands, also my colleagues from all over Europe kindly provided their DNA cohorts for LCE analysis mainly for the atopic dermatitis study. Thank you all very much. John Armour, thank you for designing the LCE genotyping method, that was the starting point for quite some chapters in this thesis. I also would like to thank Ulrike Hüffmeier for our collaboration. I was very happy to be 
involved in the first replication study of the LCE3C_LCE3B deletion. I am also very glad that I got into contact with Masashi Narita and that he was willing to share the anti-LCE2 antibody. It was very valuable 
because we could confirm our RNA data on the protein level. Moreover, without an LCE antibody I only had tables and graphs in my thesis! Akemi Yamamoto was responsible for the beautiful immunoelectron pictures in chapter 8. Thank you!Ik heb het geluk gehad dat ik tijdens mijn promotie ook vier studenten heb mogen begeleiden. Moniek, je was mijn eerste student en hebt me laten zien hoe leuk studenten begeleiden kan zijn. Lilie, helaas staan er alleen enkele zinnetjes in de discussie over jouw project, maar het goede nieuws is: we gaan ermee verder. Bovendien zijn je loempia’s nog door niemand overtroffen! Jos, je hebt je gewaagd aan het hele TAP-tag gebeuren, helaas is het nog steeds een towards hoofdstuk, maar ook hier werk ik nog aan door. En wie weet wordt Ajax komend seizoen wederom kampioen. Maria, although we had to reject our hypothesis about the interaction between LCEs and CDSN you worked it out perfectly leading 
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to chapter 9. In addition, thanks for testing all the lessons in the sport centre, now I also dare to join the power work-out lessons. Alle vier heel veel succes voor de toekomst | all the best in the future.  Waar was ik geweest zonder de start die ik maakte in Nijmegen aan de Jacob Canisstraat? Hier kreeg ik tips over allerlei nuttige dingen: zoals het praten tegen je aardappeltjes in de oven, en hoe bak ik een omelet? en was het vooral heel erg gezellig en leuk. Misschien is het wel dankzij die tijd dat ik zo aan Nijmegen verknocht ben geraakt. Bedankt Gerard, 
Eveline, Susan, Guénaëlle, Karlijn, Maaike, Jochem en Sander.Tijdens de introductie was het een beetje krap mijn zijn drieën op mijn kamertje, maar kijk eens waar we nu staan! Als tegenwoordige mede-Nijmegenaar is Annemarie voor van allerlei leuke dingen 
te porren, hardlopen, naar de film, uitgaan: ik hoop dat het nog lang zo blijft! Corien is ondertussen terugverhuisd naar Overijssel, gelukkig hebben we nog steeds contact en kunnen we onze promotie-ervaringen uitwisselen. Veel succes met het afronden van jouw promotie. Marloes en ik begonnen samen aan de studie natuurwetenschappen, en hoewel ik na 6 maanden doorging als MLWer, ik bleef toch echt een Leonardo-meisje. Allebei zijn we begonnen aan een promotietraject, gelukkig hebben we nog steeds tijd voor samen eten, carnavallen, luieren in het 
park/schaatsen op de waal (afhankelijk van het seizoen). Jij ook heel veel succes met de laatste loodjes en straks in Israël! Gelukkig waren Margot, Jasper, Liesbeth, Rik, Sylvie, Wendy, Monique, Corien O, Harm, Ivo, Julian en vele anderen met enige regelmaat beschikbaar voor avondjes pub-quizzen, spelletjes doen, poolen, naar het café of lekker samen 
eten. Dat doet een mens goed! Als laatste ben ik dank verschuldigd aan mijn (schoon)familie. Cor en Emmie, 
tegenwoordig officieel schoonfamilie, jullie worden nog helemaal expert in promoties. Bedankt dat jullie me thuis laten voelen in het mooie Breskens. Roy, bedankt voor je Zeeuwse lessen en jij ook veel succes met je verdediging over een maandje! Michel, Monique, Jolanda en René, ook al is het hele academische wereldje vreemd voor jullie, jullie zijn er 
wel altijd geïnteresseerd en dat is erg fijn. Isa, Esmee, Lieke, Tom en Anouk, jullie 
zorgen altijd voor de benodigde afleiding en entertainment. Ik ben benieuwd wat de toekomst jullie zal brengen. Shella, 
fijn dat je altijd zo vol enthousiasme mee wilt wandelen in het bos. Papa en mama, ook al zit jullie jongste dochter in het verre Nijmegen, jullie staan altijd voor me klaar en hebben me altijd gesteund. Jullie hebben me geleerd dat je het vooral leuk moet vinden wat je doet en kijk eens waar dat toe geleid heeft!  En dan de belangrijste van allemaal Dennis, mijn man (dat klinkt toch zo leuk!). Jij weet hoe het is zo’n promotie (ik wil ook wel zo’n goeie verdediging...). Misschien ben je daardoor ook wel degene geweest die me het meest en hardst heeft gesteund. Niet alleen door successen mee te vieren of me op te peppen als dat nodig was, maar je hielp me ook, zowel met praktische als computerproblemen. Jij maakt mij gelukkig en ik hoop dat al onze toekomstdromen uitkomen. Samen kunnen we de wereld aan! En dan is het moment nu daar, mijn proefschrift is helemaal klaar!
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